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Abstract
Two-component signaling systems involving receptor-histidine kinases ( R H K s )
are present in all branches of life outside of the animal kingdom. Remarkably, very little
is k n o w n concerning the extracellular ligands that presumably bind to R H K s to initiate
signaling. T h e two-component agr signaling circuit in the bacterial pathogen,
Staphylococcus aureus, is one system where the ligands are k n o w n in chemical detail.
These ligands (the AIPs) are short (7-9 aminoacyl residue) peptides containing a
thiolactone structure, in which the oc-carboxyl group of the C-terminal amino acid is
linked to the sulfhydryl group of a cysteine, which is always thefifthamino acid from the
C-terminus of the peptide. In the agr system, the AIPs generally activate virulence
expression in the producer strain and cross-inhibit virulence expression in S. aureus
strains expressing other AIPs. In this study, genetic studies on the receptor-histidine
kinase, A g r C , have demonstrated that intra-group activation and inter-group inhibition
are both mediated by the same group-specific receptors. Pharmacological analysis has
s h o w n that the AIPs compete for a c o m m o n binding site on the receptor, and this site has
been partly localized through the use of chimeric receptor analysis. Structure-activity
relationship ( S A R ) studies have identified residues within the AIPs that are critical for
receptor binding and activation. These results have facilitated the development of global
inhibitors of virulence in S. aureus, which, in one case, consists of a truncated version of
one of the naturally occurring AIPs. Cell-based in vitro assays of this peptide have
demonstrated IC50's in the n.anomolar range for inhibition of the transcription of a k n o w n
global regulator of virulence in S. aureus, RNAIII. Virulence inhibition in vivo has been
seen with native AIPs in a murine subcutaneous abscess model. Ongoing studies are
focused on peptidomimetic design to generate stable and pharmacologically relevant lead
compounds. These results collectively suggest that the design of molecules that compete
with natural agonists for binding at R H K sensor domains could represent a general
approach to the inhibition of R H K signaling.

C h a p t e r 1 - Introduction
Receptor-regulated histidine kinase signaling (or two-component signaling) is
widespread in nature, and is mainly utilized for cell-cell and cell-environment
communication. Receptor-histidine kinases (RHKs) have been extensively characterized
in bacteria, and are present in archaea, microbial eukarya, and higher plants, where
have recently been shown (in Arabidopsis) to play a role in hormone signaling

(Sakakibara et al., 2000). In bacteria, RHKs are involved in sensing the environmental
surroundings. Many of these kinases contain two transmembrane helices flanking a

periplasmic domain. This domain contains the binding site for the appropriate ligand,

such as metal ions (Mg2+ in the case of PhoP) (Groisman, 2001; Lesley and Waldburger,
2001). In the vast majority of cases, the ligands or environmental cues that trigger
histidine kinase signaling are unknown. Noted exceptions include amino acid ligands,

such as aspartate, in the bacterial chemotaxis system (Falke and Hazelbauer, 2001), an
more complex peptide ligands, such as thiolactone-containing autoinducing peptides
(AIPs), in the agr system of Staphylococcus aureus (Novick and Muir, 1999). Ligand
recognition and signaling by two-transmembrane-helix-containing chemoreceptors has

been extensively studied in bacterial chemotaxis systems (Falke and Hazelbauer, 2001;
Yu and Koshland, 2001). In contrast, relatively little is known about peptide ligand
recognition by polytopic receptor-histidine kinases (RHKs) in S. aureus or any other
species.
Many RHKs have been shown to exist as preformed dimers in the inner cell

membrane of gram-negative bacteria (Stock et al., 2000). In the case of EnvZ, a pair o
cytoplasmic a-helices from each monomer forms a four-helix bundle (Tomomori et al.,

1999), and this structure is likely shared among the vast majority of R H K s . In grampositive bacteria, pheromone-inducible RHKs usually have a polytopic sensor domain,
containing five to eight membrane spanning segments. RHKs predicted to possess this
polytopic sensor domain include: AgrC from Staphylococcus aureus (Lina et al., 1998),
ComD from Streptococcus pneumoniae (Havarstein et al., 1996), ComP from Bacillus

subtilis (Tortosa and Dubnau, 1999) and SapK from Lactobacillus sakei Lb706 (Axelsson

and Hoick, 1995). These RHKs respond to secreted signaling peptides, which bind to the
sensor domain to initiate the transmembrane signal that activates the intracellular
histidine kinase (HK). Activation of the HK domain is known to involve trans

autophosphorylation of a conserved histidine residue in the dimerizing four-helix bun

followed by phosphorelay to a downstream response regulator (Wright et al., 1993; Dut
and Inouye, 2000; Qin et al., 2000).
The ligands of the agr system in Staphylococcus aureus have been characterized
and thereby represent a model system in which to elucidate the mechanistic basis for

ligand-mediated RHK activation. As cells grow, an extracellular peptide, known as the

AIP, is secreted and accumulates. This AIP is derived from processing of the propepti
AgrD. Upon reaching a threshold concentration, the AIP triggers activation of the

receptor-histidine kinase, AgrC. This kinase activation results in increased transcri

of the unique regulator, RNAIII, that ultimately increases secretion of virulence fac

and down-regulates various surface proteins (Fig. 1.1, and Table 1.1) (Novick et al.,

1993; Tegmark et al., 1998). This signaling process is an example of density-dependent
or "quorum sensing" systems widespread in bacteria (Table 1.2) (Fuqua et al., 2001;
Schauder and Bassler, 2001; Fuqua and Greenberg, 2002).

T a b l e 1.1 - Virulence Factors in S. aureus

Factor

Systemic toxins
Enterotoxin A
Enterotoxin B
Enterotoxin C
Enterotoxin D
Enterotoxin E
Toxic Shock Toxins
TSST-1
TSST-O
Exfoliative Toxins
ETA
ETB
Cytotoxins
cx-hemolysin

P a t h o g e n i c Activity

Food
Food
Food
Food
Food

Poisoning, T S S
Poisoning, T S S
Poisoning, T S S
Poisoning, T S S
Poisoning, T S S

agr-regulated

+
+
+

TSS
None (?)

+

Scalded Skin Syndrome
Scalded Skin Syndrome

+
+

Hemolysis, Necrosis

p-hemolysin
8-hemolysin

Hemolysis, Necrosis
?

+
+
?

y-hemolysin

Hemolysis, Necrosis

+

Leukolysis

+

Spread, Nutrition
Spread, Nutrition
Spread, Nutrition
Spread, Nutrition
Inactivation of toxic
fatty acids

+

Anti-phagocytosis
?
?

+
+
?

Adhesion

+

Leukocidin
Enzymes
Proteases
Nucleases
Lipases
Hyaluronidase
Esterases
Surface Factors
Protein A
Coagulase
Clumping factors
Fibronectin Binding Protein

+
+

+, expression of these virulence factors changes in response to activation of agr
signaling, with decreased expression of surface factors and increased expression of the
other listed virulence factors. -, N o agr effect. ?, undetermined. (Novick and Muir, 1999)

T h e

agr

Locus

Pheromone

•*£, aerA IC agrC "KagrDlCagrB
_P2 P3
RNA II

RNA III

Figure 1.1. T h e agr locus is depicted, showing the various components and their putative
actions in the signaling network. This signaling system is a doubly auto-catalytic circuit,
as A g r C activation induces transcription of more receptor, along with more of the
propeptide inducer, A g r D , processed by A g r B to form the pheromone AIPs. T h e endresult of the pathway is activation of R N A I I I transcription by the response regulator,
A g r A , which leads to downstream activation and repression of virulence-associated
factors via transcriptional and translational regulation by this unique R N A molecule
(Novick et al. 1993).

Table 1.2. M a n y Bacterial Processes are Controlled by Q u o r u m Sensing

Processes

Bacterial

Signaling

species

molecules

Bioluminescence

Vibrio harveyi

HSLs, AI-2

Biofilms/virulence

P. aeruginosa

HSLs

Conjugation

Agrobacterium

HSLs

Virulence

Vibrio cholerae

CAI-1, AI-2

Virulence
/competence

S. pneumoniae

Peptide - C S P

(Morrison, 1997;
Lau etal.,
2001)

Virulence

E. faecal is

Peptide - G B A P

A l ^ ^ ^ a m a et al., A
2001; Qin et
aU2001)

Virulence

S. aureus

Competence

B. siibtilis

* Peptide-AIP
Peptide - C o m X

Reference(s)

(Freeman et al.,
2000)
(Fuqua and
Greenberg,
2002)
(Toyoda-Yamamoto
et al., 2000;
Vannini et al.,
2002)
(Miller et al., 2002)

(Novick and Muir,
1999)
(Ansaldi et al.,
2002)

Gram-positive bacteria are shaded in grey.

T h e AIPs werefirstpurified and characterized from bacterial culture supernatants and
tested by Northern blotting for their effect on RNAIII expression (Ji et al., 1995).
Bacterial supernatants from group I agr+ cells, when added to pre-exponential bacterial
cultures of similar cells, induced early RNAIII expression, due to activation of RNAIII
expression by AIP-I from the added supernatants (Fig. 1.2) (Ji et al., 1995). Later studies
also utilized Northern blotting of RNAIII expression to demonstrate cross-inhibition (or
bacterial interference) of agr activation by supernatants derived from different agr
specificity groups (Ji et al., 1997).
The sequence of the AIPs is highly variable, resulting in at least four specificity
groups of strains within S. aureus and many more (>25) in other staphylococci (Fig. 1.3)
(Ji et al., 1997; Otto et al., 1998; Jarraud et al., 2000; Dufour et al., 2002). A group is
defined as the collection of strains that produce the same AIP. The agrB, D, and C
regions vary in concert to maintain the specificity of AIP processing and function (Ji et
al., 1997). This specificity results in four different receptors for the AIPs in S. aureus,
designated AgrC-I, -II, -III, and -IV, reflecting the group that expresses them.
Remarkably, there is extensive cross-communication at the level of ligand-mediated
signaling, as most AIPs activate their cognate receptor while inhibiting activation of nonnative receptors (Ji et al., 1997). This inhibition is a form of bacterial interference that
does not result in growth inhibition but rather in the block of accessory gene functions,
presumably resulting in an advantage for the strain producing the most abundant and/or
most potent AIP. The native AIPs in S. aureus are referred to as AIP-I, -II, -in and -IV,
reflecting the group that expresses them.

Normal A g r Induction in growing bacterial cultures
hrs

M

RNAIII

Induction with stationary-phase bacterial supernatants

hrs

0

0.3

0.6

1

1.2
RNAIII

Figure 1.2. Northern blots of RNAIII induction in a Group I, RN6390b, strain. The
stationary-phase supernatants were collected as described in Methods and added at 1/10*
volume to pre-exponential bacterial cultures. Addition of supernatants induces early
RNAIII expression. The population doubling timeof S. aureus in culture is approximately
30 minutes, and, depending on the initial inoculum size, the time to reach stationary phase
of growth can be from 6-12 hours. Control experiments monitoring cell density revealed
no difference in cell growth between the strains with and without added supernatants. This
experiment was performed by Naomi Balaban.

Figure 1.3. L i n e u p of Predicted A g r D Propeptide Sequences f r o m
Various Staphylococci
SaureusI
MNTLFNLFFDFITGILKNIGNIAA YSTCDFIM
Saurll
MNTLVNMFFDFIIKLAICAIGIVG GVNACSSLF
Saurlll
MKKLLNKVIELLVDFFNSIGYRAAY INCDFLL
SaurlV
MNTLLNIFFDFITGVLKNICi:VAS YSTCYFIM
Slugdl
MNLLSGLFTKGISAIFEFIGNFSAQ DICNAYF
SlugdII
MNLLSGLFTKGISVIFEFIGNFSVQ DMCNGYF
Sarlettael
jMNLLNSFFSFFAKKFFELIGTVAG VNPCGGWF
SauricI
MMKLVNLLLSSTTSILQMVGNRQK AKTCTVLY
SauricII
MMK-DNLLLSSTTSILQMVGNRSK TKTCTVLY
ScapitisI MIMNSLFNLIFKFFTVIFEFIGFVAG ANPCQLYY
ScapII
MIMDALFNLIFKFFTVIFEFIGFVAG ANPCALYY
Scaprael
MMQIINLLFKVITAVFEKIGFIAG YSTCSYYF
Scaprll
MKMMQIFDLLFKVISAVFEKIGFLAG YRTCNTYF
Scamosus MNFNMDILNGIFKFFAFIFEQIGNIAK YNPCVGYF
Scone**
MHIFESIINLFVKFFSVLGAISG GKVCSAYF
Sconu***
MNIFESIINLFAKFFAFIGTISS VKPCTGFA
Sepil
MNLLGGLLLKLFSNFMAVIGSAAK YNPCASYL
Sepill
MEIIFNLFIKFFTTILEFIGTVAG D..3VCASYF
Sepilll
MNKLLGGLLLKIFSNFMAVIGNASK YNPCSNYL
SepilV
MNKLLGGLLLKIFSNFMAVIGNAAK YNPCANYL
Sgallinarum
MNILDSLLNLATKFFSALGASVG ARPCGGFF
Sintermedius* MRILEVLFNLITNLFQSIGTFA RIPTSTGFF
SsimulansI
MDLLNGIFKLFAFIFEKIGNLAK YNPCLGFL
Ssimll
MELLNGIFKLFAFIFEKIGNLAK YYPCFGFL
Sxylosus
MNIFESILNLFAKFFSVLGVMAG AKPCGGFF
Swamerii
MEFLVNLFFKFFTSIMEFVGFVAG YSPCTNFF

DEVEVPK r' .jTQLHE - DEPKV! ALLTNLYDKDEAEVFKSLTQLHE-DEVSVPK.'l.TQLHE-DEPEVPQELIDLQRKDEPEVPQELIDLHRNDEPEVPEELTKYSE- DEPEV-KELTQELEKDEPEV-KELIQELEKDEPEVPEELSKLYE-DEPEVPDELSKLYE-DEPEVPKELLEIYKKDEPEVPKELFETYQKDEPEVPSELLDEQK-DEPEVPKEIKDLYK-DEPEIPKELTDLYK-DEPQ7PEELTKLDE-DEPEVPEELTKLYE-DEPQ'/LPEELTKLDEDEPQVLPEELTKLDEDEPEVPAEITELHK-DEPEIPAELLEEEK-DEPTVPKELLEEDK-DESEVPQE'^LDEDK-DEPEVPSEITKLYE-DEPEVPSEI.TKIYES-

* S. intermedius AIP containing a serine in place of the conserved cysteine.
** S. cohnii cohnii
*** S. cohnii urealyticum
• Note the conserved D E (Asp-Glu) processing motif C-terminal to the mature AIP, and the
conserved Glycine several residues N-terminal to the mature AIP.
• All AIPs contain hydrophobic amino acids as the two C-terminal residues.
• The length of the AIPs varies from 7-9 residues. Therefore, at the beginning of this
study, only AIP-I, AIP-II, and S. epidermidis AIP-II had been fully characterized by mass
spectrometry and shown to encode an octapeptide, a nonapeptide, and an octapeptide,
respectively (Otto et al. 1998, Mayville et al. 1999). There is also evidence from Nterminal sequencing of a purified S. lugdenensis AIP that it is comprised of a
heptapeptide (Ji et al. 1997). All other AIPs listed had an undefined N-terminus relative
to the conserved D E processing motif at the beginning of this study.

Structure-activity relationship ( S A R ) studies have been performed on the AIPs
(Otto et al, 1998; Mayville et al., 1999; Otto et al., 1999), and have shown that (Fig. 1.4):
i) the AIPs contain a thiolactone structure that is absolutely required for potent biological
activity; ii) the thioester linkage is formed from the condensation of the a-carboxyl group
of the peptide with the sulfhydryl group of a conserved cysteine; iii) the conserved
cysteine is always the fifth amino acid from the C-terminus; iv) the lactam and lactone
analogs of AIP-II are potent agr cross-group inhibitors, but lack activity against self, at
concentrations up to 5 uM (Mayville et al., 1999); v) the N-terminal four amino acids of
the group II AIP, collectively referred to as the "tail region", are necessary for selfactivation but not for cross-group inhibition (Mayville et al., 1999); and vi) the sixteen
atom-membered ring of the AIPs is also .known as the macrocycle.
The structure-activity relationships summarized above were determined by
analyzing the effects of chemically synthesized AIPs on agr activation. The strategy for
the chemical synthesis of the AIPs is shown in Fig. 1.5. This strategy uses unprotected
peptides in solution or on resin and relies on a chemoselective transthioesterification
reaction that proceeds quantitatively and with no epimerization of the C-terminal amino
acid (Dawson et al., 1994). All peptides synthesized, tested and reported up to and
including the year, 1999, when this study commenced, are listed in Table 1.3. Much of
the information provided by these AIPs formed the basis for many of the questions
addressed in this study. Furthermore, the alanine scanning results of AIP-II are shown in
Fig. 1.6. These results suggest that residues in the tail region of AIP-II might be critical
for receptor activation, while certain residues in the macrocycle might be critical for
receptor binding, as these latter alanine analogs have no activity whatsoever.
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A)

AIP-I

AIP-II l a c t o n e

AIP-II

AIP-II l a c t a m

B)

Figure 1.4. A I P structures. A ) Chemical structures of AIP-I, AIP-II, AIP-II lactone and
AIP-II lactam. B ) A n energy-minimized structural model of AIP-II (using Insight II,
MSI). The AIPs consist of a flexible "tail region" and a thiolactone macrocycle.

H2N—<g|^

HS-.
^CONH

SPPS
,S-MEB

£
Boc-NH—| Protected Peptide K ^s^.
^CONH
O
HF

^SH
H2N—[Unprotected Peptide~h^ ^S„
vCONH—<gg^

Y
O

pH=7.0, Phosphate Buffer

^scH,NAgr Thiolactone

F i g u r e 1.5. C h e m i c a l synthesis of A g r D thiolactone-containing autoinducing
peptides via a solid-phase intramolecular chemical ligation strategy. Key to this
process is the ability to prepare a fully unprotected peptide immobilized on a solidsupport through a reactive thiol ester bond. Simply swelling such an unprotected peptide[thioester]-resin in aqueous buffer results in a chemoselective ligation reaction and
concomitant cleavage of the peptide from the support (Mayville et al., 1999).
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T a b l e 1.3. A I P s synthesized u p to a n d including the year, 1999.

AIPs

Exocyclicl

AIP-I

m a s s expected

Endocyclic

m a s s observed

Y

s

• T ,

c2

D

F

I

M

961.1

960.9

AIP-II

Q

V

N

A

c

s

S

L

F

879.0

878.9

AIP-II lactam

G

V

•N

-A

X3

s

S

L

F

861.9

862.0

AIP-II lactone

G

V

N

'A

s4

s

S

L

F

863.0

861.9

AIP-II linearfreeacid

G

V

N

A

c

s

S

L

F

897.0

896.4

G

v'

N

A

A

s

S

L

F4

953.0

952.0

AIP-II Gl A

G

V''
t

H

A

c

s

s

L

F

893.0

893.0

AIP-II V 2 A

G

V

N

A

c

s

s

L

F

850.9

850.0

AIP-II N 3 A

a

V ' N ' A'

c

s

s

L

F

836.0

835.9

AIP-H S6A

G

V

N

,AA

c

s

s

L

F

862.9

861.9

AIP-n S7A

G

V

N

A

c

s

s

L

F

862.9

862.0

AIP-O L 8 A

G

V

N

A

c

s

s

L

F

836.9

836.0

AIP-n F9A

G

Y

Kj

A

c

s

s

L

F

802.9

803.0

AIP-III octapeptide

Y

I

N

c

D

F

L

L

982.2

981.9

S. epidermidis AIP 9-mer G

D

S*

V ;

c

A

s

Y

F

930.0

Mass not reported

G

D

s

V

c

A

s

Y

F

948.0

Mass not reported

S. epi. AIP8-mer

D

s

V

c

A

s

Y

F

873.0

Mass not reported

Linear S. epi 8-mer

D

s

V

c

A

s

Y

F

891.0

Mass not reported

S. epi. AIP 8-mer .Lactone

D

s

V

s4

A

s

Y

F

857.0

Mass not reported

S. epi. AIP 8-mer Lactam

D

s

- V

X3

A

s

Y

F

856.0

Mass not reported

AIP-II linear thioester

Linear S. epi 9-mer

S. epi. AIP 7-mer

s ' 'V

c

A

s

Y

F

758.0

Mass not reported

Linear S. epi 7-mer

s

V

c

A

s

Y

F

776.0

Mass not reported

ac: acetylation; bi, biotinylaied; fl, fluorescein-conjugated
'exocyclic residues are shaded in the table; 2A11 of the peptides with a conserved cysteine contain a thiolactone
formed via the condensation of the a-carboxyl group of the AIPs with the sulfhydryl group, except for the linear
peptides;3 X = D a p a : diaminopropionic acid;4 The marked serine contributes its hyrdroxyl group to condense with the
a-carboxyl group of the AIP; s There is a C-terminal thioester linker on this peptide after H F cleavage;6 These AIPs
were synthesized by another group, that of Otto and Goetz (Otto et al., 1998; Otto et al., 1999), while all other M P s
were synthesized by Mayville et al. 1999.
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Figure 1.6. Alanine Scanning of AIP-II. Effect of replacing each residue within AIP-II with
alanine on activation (A) and inhibition (B) activity. The results are superimposed on a
model of AIP-II created using the program Discover (Biosym/MSI, San Diego, C A ) . The
E C 5 0 values (activation, group II cells) were as follows: AIP-II, 3.6 ± 1.1 n M ; Alal, 3.2 ±
2.2 n M ; Ala2, 73.7 ± 1.9 n M ; Ala3, no activity; Ala6, 33.6 ± 1.5 n M ; Ala7, <1 n M ; Ala8, no
activity up to 10 u M ; Ala9, no activity up to 10 uM. The IC50 values (inhibition, group I
cells) were as follows: AIP-II, 2.9 ± 1.2 n M ; Alal, <1 n M ; Ala2, <1 n M ; Ala3, <1 n M ;
Ala6, « 1 n M ; Ala7, <1 n M , Ala8, no activity up to 10 u M ; Ala9, no activity up to 10 uM.
Note, none of the peptides activated the agr response in group I S.aureus strains. Published
results also indicated that none of these peptides were self-inhibitors of group II, although see
Results section for clarification of this (Mayville et al, 1999).
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It has been suggested that the N-terminal region of A g r C , the sensor domain,
contains the binding site for the agonist AIP (Ji et al., 1995; Ji et al., 1997). In contrast
with the conserved HK domain, the sensor domain is highly variable, thus suggesting a
means for discriminating among AIPs from different groups. Suggestive evidence
supporting AIP binding to AgrC was obtained in an AIP pull-down experiment in which
cells overexpressing AgrC titrated out AIP-I from biological supernatants (Figure 1.7).

Paranthetically, this is indirect proof, as it is formally possible that AgrC is or induces an
enzyme that destroys the AIP or induces a second protein that binds the activator.
Topological mapping via hydropathy analysis and PhoA fusions (Manoil and Beckwith,
1986) suggests that the sensor domain is composed of five or six transmembrane helices,
depending on whether the N-terminus of the protein is placed on the inside or outside of
the cell (Lina et al., 1998). This same study suggested that the third extracellular loop of
AgrC-I is critical for AIP-I induced activation, as an MBP-AgrC fusion protein
containing only the third extracellular loop, one transmembrane helix and the HK domain
was activated by group I derived supernatants. In this study, attempts have been made to
confirm these results using synthetic AIPs. Although these results were not confirmed
(see Results), other studies described in this thesis implicate the C-terminal half of the
sensor domain of AgrC in AIP-induced receptor activation (see Section 2.5).
The lack of agonist activity of the lactone and lactam analogs of AIP-II (see Fig.
1.4 for structures) led to the hypothesis that the AIPs might activate AgrC through
covalent reaction of the thioester with a nucleophile in AgrC (Mayville et al., 1999). The
obvious candidate for such a nucleophile is a cysteine, but there is no such residue in the
sensor domain of AgrC-II, although other putative nucleophiles are present. As no ligand-
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Figure 1.7. A I P Titration by AgrC-overexpressing cells. Agr null group IRN6911
strains carrying different agr genes cloned under control of the blaZ promoter were
induced with 5 pg CBAP per mL for two hours, washed with 20 mM Tris-HCl buffer (pH
7.5), incubated for one minute with a standard amount of activator AIP-I from

supernatants, and then centrifuged to remove the cells. The resulting supernatants we
then assayed for activity (Ji et al., 1995).
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receptor signaling cascade has yet been shown to proceed through covalent reaction of
the ligand with the receptor, the testing of this hypothesis was of the utmost priority in
this work. This analysis has led to the synthesis and characterization of the AIPs from the
four known agr groups of S. aureus, thus yielding significant insight into the mechanism
of interaction of the AIPs with the receptors (both as agonists and antagonists).
Agr mutants are greatly attenuated for virulence in several animal models of
infection (Abdelnour et al., 1993; Cheung et al., 1994; Booth et al., 1995; Gillaspy et al.,
1995; Giraudo et al., 1996; Tegmark et al., 1998). This suggests that blockade of agr
signaling in vivo might have therapeutic utility. Toward this end, the availability of
naturally occurring peptide-based agr antagonists has opened the door to peptidomimetic
and/or small molecule drug discovery efforts. In fact, the agr system is the only system
described thus far where interfering with quorum sensing can attenuate virulence in vivo
(Mayville et al., 1999). A subcutaneous abscess mouse model of S. aureus infection was
used to demonstrate that co-injection of agr group IS. aureus with the antagonist, AIP-II,
led to greatly attenuated abscess formation (Fig. 1.8). This co-injection experiment has
now been repeated several times with similar results, although preliminary experiments
with injection of AIP-II at different sites from the bacterial injection site have not
revealed any effect (unpublished observations, Jesse Wright). This outcome could be
caused by the base-lability and putative exo- and endopeptidase susceptibility of AIP-II
in vivo. Therefore, one aspect of this work has included a focus on the development of
potent and stable AIP analogs that inhibit agr signaling (in all agr groups) for future
testing in animal models of infection.
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F i g u r e 1.8. A t t e n u a t i o n of staphylococcal skin abscesses b y a synthetic thiolactonecontaining peptide (Mayville et al., 1999). Mice were injected subcutaneously with IO8
cfu of either the agr+ wildtype group I strain, RN6390B (B), or an agr-null derivative,
RN6911 as the negative control (C). For RN6390B, the synthetic AgrDII peptide, at 5
(D) or 10 mg per mouse, was included with the injected bacteria in two of the three
groups of mice. Photographs were taken on day 5.
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Although not studied in this thesis, the mechanism by which the AIPs are
processed from the propeptide, AgrD, and subsequently secreted could bear upon the
subject of how the AIPs evolved. Therefore, AgrD processing by AgrB is being studied
by several groups. AgrB/AgrD swapping experiments have been used to address the
mechanism of processing. Strains containing mixed and matched agrB and agrD genes

were cultured and stationary-phase supernatants collected. These supernatants were th

assayed for their ability to activate or inhibit AgrC-I (Ji et al., 1997) (see Fig. 1
partial AgrD sequences, including the AIP sequences). For the matched AgrB-I/AgrD-I

strains, the expected results were obtained: AgrB-I can process AgrD-I to form AIP-I,

the supernatant from this strain activates AgrC-I, and AgrB -II, -111, and S. lugdune
AgrB process AgrD-II, -III and S. lug. AgrD to form AIP-II, -III, and S. lug. AIP,

respectively, which all inhibit AgrC-I activation. For the mixed strains, e.g. AgrB-I
AgrD-II, the result was that AgrB did not process heterologous AgrDs, with notable
exceptions. This included AgrB-IH processing of AgrD-I to generate an activator of
AgrC-I, which was presumably AIP-I, and AgrB-I processing of AgrD-III to generate an

inhibitor of AgrC-I, which was presumably AIP-III. The caveat to these results is tha

AIPs themselves were not analytically characterized, so it is impossible to know what

was formed in the mixed AgrB/AgrD experiments. This is particularly important because

the AIPs vary in length, ranging in size from 7-9 amino acids. Thus, it is possible, f

example, that AgrB-I could process AgrD-III to form an octapeptide version of AIP-III

even though AIP-III is itself a heptapeptide (see Section 2.4). In fact, this logic w

initially used to conclude erroneously that AIP-III might be an octapeptide, as AgrBcould process AgrD-III to form a group I inhibitory peptide (Ji et al., 1997).
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Figure 1.9. A g r D processing by AgrB. A ) The putative topology of AgrB-I is shown,
with the cysteine residue boxed in red that is speculated to be of importance in AgrD
processing. The location of the AgrB-PhoA fusion points are indicated with triangles and
rectangles: triangle, high PhoA activities; rectangle, low PhoA activities. This figure has
been reproduced from Zhang et al. (2002) JBC, 277, 34736. The entire N-terminus of the
protein is not shown here, presumably due to space considerations or alternative start site
locations. B ) A portion of the AgrD propeptide sequence from various groups is shown
below AgrB for reference. Note that all AIPs contain a conserved cysteine, with the
exception of a substituted serine in the AIP of S. intermedius. The predicted
transmembrane alpha helices by TopPred II, T M H M M , and D A S analyses are indicated
by filled shapes.
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Recently, two papers have studied AgrB in more detail (Saenz et al., 2000; Zhang

et al., 2002). One group overexpressed AgrB and AgrD in S. epidermidis and showed that

the concentration of AIP produced was equivalent to that produced in wild-type strain

-20 nM (Saenz et al., 2000). This result led to the suggestion that processing or secr

of the AIPs might require some other rate-limiting factor besides AgrB or AgrD, altho
no agr-independent factor has ever been shown to be required for agr signaling. The
same group raised antibodies against AgrB and demonstrated that AgrB is localized in

the membrane fraction, thus suggesting that it is a membrane protein, consistent with
hydropathy analysis (Saenz et al., 2000). These authors could only detect AgrB in the

overexpressing strains and not the wild-type strains, which is consistent with the id

agr proteins are expressed at very low levels. The second group utilized a His-tagged

version of AgrB expressed in S. aureus and E. coli. The authors report confirmation o

the membrane localization of AgrB in S. aureus using an anti-His antibody (Zhang et a
2002). Secondly, using PhoA fusion analysis, the authors derive a transmembrane
topology model of AgrB (Fig. 1.9A) that is consistent with some, but not all, of the
computer-predicted transmembrane helices. In fact, this new model contains two

transmembrane helices that are only twelve amino acids in length, which is not normal
long enough to span the membrane The use of PhoA fusion analysis to determine

membrane topology relies on the assumption that the C-terminal portion of the membran

protein plays no role in the assembly of the correct topological structure, an assump
that is not always the case and has formed the basis for the development of PhoA

"sandwich-fusion" approaches (Ehrmann et al., 1990). Thirdly, the authors detect, upon

co-expression of a His-tagged version of the propeptide, AgrD, with AgrB in S. aureus
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His-tagged cleavage product of A g r D that derives either from cleavage at the N - or Cterminus of the AIP; the resolution of SDS-PAGE analysis does not allow distinction
between the two possibilities. Finally, the authors speculate that processing of AgrD by
AgrB could proceed through an acyl-enzyme intermediate resolved by nucleophilic attack
by the thiolate anion of the cysteine side-chain in the AIP. As shown in Fig. 1.9A, there
is a conserved cysteine in AgrB that could very well play a role in forming a thioester
acyl-enzyme intermediate that could be resolved by nucleophilic attack by the cysteine
thiolate anion in the AIPs. Future efforts should elucidate the mechanism by which this
putative membrane protease/ secreting enzyme produces active AIP.
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Objectives of Thesis
Outlined below are the specific aims of the thesis proposal, originally submitted
in May, 2000. Significant progress toward each of these aims is reported herein.

Specific aim #1 -- Develop a more efficient assay system for testing
synthetic analogs of the A I P s . A s the previous assay system was
problematic for a n u m b e r of different reasons, the development of n e w
strains of S. aureus containing reporter genes should enable one to assay
n e w c o m p o u n d s m o r e efficiently.

Specific aim #2 -- Design, synthesize and assay analogs of the AIPs to
discover w h i c h parts of the structure are crucial for activation a n d
w h i c h parts for inhibition. Such studies should lead to a m o r e general
understanding of h o w these peptides function, which will lend itself to
rational design of potent global inhibitors of S. aureus virulence.

Specific aim #3 -- Address by genetic and biochemical means whether
activation a n d inhibition of the agr response proceeds directly through
the receptor, A g r C . Begin to test experimentally a model that holds that
activation and inhibition of virulence involves specific binding of the
A I P s (perhaps via covalent acylation) to the cell surface receptor, A g r C .

Specific aim #4 -- Begin to explore genetically and biochemically how
activation of A g r C leads to a transcriptional response. Begin to address
which parts of A g r C are crucial for its function, including the regions that
m a y interact with the AIPs and the regions that m a y be involved in
receptor dimerization.

23

C h a p t e r 2 - Results

Section 2.1 -- Assays utilized to study AlP-induced AgrC

signaling

Perhaps the most important predictor of success in experimentation is the amount
of thought and effort that goes into assay development. There are various methods by

which one could assay the effects of various AIPs on agr activation in S. aureus. Som
these have been developed, tested and refined herein.

Northern blotting to determine agr-regulated RNAIII production
Northern blotting was used initially to investigate RNAIII expression in a newly
discovered agr variant, named group IV, with an AIP of predicted sequence YSTCYFIM
(Jarraud et al., 2000), which has now been confirmed through synthetic means (see

Section 2.4) and tandem mass spectrometry of biological supernatants (see Section 2.7

As an example of this type of analysis, group HI bacterial cells (RN8465) were incuba

with or without addition of culture supernatants from a group IV agr+ strain, RN4850,
and aliquots removed at various timepoints from zero to four hours and analyzed by
Northern blotting. As illustrated in Figure 2.1, RNAIII expression was up-regulated
dramatically in group IH cells by four hours, reflecting the normal timing of RNAIII
expression in this strain, whereas RNAIII expression was strongly inhibited by the

addition of group IV culture supernatants. This inhibition by AIP-IV of agr group III
activation was later confirmed using a group IH reporter strain and synthetic AIP-IV
(vide infra) (Lyon et al., 2002).
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Figure 2.1. Northern blot hybridization analysis of the effects of group IV (RN4850)

supernatant on agr activation in group III (RN8465) cells . One-tenth volume of post

exponential RN4850 supernatant (+) or broth (-) was added to a mid-exponential phas
culture of RN8465 and hourly samples were taken for Northern blot hybridization

analysis using an RNAHI-specific probe. The population doubling time is approximate
every 30 minutes, and it takes approximately 6-12 hours of growth before S. aureus

enter the stationary phase, depending on the initial inoculum size. For this agr gro
RNAIII expression is turned on relatively late, after 4 hours of growth. Control

experiments monitoring cell density revealed no difference in cell growth between t
strains with and without added supernatants.
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Analyzing agr expression via R P - H P L C analysis of 5-toxin levels
6-toxin is a -25 amino acid hemolytic peptide encoded by RNAIII, and the level
of this translation product is proportional to the level of RNAIII in the cell (Otto et al.,
1998; Mayville et al., 1999; Otto et al., 1999). 5-toxin is an amphiphilic molecule with
surfactant-like properties that was discovered to bind under hydrophobic interaction
chromatography conditions to a phenyl-derivatized column (Otto and Gotz, 2000). With
the relatively harsh washing conditions of water/organic solvents, 5-toxin selectively
binds to the column in preference to most other proteins in bacterial supernatants. The
reason for this is likely because of the extreme amphiphilic nature and a-helical structure
of 5-toxin, although it is unknown how much of this secondary structure is retained
under acidic conditions. Very tight binding of such amphiphilic molecules to reversedphase matrices has been described (Zhou et al., 1990). Therefore, HPLC analysis of
5-toxin binding to a Resource Phe 1-mL column (Amersham Pharmacia Biotech)
provides a quantitative readout of RNAIII expression.
This relatively simple assay was utilized in lieu of Northern blotting to monitor
RNAIII expression in staphylococcal strains for which reporter strains were not yet
available (vide infra). For example, construction of a reporter strain for group in was
initially problematic for technical reasons, so 5-toxin expression was monitored to
analyze the effects of various synthetic AIPs. Two such AIPs are AIP-II and trAIP-II, a
truncated version of AIP-n (see Section 2.2). Inhibition of RNAIII expression in early
exponential-phase cultures of group I and III agr+ cells was monitored by HPLC analysis
of 5-toxin production in the presence of increasing concentrations of AIP-II or trAIP-I.
Supernatants were collected after nine hours of growth and the amount of 5-toxin
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quantitated in each sample. Inhibition of group III agr activation by AIP-II and trAIP-II
was demonstrated, with IC50 values of 17 nM (95% CI, 4-70 nM) and 10 nM (95% CI, 520 nM), respectively. A representative curve for inhibition by trAIP-II is shown in

Figure 2.2. TrAIP-II also inhibited group I agr activation, with an IC50 of 200 nM (9

CI, 10-3000 nM). These results were later confirmed with group I and III reporter str
This assay has also been utilized to assess the activity of AEPs in alternative
staphylococcal species (vide infra).
It is notable that unknown components were detected by ESMS on fractions
separated from 5-toxin by optimized RP-HPLC gradient conditions (see Methods), with

one mass in particular, 4667.0 Da, repeatedly observed in S. epidermidis strains. Unl

an optimized HPLC gradient is used to separate these components, it is not possible t

quantitate 5-toxin in isolation, although this appears to have been done in the orig

assay (Otto et al., 1998; Otto et al., 1999). This was only possible because these ot

components are also agr-regulated, as their expression levels decrease in parallel wi

inhibition of 5-toxin expression (as assessed by the HPLC traces). Furthermore, contr

experiments with agr-null strains, RN6911 for S. aureus (Novick et al. 1993) and Tu38

for S. epidermidis (Vuong et al., 2000) (kindly provided by M. Otto) demonstrated tha
these other components as well as 5-toxin are absent from post-exponential phase

bacterial supernatants. This confirms that the other components binding and eluting f
the Pharmacia Resource PHE column are agr-regulated.
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Figure 2.2. 5—toxin Assay with group III cells. The Group III strain, RN8465, was

grown in the presence of differing concentrations of trAIP-II for nine hours, after w

the supernatants were collected. A representative inhibition curve derived from rever

phase HPLC analysis of 5-toxin levels in culture supernatants is shown. Quantitation
5-toxin levels was obtained by integration of peak area from the HPLC trace.
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Development of Reporter Strains through reconstitution of agr signaling in agr-null
host backgrounds
Shuttle vectors containing agrC and agrA under control of the agr-P2 promoter,

along with a p-lactamase reporter gene driven by the agr-P3 promoter, were introduced

into agr-null strains (see Fig. 2.3, and Table 2.1 for bacterial strains and plasmids
was reasoned, based upon prior studies (Ji et al., 1997) that these constructs would
sufficient for signaling to occur in agr-null backgrounds in response to exogenously

added AIP. This was confirmed for the group I and II reporter strains, as shown in Ta
2.2 and by example in Fig. 2.4. Two strains were used in these experiments, RN9222
(CAI-I) and RN9372 (CA2-II), containing the cloned agrCA/pMactamase in the
corresponding agr-null S. aureus strain (the reconstituted strains are provided with

descriptor in the format; CAx-y, which indicates Group x agrC and agrA on the Group y

agr-null background). In both cases, dose-dependent activation of the agr-response was

observed upon addition of the cognate synthetic AIP (for example, see Fig. 2.4), with

EC50 values listed in Table 2.2. No dose-dependent agr-activation was observed in the
control strains, RN9033 and RN9416, which contain the vector alone (for example, see
Fig. 2.4A).

A similar strategy was utilized to construct a reporter strain for group IV, and this

and the group I and II reporter strains were used to characterize bacterial supernata

from the three groups. As shown in Fig. 2.5A, there was no detectable RNAIII activati
in cultures of the group IV reporter strain, RN9371, treated with group I, n, or EI
supernatants (note that 8-lactamase is produced endogenously in group EI cells and

complicates this assay), whereas there was a strong signal in cultures treated with t
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autogenous group IV (RN4850) supernatant. The groups 2 and 3 supernatants inhibited

activation by the RN4850 supernatant, as is usually the case with heterologous AIPs (
al., 1997). The Group 1 supernatant, however, did not inhibit group IV agr activation
RN4850 supernatant. Conversely, as shown in Fig. 2.5B, the group IV (RN4850)

supernatant inhibited agr activation of group II; however, it activated the group I s
approximately 30% of the level seen with the group 1 supernatant. These results were

later confirmed for groups 1 and 2 with synthetic AIPs (see Table 2.3). Lastly, as ea

demonstrated by Northern blotting analysis, group IE agr activation is inhibited by g

IV culture supernatants. Eventually, a group III reporter strain was constructed whic
provides a reliable readout of agr activation by group IE supernatants and synthetic
III (see Methods). This strain was utilized to confirm the above findings with group

supernatants, and to test synthetic AIP-III and other AIPs, including AIP-IV (vide in
and Table 2.3).
This reporter gene assay method has been extended to the study of various other

agr groups (vide infra) and is different from a previously utilized assay (Ji et al.,
Mayville et al., 1999), in enabling an assessment of AIP activity in the absence of

skewing effects of endogenous AIP production. In addition, the previous assay utilize

cells in which the plasmid was genetically unstable, perhaps due to the presence of t
P3 promoters in the cell, one on the chromosome and the other on the plasmid. This
resulted in the generation of promoter-negative mutants, as confirmed by DNA
sequencing of the recovered plasmids (Novick et al, unpublished data), thus rendering
assay unreliable.
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Receptor - H P K
Effector of target
gene expression

F i g u r e 2.3. D i a g r a m illustrating a n e x a m p l e of the t y p e of reporter p l a s m i d
developed to monitor P3 promoter activity in response to added AIPs (Jarraud et al.

2000).

31

A)
•

RN9222(CA1-I)

•

RN9033 (vector alone)

6-1
c
I
Q
O
E

1 2"
>

- 2 - 1 0

1

2

3

4

log cone [ AIP-I ] in n M

B)
G r o u p I Inhibition by AIP-II
60
.£ 50"
^ 40
O
E 30c
£ 20
>
10-1
A A

0log c o n e [ AIP-II ] in n M

Figure 2.4. Synthetic thiolactone peptides are biologically active in reconstituted
strains. S h o w n are representative data for activation (A) and inhibition (B) of the agr
response by synthetic AIPs. Degree of activity based upon 8-lactamase activity is s h o w n
as a plot of V^t (initial velocity) versus peptide concentration. (A) Activation of the agr
response in R N 9 2 2 2 ( C A M ) by AIP-I. T h e R N 9 0 3 3 (vector alone) control is shown. (B)
Inhibition of the agr response in R N 9 2 2 2 (CAI-I) by Group E A I P in the presence of
activating AIP-I at 100 n M .
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Table 2.1. Bacterial Strains and plasmids used for cloning and/or monitoring of
native agr activation
Strains
Comments
References
S. aureus
RN4220

(Novick, 1991)

mutant of 8325-4 that accepts foreign

RN6390b
RN6734
RN6911

(Kornblum et al., 1988)
(Kornblum et al., 1988)
(Novick et al., 1993)

RN7206

(Novick et al., 1993)

RN6607
RN9120

(Ji et al., 1997)

RN8465

(Ji et al., 1997)

Group I prototype
Group I strain, <s)l3 lysogen of 6390b
Group I, RN6390b, with tetM
replacing agr (agr-null)
Group I prototype, RN6734, with tetM
replacing agr
Group II prototype
Group II with tetM replacing agr (agrnull)
Group III prototype

CAI-I (RN9222)

(Lyonetal., 2000)
(Lyon et al., 2000)
(Lyon et al., 2000)

Group IV prototype from U. Minn.,
strain K G , kindly provided by Dr.
Patrick Schlievert
Group IV with tetM replacing agr
(agr-mil\)
RN6911 withpRN7035
RN6607 with pRN7105
RN6911 withpRN7062

CA1-I(RN9365)
CA1-II(RN9366)
CA2-II (RN9372)
CA2-I (RN9367)
CA4-IV(RN9371)

(Lyon et al., 2000)
(Lyonetal., 2000)
(Lyon et al., 2000)
(Lyon et al., 2000)
(Lyon et al., 2000)

RN7206 with pRN7062
RN9120 with pRN7062
RN9120withpRN7105
RN7206 with pRN7105
RN9121 withpRN7107

CA4-I (RN9380)
Group UI reporter (RN9532)
S. epidermidis
RN2375, RN9420, RN9421, RN9422,
RN8111, A T C C , TU3298, TU38 (agrnull)
S. wamerii, RN3178
S. intermedius, RN9423

(Lyon et al., 2000)
(Lyon et al., 2002)
(Lyon et al., 2000)

RN7206 with pRN7107
RN6911 withpRN7131
clinical isolates, and A T C C , Tii3298,
TU38 (agr-null) kindly provided by Dr.
Michael Otto

(Lyon et al., 2000)

E. coli, D H 5 a
Plasmids
pRN7035

clinical isolate
clinical isolate, kindly provided by Dr.
Gerard Lina
cloning strain

(Lyon et al., 2000)

pRN7062

(Lyon et al., 2000)

pRN7105

(Lyonetal., 2000)

pRN7107

(Lyonetal., 2000)

pRN7128

(Lyonetal., 2002)

pRN7131

(Lyon et al., 2002)

Shuttle vector containing only agrP3::blaZ fusion
Shuttle vector containing agrCA-l and
agr-P3::blaZ
Shuttle vector containing agrCA-U and
agr-P3: JblaZ
Shuttle vector containing agCA-YV and
agr-P3::blaZ
pRN7107 modified to include an Aflll
site between the sensor domain and the
H K domain of AgiC
Shuttle vector containing AgrC-III
sensor domain fused to the H K domain
of AgiC-IV, and AgrA-IV and agrP3::blaZ

DNA

RN4850
RN9121
RN9033
RN9416
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Table 2.2. Agr Activation and Inhibition in different genetic backgrounds
Activation E C 5 0 ( n M )

AIP-I

RN9222

RN9366

RN9372

RN9367

(CAI-I)

(CAI-II)

(CA2-E)

(CA2-I)

30 ± 1 0

23 ± 7

AIP-II

30 ± 1 0

28 ± 1 4

Inhibition IC50(nM)*
AIP-l

AIP-II

26 ± 7

90 + 30

135 ± 52

78 ± 1 2

All results were from G-lactamase assays. Errors are quoted as ± S E M , which provides
a smaller error range than from 9 5 % CI.
•

These values were obtained with a constant concentration, 100 n M , of the synthetic
autologous (activating) AIP.
N o detectable activity up to a concentration of at least 10 |±M.
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Figure 2.5. A g r activation and inhibition by culture supernatants. A & B. One-tenth
volume of postexponential phase culture supernatants or C Y broth was added to midexponential phase cultures, growth was continued for an additional 1 hr with shaking at
37°C, and samples were then assayed for p-lactamase by the nitrocefin method. Note that
P-lactamase activity in samples treated with Group EI supernatant (cross-hatched)
represents the endogenous P-lactamase activity released from the group EI strain into the
supernatant and does not represent activation of group IV, as determined in control
experiments without the addition of any cells. Furthermore, there is one instance (panel B )
where the combination of I and IV supernatants results in greater than 1 0 0 % activation of
group I cells, as compared to the value obtained with Group I supernatant alone. This
activation enhancement is thought to result artefactually from p H and/or salt differences
brought about by the addition to the cells of 2/10th volume of supernatant rather than 1/10',th

volume.
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Table 2.3. A g o n i s m a n d A n t a g o n i s m b y native A I P s a n d trAIP-II
Activation ( E C S 0 )

AIP-I

Group
I
30 nM

Group
E

Group
III

(20-50)
AIP-II

Inhibition (IC50)

Group
IV
26 (iM
(23-29 uM)

trAIP-II

62 n M
(50-75)

Group
IE
3nM

(14-45)

(2-5)

Group
IV

30 nM

40 nM

InM

86 nM

(12-140)

(0.7-2.6)

(65-111)

70 n M
(30-150)

(22-31)
AIP-IV

Group
E
25 nM

(10-90)

26 nM

AIP-III

Group
I

6nM
4nM

InM

(3-5)

(0.5-3)

230 n M
(190-270)

4nM

13 nM
(7-40)
260 n M
(95-695)

150 nM
(104-207)

(5-6.5)

(3-5)

150 nM
(90-260)

N o detectable activity up to a concentration of > 1 0 p M .
All results were from 6-lactamase assays. Inhibition values were obtained using the
standard reporter strains for groups I-IV with a constant concentration, 100 n M , of the
synthetic autologous (activating) AIP. Errors are quoted as ( 9 5 % CI). T h e group III
reporter strain includes a chimeric receptor, with the AgrC-EI sensor domain attached to
the AgrC-IV H K domain (see methods). There is no evidence that this would change in
any w a y the behavior of the AIPs on native AgrC-III, as all data support the notion that
the AIPs act only at the level of the sensor domain (see Results).
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Section 2.2 -- Rational D e s i g n of G l o b a l Inhibitors of Virulence

in S. aureus

The development of anti-infective compounds that target virulence, rather than
bacterial growth per se, is a relatively new concept requiring rigorous testing. In the
clinical setting, it is unlikely that the agr grouping of S. aureus clinical isolates will
always be known. Therefore, in order to test the efficacy of agr inhibitors in vivo, it is
important to develop compounds that turn off agr signaling in all strains of S. aureus,
independent of their agr grouping.

Modification of one residue in AIP-II converts an agonist into an antagonist
It was originally observed that an AIP-II analog with alanine in place of
asparagine (N3A) in the tail region was a potent cross-inhibitor but was unable to selfactivate and seemed also unable to self-inhibit (Mayville et al., 1999). Using the newly
developed reporter gene assay in which no endogenous AIPs are produced (vide supra), it
has now been discovered that this peptide is, in fact, an antagonist of self-activation, with
an IC50 value of 180 nM (95% CI, 120-270 nM), as well as an antagonist of group I
activation as previously published (Mayville et al., 1999). These data suggest that a key
molecular determinant of AIP-E-mediated receptor activation resides in the side-chain of
the asparagine residue, and that modification of this residue to alanine still allows for
receptor binding but without receptor activation. This is one of the first AIP analogs
synthesized that has the property of self-inhibition, thus opening the door to the design of
global inhibitors of virulence. The other alanine-modified peptides synthesized
previously have been re-tested in the new reporter strains and the published results
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(Mayville et al., 1999) confirmed. This includes the lack of self-inhibition (up to 5 u M )
by AIP-II analogs in which the remaining amino acids in the tail region and cyclic
portion of the peptide were replaced by alanine, and the complete lack of activation or
inhibition by AIP-E L8A and F9A, suggesting that these conserved hydrophobic residues
in the AIPs may be critical for receptor binding.

Global inhibitors of virulence in S. aureus
It was reasoned that a truncated AIP analog containing only the thiolactone ring
structure with the conserved hydrophobic residues and lacking the activating tail (and
thus the asparagine residue) might be able to bind AgrC but would not have the tail
necessary for activation. This analog would therefore be a good inhibitor not only in a
cross-group manner but also within the same group. Conversion of a receptor agonist into
an antagonist of its autologous group as well as an inhibitor of heterologous groups
would result in a global inhibitor of virulence in S. aureus.
A truncated group II thiolactone peptide (trAIP-II) was synthesized (see Figure
2.6A for structure) and tested for its ability to activate and inhibit the agr-response in
group I, II, III and IV reporter strains. TrAIP-II had no detectable activation activity for
the four groups. Furthermore, the peptide was an inhibitor in the nanomolar range of the
agr-response in all four groups (Table 2.3, Figure 2.6B). TrAIP-II is therefore a potent
inhibitor for all four agr-specificity groups of S. aureus.
The activity of trAIP-II and AIP-E were also tested in alternative staphylococcal
species, using HPLC analysis of 5-toxin production. The results showed weak inhibition
(in the uM range) of S. epidermidis strain, RN2375, by AIP-II and trAIP-E, and strong
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A)

V

trAIP-II thiolactone
IC50 ~ 200-500 n M

/OH

tr AIP-n lactam
IC50 ~ 40 ,uM

B)
40-,

•

trAIP-II

a

trAIP-II lactam

log c o n e [trAIP-II or trAIP-II lactam]
in n M
Figure 2.6. Testing of trAIP-II and trAIP-II lactam for inhibition of group II agr
activation. A ) The structures of trAIP-II thiolactone and trAIP-II lactam are shown,
illustrating the one atom difference between them, colored in red. B) Both AIPs were
tested for inhibition of agr activation in group II cells, using the nitrocefin method to
quantitate the P3 reporter readout. The degree of activity based upon G-lactamase activity
is shown as a plot of Vinit (initial velocity) versus peptide concentration.
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inhibition of agr expression in the S. warnerii strain, RN3178, by trAIP-E, with an IC50
value of 20 ± 12 nM. Thus, trAIP-II represents a significant advance toward the

development of a global agr inhibitor of staphylococci (Lyon et al., 2000). From a dru
development perspective, this compound is relatively small (579 Da) and should be

resistant to exopeptidase cleavage, due to its macrocylization and N-terminal acetyla

However, the compound does suffer from base-lability, due to the thioester linkage, a
putative endopeptidase susceptibility, due to the presence of multiple amide bonds.
To address the first problem of base-lability, the lactam analog of trAIP-II
(Figure 2.6A) was synthesized and assayed. While this lactam analog is completely
stable to base-hydrolysis (no decomposition or hydrolysis was observed by HPLC

analysis after treatment with 0.5 M NaOH for 30 minutes), the compound is dramaticall
less potent (~ 100-fold) in terms of agr inhibition (Figure 2.6B). The dramatic loss
potency of the lactam analog versus the thiolactone analog has been explained in

structural terms by two-dimensional NMR studies of the two peptides in solution (vide
infra). Efforts are underway to develop more potent and stable peptidomimetic
compounds (see Section 2.8).
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S e c t i o n 2.3 - A g o n i s m / A n t a g o n i s m o c c u r s t h r o u g h c o m p e t i t i v e

binding at the sensor domain of AgrC

A high priority of this work involved testing the hypothesis that the AIPs, with
their highly reactive thioester linkage, react covalently with AgrC. Pharmacological

analysis of the AlP-receptor interaction (in collaboration with Dr. Arthur Christopou

yielded insights into this hypothesis and the mechanistic basis of the interaction, a
with providing suggestive evidence concerning the dimeric status of the receptor.

Reconstitution of cross-strain inhibition in the absence of AgrB
As previously demonstrated (Ji et al., 1997), S. aureus culture supernatants inhibit
agr activation in heterologous strains. A prior study using a reporter gene assay in

containing the endogenous agr locus (Mayville et al. 1999), demonstrated that syntheti

AIPs could reproduce these effects. However, the site of action for the inhibition by
peptides was not determined. Although the most likely site seems to be AgrC, the

diversity of sequences among inhibitory peptides and their analogs suggests that some
mechanism other than competitive blocking of activator binding could be responsible.
One possibility would be binding to the putative processing-secretion enzyme, AgrB,

causing interference with production or secretion of the activator. Alternatively, th

peptides could bind to any range of targets on or within the cells and interfere with
agr signaling pathway up- or downstream of AgrC activation.
As was already shown in Figure 2.4B, the new group I reporter strain was
incubated with AIP-I at 100 nM along with various concentrations of AIP-II. AIP-E

inhibits agr activation in a dose-dependent fashion, thus demonstrating that inhibiti
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occurs in the absence of AgrB. Similar experiments were performed with the group II

reporter strain and AIP-I, yielding similar results (Table 2.3). These results, in tw

different agr specificity groups, confirm that AgrB cannot be the target of inhibitio
the new strains lack AgrB.

The agr AC two-component module is necessary and sufficient for group-specific
activation and inhibition
It was asked whether AgrC determines the group-specificity of the AIP response.
This was addressed by testing the two-component module in agr-null host backgrounds

derived from different agr groups. Transfer of the group-specific signaling phenotype

with agrCA would argue against any other group-specific determinant. Accordingly, two

strains, RN9366 (CAI-II) and RN9367 (CA2-I), were tested for their ability to respond

supernatants from agr ± strains, as well as to AIP-I and -II. The identity of the Agr
being expressed on which genetic background is included in the CA nomenclature given
to each strain, where CAx-y stands for group x agrC and agrA on a group y agr-null
background.
The two strains were compared with the appropriate controls, RN9222 (CAI-I)
and RN9372 (CA2-E), which are the normal reporter strains, for activation by post-

exponential phase supernatants from a series of agr ± strains and by the synthetic AI

As illustrated in Figure 2.7, only supernatant from the group II agr wild-type strain
RN6607, was able to activate P-lactamase expression in RN9372 (CA2-E) and RN9367

(CA2-I). In addition, similar EC50 values for activation were obtained for both strai
using AIP-II (see Table 2.2). Analogous results were obtained using RN9222 (CAI-I)
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Figure 2.7. Group II agr Activation in different genetic backgrounds. A
representative example of activation of RN9372 (CA2-E) and RN9367 (CA2-I) by postexponential supernatants collected from Group 1, 2, and 4 agr± cells. Data were

collected as 8-lactamase activity (Viral in mOD/min) and then normalized to percenta
activation.
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and R N 9 3 6 6 (CAI-II): these were activated by wild-type group I supernatants (RN6734)

and not by Group II supernatant or by agr-null supernatants from either group. Moreov
similar EC50 values for activation were obtained for both strains using AIP-I (Table
Therefore, the group-specificity of agr signaling does not depend upon the host
background. Furthermore, the conversion of an agr-null group I strain, RN7206, into a
group II responsive strain, RN9367 (CA2-I), by the insertion of plasmid-encoded group

agrC and agrA (and vice versa), suggests strongly that the group-specificity of the ag
response depends upon the expression of the two-component module containing agrC

and agrA. Since AgrC is a variable transmembrane receptor (Lina et al. 1998) and AgrA

is identical at the protein level in all four groups, it is very likely that the agon
the level of AgrC.
The next question was whether cross-strain inhibition also proceeds through the
AgrC/A two-component cascade. E so, a Group E agr-null strain (RN6607) reconstituted
with Group I agrC and agrA, i.e. RN9366 (CAI-II), should be inhibited by Group E agr+

supernatants or by AIP-II. Alternatively, if inhibition were to involve a group-specif

factor outside of the agr locus, then inhibition would depend upon the host backgroun
which AgrC and AgrA are expressed. The former scenario was shown to be correct, as
very similar IC50's for inhibition by AIP-II in RN9366 (CAI-II) and RN9222 (CAI-I)
were obtained (Table 2.2). The same was true for inhibition of RN9372 (CA2-II) and

RN9367 (CA2-I) by AIP-I, albeit with a slight difference in the IC50's (Table 2.2). I
apparent that inhibition by the AIPs is dependent upon which agrC and agrA genes are
expressed and not upon the genetic background in which they are expressed, thereby
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indicating that the site of inhibition must lie within A g r C, since A g r A is identical at the
protein level in all four groups.

The sensor domain of AgrC determines group-specificity of agonism and
antagonism
AgrC consists of a divergent N-terminal sensor domain, and a conserved Cterminal histidine kinase (HK) domain (Ji et al., 1995; Lina et al., 1998), of which the
former is predicted to contain the determinant of group specificity. To confirm this
prediction, chimeric receptors were constructed (shown in Fig. 2.8) in which the sensor
domain of AgrC from either group I or E was fused to the HK domain of the group IV
receptor (Jarraud et al., 2000). As shown in Fig. 2.9, the chimeric receptors were
activated or inhibited only by AIP-I or AIP-II (from culture supernatants or chemically
synthesized) according to their respective sensor domains, thus confirming the above
prediction. The group I chimera was activated not only by group I supernatant but also
marginally by group IV supernatant, consistent with previous results (vide supra)
(Jarraud et al., 2000). Activation and inhibition titration curves of the chimeric receptors
with synthetic AIP-I or AIP-E yielded curves similar to those for the wild-type receptors
(not shown). As the AIPs appear to activate or inhibit only AgrC, activation or inhibition
of each group will henceforth be referred to according to the group-specific sensor
domain of the activated or inhibited receptor. For example, group II activation will be

referred to as AgrC-II activation, and inhibition of group I activation will be referred to as
AgrC-I inhibition, thus reflecting the mechanistic basis for these processes.
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G r o u p IV A g r C

Group I AgrC

G r o u p II A g r C

G r o u p I chimera

G r o u p II chimera

Figure 2.8. Schematic representation of the sensor-domain-swapped A g r C R H K s .
The Group I and Group II chimeras have the polytopic sensor domains from the Group I
and Group II receptors, respectively, fused to the Group IV receptor HK domain.
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Figure 2.9. Sensor D o m a i n - s w a p p i n g results. A ) Testing of the Group IV receptor with
bacterial supernatants from the four agr groups, collected as previously described (Lyon et
al., 2000). Cross-group inhibition was confirmed by co-incubating cells with AIP-II at 1 u M .
B ) Testing of the Group I chimera with bacterial supernatants from the four agr groups.
Cross-group inhibition w a s demonstrated as in (A). C ) Testing of the Group II chimera with
bacterial supernatants from the four agr groups. Cross-group inhibition was demonstrated by
co-incubating cells with AIP-I at 1 u M . Data were collected as 6-lactamase activity (V,ral in
m O D / m i n ) and are shown ± standard error of the m e a n ( S E M ) . Unless otherwise visible,
error bars are contained within the confines of the border of the bar.
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Activation by the native A I P is reversible
Reversibility of agonist AIP binding to the receptor was analyzed by determining

whether agonism could be reversed by washing or by competition from added antagonist.

As a direct binding assay has thus far not been developed (vide infra), functional as

of ligand binding and release were utilized, in which downstream reporter gene activa

was used as a read-out of upstream ligand binding at the receptor (Lyon et al., 2000).

Such assays are highly sensitive owing to downstream amplification of the binding eve
In these experiments, group I cells were incubated with AIP-I at 1 uM, followed by

washing as indicated in Fig. 2.10A. 6-lactamase activation was monitored and the dat

normalized at each time point. In the standard AIP assay without washing, the agr sys
was activated 25-fold during 180 minutes of incubation. Two washes decreased the

activation to about 10-fold, and five and ten washes variably decreased the activatio

further but never completely eliminated it. Competition experiments were conducted af

two washes by adding AIP-E at 1 \jM to resuspended cells. As can be seen in Fig. 2.10
this completely abolished activation. An analogous experiment was performed with
group II cells, where it was shown that 40-fold activation was reduced to 15-fold by

washes, and was eliminated by addition of AIP-I at 1 uM. Similar results were obtaine
when the truncated AIP-E (trAIP-E) was used as the antagonist of group E activation.
this case, 70-fold activation was reduced to 15-fold with two washes and abrogated
completely by addition of trAIP-II (Fig. 2.10B).
A low level of 6-lactamase activity was consistently observed in all experiments

in the absence of added AIP. To test for the possibility that this might be agr-depen
the basal transcription level of the 6-lactamase reporter gene was monitored in the
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F i g u r e 2.10. Functional binding a n d competition studies. A ) G r o u p I cells w e r e
activated with buffer or AIP-I at a concentration of 1 uM, followed by washes as
indicated. For one set of cells, AIP-E was added after two washes at 1 pM. Data were
collected as 6-lactamase activity (Vinit in mOD/min) and then normalized to an induction
ratio (induced/basal). The data points from the final time point of activation (at 210
minutes) were combined from four separate experiments, and are shown ± SEM. B)
Similar to (A), except that Group II cells were used with AIP-II as the agonist and trAIPII as the antagonist.
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presence or absence of antagonists. Group II cells were incubated for one hour in the
absence of agonist, followed by the addition of buffer, AIP-I or trAIP-II (both at 1 uM)
and monitoring of 6-lactamase activity and cell density over the next three hours. Basal
transcription proceeded at a constant rate per unit of cell mass, and this activity was not
diminished in the presence of antagonists, demonstrating that this basal level is
independent of agr regulation (data not shown).

Cross-group inhibition of agr signaling is reversible
There are a number of possible mechanisms for inhibition by the antagonist AIPs
depending on whether or not the observed inhibition is reversible. If inhibition is
reversible, pre-treatment with antagonist should have no effect on subsequent activation.
However, if inhibition is irreversible, pre-treatment with antagonist followed by washout
should prevent subsequent activation. This was tested by pre-incubation of group I cells
with AIP-II, followed by washing and then challenge with AIP-I. Pre-treatment with the
antagonist versus buffer (followed by washing and then addition of agonist) did not affect
subsequent activation, as the induction ratios for pre-treatment with buffer versus pretreatment with antagonist were 14.8 ± 2.7 and 13.9 ± 2.9, respectively (Fig. 2.11A).
Thus, inhibition is reversible. Varying the time of pre-incubation from 5 minutes up to
one hour (or, in the case of activation, from 30 minutes to one hour) gave results similar
to those observed in the above experiment.
The kinetics of inhibition were analyzed by titration of AIP-E in the presence of
AIP-I. In these experiments, the agonist was added to group I cells five minutes before,
simultaneously, or five minutes after the antagonist, followed by a one hour incubation
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Figure 2.11. Pre-incubation and washing studies. A) AIP-II preincubation, followed
by washing and subsequent activation of Group I cells with a fixed concentration of AIPI. Data were collected as 6-lactamase activity (Vimt in mOD/min) and normalized to an
induction ratio (induced/basal). Data are shown ± SEM, and are derived from several
timepoints (150, 180 and 210 minutes) combined after normalization. B) TrAIP-II
preincubation, followed by washing and subsequent activation with AIP-II of group II
cells. Data were collected as 6-lactamase activity (Viml in mOD/min). Data are shown ±
SEM, and, unless visualized, error bars are within the confines of the symbol.
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period. Under the conditions used in this experiment, the three curves were
indistinguishable within experimental error, with an IC50 value of 281 ± 19 nM, and the
maximal stimulation achieved was the same as that seen with activation by AIP-I alone
(Fig. 2.12A).

Self-inhibition by trAIP-II is also reversible
Since trAIP-E has the same ring structure as the native AIP, it is likely to bind to
the same receptor site. Because this AIP derivative shows self-inhibition, it was
investigated whether its antagonism is reversible, similarly to that of the cross-inhibitory
AIPs. Activation of group II cells by AIP-II over a 60 minute incubation was unaffected
by prior incubation with trAIP-II, yielding indistinguishable EC50 values of 45 ± 5 nM
(Fig. 2.11B). To probe the mechanism of self-inhibition further, inhibition concentrationresponse curves were measured where ADMI was added before, during or after the global
inhibitor. The three inhibition curves were indistinguishable within experimental error,
with an IC50 value for group II inhibition of 244 ± 12 nM (Fig. 2.12B).

Pharmacological analysis of concentration-response curves
Agonist concentration-response curves were generated with increasing
concentrations of antagonist. Shown in Figure 2.13A is an example of this type of
experiment, in which AIP-I was used to activate AgrC-I in the presence of [AIP-E] at 0,
10, 100, and 1000 nM. In this example and in other experiments of this type, the agonist
curves shifted in a parallel, dextral fashion with increasing concentrations of the
antagonist, with no significant effect of the antagonist on the maximum response to the
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m i n u t e s with AIP-II at various concentrations, followed b y addition of AIP-I at a fixed
concentration of 1 0 0 n M , or both peptides w e r e a d d e d simultaneously. In a third instance,
A I P - I w a s a d d e d at a fixed concentration five minutes before titration of AIP-II.
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Similar to ( A ) , except that G r o u p II cells w e r e used, with AIP-II as the agonist a n d trAIPII as the antagonist. D a t a w e r e collected as 6-lactamase activity (Virat in m O D / m i n ) a n d
then normalized to percentage m a x i m a l activation. D a t a are s h o w n ± S E M .
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Figure 2.13. Pharmacological analysis. A ) Group I cells were treated with varying
[AIP-I] in the presence or absence of AIP-II at concentrations indicated as + zero, 10,
100, or 1000 nM. Data were collected as 6-lactamase activity (Vinit in mOD/min). Data
are shown ± SEM. B) Non-linear regression analysis (equation 2 in Methods), showing
the relationship between antagonist concentration and the shift of the agonist
concentration-response curve location parameter (pEC50). Shown on the plot is the
nonlinear curve-fit to the data compiled from four separate experiments. C) Clark plot,
displaying the data from (B) in linear fashion. D) Group II cells were treated with
varying [AIP-I] in the presence or absence of AIP-II at concentrations indicated as + 10,
100, 500, or 1000 nM.
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agonist. Other combinations giving qualitatively similar translocations of concentration
response curves were: group E cells with AIP-E in the presence of differing [AIP-I],
group II cells with AIP-II in the presence of differing [trAIP-II], group I cells with AIP-I
in the presence of differing [trAIP-II], and group I cells with AIP-I in the presence of
differing [AIP-II lactam]. As there is a reciprocal relationship between the AIPs in terms
of activation and inhibition of their respective groups, we also performed the reciprocal
experiment, namely antagonism by AIP-I of AgrC-II activation in the presence of
differing agonist [AIP-II]. Fig. 2.13D shows representative data from two experiments
using a wide range of agonist concentrations. The data show that the inhibition curves
also shift in a parallel, dextral fashion in the presence of increasing (maximallyactivating) concentrations of agonist.
The use of a wide range of antagonist concentrations in multiple experiments
allows for the assessment and quantification of the data according to a model of simple
competitive antagonism (equation below and repeated as equation 2 in Methods), using
nonlinear regression analysis (Lew and Angus, 1995; Christopoulos et al., 2001).
pEC50 = -log([B]5+10pK)-logc
where pECS0 is the negative logarithm of the EC50, [B] is the antagonist concentration, pK
and log c are fitting constants, and s is equivalent to the Schild slope factor.
This method provides greater precision than the standard and older linear
regression method of Arunlakshana and Schild (Arunlakshana, 1959), for the following
two reasons, first, the control curve pEC50 values (i.e., absence of antagonist) are included
in the analysis, increasing the degrees of freedom; second, the data weighting is more
even because the control pEC50 values are treated equally to all other pEC50 values; in
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contrast, the Schild method relies heavily on the determination of the "concentrationratio", which could be overly and incorrectly biased by a poorly defined control agonist
curve. Importantly, an advantage of all analyses based on the method of Schild and its
variants is that the determination of the Schild slope parameter (s in the above equation)
tests the conformity of the data to a competitive model while the pK parameter allows for
the quantification of antagonist potency when the slope is equal to one.
Concentration response curves of Group I cells with AIP-I in the presence of
differing [AIP-II] were analyzed. Fig. 2.13B shows the relationship between antagonist
concentration and the shift of the agonist concentration-response curve location
parameter (pEC50) with data combined from four experiments. Also shown on the plot is
the nonlinear curve-fit to the data. The equation with the variable Schild slope parameter
generated the better fitting curve, as judged by the extra sum of squares test, with a P
value of 0.016. The slope value obtained in this case was 0.55 ±0.14, which is
significantly less than the value of unity seen with simple competitive inhibition. The
results from the nonlinear regression analysis can be displayed in linear fashion in the
form of a Clark plot (Fig. 2.13C) (Stone and Angus, 1978; Lew and Angus, 1995).
Because the data did not conform to simple, competitive antagonism, pKB could not be
estimated. However, an estimate of antagonist potency, pA2, could be obtained (see
Methods), and this value was 8.90.
The Schild slopes, p values and pA2 values obtained from various analogs tested on
AgrC-I or -II are summarized in Table 2.4. It is notable that in all cases tested, the Schild
slope values are considerably less than the value of unity normally seen with simple
competitive antagonism. Thus, the application of a competitive model of agonist-
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T a b l e 2.4. Schild slopes, p A 2 values, a n d E C 5 0 values

G r o u p I inhibition3
AIPs

slope

AIP-II

0.55 ± 0 . 1 4

P value
0.016

pA2c
8.90

Tr d
40 n M
(12-140)

AIP-II L a c t a m

0.71 ± 0 . 0 9

0.012

7.60

155 n M
(75-315)

trAIP-II

0.62 ± 0.05

0.130

6.50

260 n M
(95-695)

G r o u p II inhibition

b

AIPs

slope

P value

AIP-I

0.45 ± 0.09

0.004

pA2c
9.70

IC d
25 n M
(14-45)

trAIP-II

0.55 ± 0.09

0.005

7.50

230 n M
(190-270)

a,b All experiments were performed at least in duplicate, yielding concentrationresponse curves in the presence of at least five different antagonist concentrations.
Curves were generated with either the Schild slope held constant at unity or with the
slope allowed to vary, and the better-fitting model w a s determined by an extra-sum-ofsquares test using P R I S M . In this test, a P value < 0.05 indicates a slope value
significantly less than one. In the case of trAIP-II group I inhibition, the p value w a s
trending toward <0.05.
c T h e p A 2 is an estimate of antagonist potency, irrespective of underlying mechanism,
determined via the relationship, p A 2 = pK/s (Christopoulos et al., 1999).
d T h e IC50 values from bioassays are shown, with their 9 5 % CI in parentheses, for
comparison to the p A 2 values, thus revealing a trend between biological activity of the
inhibitors and their empirical binding estimates.
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antagonist interactions to the data reveals significant deviations from the predictions of
simple competition. As a consequence, estimates of antagonist dissociation constants
(pKB values) cannot be obtained, but empirical estimates of antagonist potency, pA2, are
still possible and at least provide a semi-quantitative basis for comparing antagonist
activities. The pA2 values are consistent in their trend with the IC50 values for inhibition
by various analogs (Table 2.4), albeit with the relatively wide 95% confidence intervals
for the IC50 values (reflecting the inherent sources of error in this assay- see Methods)
and the errors associated with the Schild slope determinations. This provides suggestive
evidence that the differences in IC50 values between these analogs results from decreased
binding to the receptor, rather than from post-binding effects on receptor activation.
On the basis of sequence similarities to other bacterial RHKs that are known to be
dimeric (Stock et al., 2000) along with structural homology modeling (vide infra), it is
very likely that AgrC is also dimeric with two agonist binding sites. Therefore, it is
possible that the competitive interactions of agonist and antagonist at the receptor might
involve cooperativity between the binding sites (see Figure 2.14 for a model of this
process). For example, an allosteric change induced upon binding of antagonist to one
sensor domain in a dimer could inhibit binding of antagonist to the second, in addition to
directly competing with the agonist at the first domain. Such negative cooperativity
between antagonist molecules would make the antagonists appear less potent at higher
concentrations, thus yielding a Schild slope substantially less than 1.0. A similar type of
cooperativity has been observed in the chemotactic aspartate receptor (Koshland, 1996),
which lends indirect support to this hypothesis.

58

Agonist

AIP
Negative

Antagonist

AIP

Cooperativity?

V i r u l e n c e

o n

Figure 2.14. A putative model of AgrC, indicating the dimeric nature or the receptor,

mediated via a cytoplasmic 4-helical bundle and possibly via interaction between the
sensor domains, which themselves each have six transmembrane helices. The
pharmacological data suggest possible allosteric negative cooperativy between the
binding sites in a receptor dimer.

59

A different possible explanation for the observed Schild slopes is the lability of
the thioester bond in the AIPs. It is well-documented that drug-removal mechanisms are a
common cause of Schild slope values less than one (Kenakin, 1997). E the slope values
are artificially low due to AIP breakdown, the agonist-antagonist interaction could
represent simple competitive antagonism after all. However, experiments utilizing the
stable AIP-II lactam analog as antagonist still yielded a slope value significantly less than
one (0.71 ± 0.09). Unfortunately, all available potent agonists contain a labile thioester
bond by necessity, thus making it difficult to rule out definitively drug-removal and/or
other possible explanations. Further studies in this area are focused on confirming the
dimeric nature of the receptor, especially at the level of the transmembrane sensor
domains, and on the continued development of a direct AIP binding assay (vide infra),
which will enable a definitive test of the deviation from simple competitive antagonism
and the determination of its basis.
Ligand binding to a site that is structurally distinct from the primary site can lead
to reversible allosteric modulation of receptor activation. However, in this instance, one
would expect eventual saturation of the allosteric site with increasing concentrations of
the antagonist. Therefore, this sort of allosterism would result in a rightward shift of the
curves similar to competitive antagonism, but, unlike the latter, a maximal shift would be
obtained when the allosteric site becomes saturated (Kenakin, 1997). The concentrationresponse curves in this study were generated in the presence of increasing antagonist
concentrations that spanned a 1000-fold range. In no instance was a maximal, limiting,
shift demonstrated, a finding which is inconsistent with a mechanism of allosteric
modulation from a separate site on the receptor.
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T h e lactam analog of AIP-II is a n agonist at high concentrations
A central question of this research revolved around whether the AIPs bind
covalently to AgrC, given their highly reactive thioester linkage. The above
pharmacology data suggest that a stable covalent linkage does not form between AIP and
receptor, although the data do not necessarily rule out a transient covalent linkage. A
previous study speculated that a stable or transient covalent linkage might occur, as
supported by the inactivity of a lactam analog tested up to a concentration of 10 uM
(Mayville et al., 1999). As the pharmacology data are inconsistent with stable covalency,
the lactam analog was re-tested at higher concentrations. As shown in Figure 2.15 A,
starting at around 10 uM, activation increases linearly with increasing concentrations of
AIP-II lactam. The lactam analog was also tested for its ability to cross-inhibit group I
and IV cells and to self-inhibit group II cells. Potent cross-inhibition was observed, with
an IC50 value of 140 ± 70 nM for Group I and 48 ± 22 nM for Group IV, consistent with
previous results (Mayville et al., 1999). Significant self-inhibition was not detected at any
concentration tested up to 20 uM. These results suggest that the lactam analog binds to its
own receptor extremely weakly, although it binds heterologous receptors quite strongly.
This suggests that activation of AgrC requires very specific AlP-receptor interactions,
while cross-inhibiton does not. This will be addressed further in the Discussion.
The activation seen with the lactam analog was unusual in that the Hill slope of
activation was shallower as compared to AIP-II and a maximal activation level, i.e. a
plateau, was not observed up to the solubility limit of the peptide. Thus, it was uncertain
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Figure 2.15. AIP-II lactam studies A) Group II cells, RN9372 (CA2-E), were incubate
with varying [AIP-II lactam]. The AIP-E concentration-response curve is shown for

comparison. B) Cells expressing Group II agrC-A in an agr-null group I background,

RN9367 (CA2-I), were incubated with the AIP-II lactam analog at various concentrati
in the absence or presence of AIP-I at 0, 100, or 1000 nM. Data were collected as
lactamase activity (V^, in mOD/min) and are shown ± SEM.

62

whether the activation by the lactam analog w a s truly specific to the receptor or a result
of non-specific effects of the peptide at such high concentrations. In order to address this
specificity issue, two variables were investigated. First, if the activation were specific, it
should be inhibited in a concentration-dependent manner by the antagonist, AIP-I. This is
exactly what was observed, as shown in Fig. 2.15B. Second, it has been previously
demonstrated that group-specific activation is independent of strain background (see
above). E the activation seen by AIP-II lactam occurs via the receptor, then it should also
be independent of genetic background. This was indeed the case, as is shown in Figure
2.15B, where activation of RN9367 (CA2-I) cells, similar to that seen with RN9372
(CA2-II) cells, was observed.
Williams and co-workers have recently reported that the AIP-I lactam analog is
also an activator at concentrations higher than 5 uM (McDowell et al., 2001), thus
lending support to the notion that activation by the AIPs does not require the thioester
linkage, albeit with a substantial loss in potency for the lactam analogs and a shallower
Hill slope. This difference in bioactivity between the thiolactone and lactam analogs is
partially explained by dramatic differences in their structures in solution, as characterized

by 2D NMR (vide infra).

Attempts to Detect AIP-I Binding to AgrC-I
As an initial foray into the detection of an AlP-receptor complex, a previously
published pull-down experiment ((Ji et al., 1995) and see Introduction) was re-visited. A
cell line, RN8559, overexpressing AgrC from a 6-lactam inducible promoter (via BlaR
signaling) was utilized to investigate AIP binding (Figure 2.16A&B). As in the previous
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study, different amounts of induced cells were added to a fixed concentration of A I P for
five minutes, followed by spin-down of the cells and recovery of the supernatant. This
supernatant was then assayed on a reporter strain, in this case, the group IRN9222 strain,
for any remaining AIP activity. In this experiment, the AIP was synthetic, rather than
purified from bacterial supernatants, as in the published study (Ji et al., 1995). In
confirmation of previous results, increasing amounts of cells titrated out AIP-I, as
assessed by remaining biological activity (Figure 2.16C). In contrast, attempting to use
the group I reporter strain, RN9222, or agr-null cells, RN6911, did not result in any
titration of AIP-I, indicating that overexpression of AgrC is critical for significant and
detectable AIP-I depletion. An alternative explanation is that treatment of the cell line,
RN8559, with methicillin results in physiological changes to the cell wall that cause
increased uptake or non-specific binding of AIP-I to the cells. According to the previous
study (Ji et al., 1995), the same cell line expressing AgrA alone and also treated with

methicillin did not titrate AIP-I, thus indicating that methicillin treatment is not the cause
of increased AIP-I binding. This control was not repeated in the present study, although it
probably should be repeated in future experiments involving this cell line.
AIP-I was labeled with fluorescein to undertake fluorescence studies of AIP
binding to AgrC-I- cells, RN8559 and RN9222 (Figure 2.17A and vide infra for
biological activity data). However, endogenous and variable auto-fluorescence, with a
maxima near to the fluorescein emission wavelength, of S. aureus cells complicated the
interpretation of the resulting data, as assessed by fluorescence spectroscopy and
microscopy (not shown). SDS-PAGE analysis, followed by in-gel fluorescence detection,
of whole cell lysates from bacterial cultures pre-treated with fluorescein-AIP-I or buffer
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Figure 2.16. A g r C over-expression. A ) A cell line overexpressing A g r C from a plasmid
in response to a 6-lactam c o m p o u n d w a s investigated for use in a direct binding assay. B )
After methicillin induction, the production of B-lactamase from the chromosomal pBIa
promoter w a s monitored as an indirect readout of plasmid pBIa activity, leading to A g r C
over-expression. C ) AgrC-I overexpressing cells (RN8559), agr-null cells ( R N 6 9 1 1 ) and
uninduced AgrC-I expressing cells ( R N 9 2 2 2 ) were titrated with a fixed amount of AIP-I,
followed by spin-down and bioassay of supernatants. Control experiments quantitating
the bioactivity of the same amount of AIP-I in the absence of cells showed little to no
depletion of AIP-I by the addition of the agr-null cells.
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Figure 2.17. AIPs for Direct Binding Assays. A ) The structures of various N-terminally
modified AIPs are shown. A n asterisk :: indicates the site of tritium [3H] incorporation in
acetylated AIP-I. B ) Dose-response curves s h o w activation of group I and inhibition of
group II b y acetylated AIP-I. Similar analyses were performed with the tritiated and/or
otherwise N-terminally modified analogs, yielding similar results, albeit with slightly
different EC50 and IC50 values.
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did not reveal a fluorescent protein of the approximate molecular weight of A g r C , - 5 0
kDa, even though the free fluorescent AIP-I was readily detected and agr-activation of
the AlP-treated cultures (in the case of RN9222) or 6-lactamase induction (in the case of
RN8559, Figure 2.16B) was demonstrated.
Furthermore, biotinylated AIP-I was utilized in efforts to demonstrate covalent
binding of the AIPs to AgrC (Figure 2.17A and vide infra for bioassay data). In cell
lysates of bacterial cultures pre-treated with biotinylated-AIP-I or buffer, no AgrCspecific signal was ever detected via Western blotting with streptavidin-conjugated
horseradish peroxidase, even though parallel experiments demonstrated agr-activation in
the AlP-treated cultures (data not shown). As the receptor, AgrC, was not epitope-tagged
and as all efforts to develop an anti-AgrC antibody have thus far failed (vide infra), it is
formally possible that AgrC was degraded or otherwise absent from the cell lysates,
either before or after SDS-PAGE analysis. However, the lack of detection of a covalent
AlP-receptor adduct by the above methods is consistent with the pharmacology results
demonstrating that the AlP-receptor interaction is reversible.
Efforts were then undertaken to prepare radioactively labeled AIPs for binding
assays with whole AgrC+ cells. Radioiodination of the tyrosine amino acid in AIP-I was
attempted (by B. Ayers and T. Muir); however, this was abandoned due to extremely
facile hydrolysis of the thioester linkage in the AIPs during the labeling procedure (data
not shown). Acetylation in solution of the N-terminus of AIP-I with tritiated acetic
anhydride, followed by hydrophobic column chromatography, produced a pure, tritiated
AIP-I, which was shown to activate agr in group I cells (Figure 2.17A&B and not
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shown). However, whole cell binding assays, utilizing filter binding or cell pelleting
methods, yielded mixed results, mainly due to a high level of non-specific binding of
AIP-I in parallel with low specific activity of the radioligand and unknown receptor
expression levels. For example, in some experiments, binding of tritiated AIP-I to cells
overexpressing AgrC appeared to be greater than in uninduced or agr-null cells (Figure
2.18A&B). This difference was reproducible with uninduced versus induced RN8559
cells. However, the difference between induced RN8559 cells and agr-null RN6911 cells
was not reproducible and, in fact, indicated more binding to RN6911 cells on one
occasion, despite considerable efforts to equalize cell densities between the different
populations. Furthermore, attempts at competition with cold non-radioactive AIP-I or -II
actually increased the amount of tritiated AIP-I bound to the cells (Figure 2.18B), a
result inconsistent with receptor-specific binding of tritiated AIP-I. In binding
experiments comparing agr+ RN9222 cells with agr-null RN6911 cells, no difference in
binding of tritiated AIP-I was ever detected, a result consistent with the pull-down
experiments (vide supra). Successful development of a direct radioactive binding assay
may hinge upon the use of radioligands with much higher specific activities;
overexpression of an epitope-tagged receptor using a metal ion-inducible promoter such
as cadmium, instead of a cell wall disrupting drug like methicillin (which could indirectly
lead to an increase in non-specific binding); and/or enrichment of receptor levels through
the use of bacterial cell membrane preparations or liposomal reconstitution.
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Figure 2.18. W h o l e cell binding assays. A ) R N 8 5 5 9 cells (± methicillin induction and
corrected for cell density differences) were incubated with tritiated AIP-I at 1 u M for 20
minutes, followed by spin-down, washing, and radioactive counting of the pellet. B )
Binding of tritiated AIP-I to induced R N 8 5 5 9 cells was higher than binding to agr-null
cells, R N 6 9 1 1 . T h e same binding experiments with R N 8 5 5 9 cells were conducted with a
ten-minute competition with a large excess of non-radioactive (cold) AIP-I (DI) or AIP-II
(D2). These results are counter-intuitive, as one should expect to observe decreased
binding of radioactive AIP-I in the presence of cold AIP-I (see Results).
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S e c t i o n 2.4 « K e y Determinants of Receptor Activation in the A I P s

AlP-induced receptor activation proceeds through specific, reversible and

extracellularly-mediated AIP binding to the sensor domain of AgrC, followed by recept
activation. A central question therefore revolves around which components (or

determinants) in the AIPs are important for receptor binding and/or activation. Towar

this end, a chemical approach was taken to analyze the AIPs, complemented by a geneti
approach to analyze the receptor (this section and section 2.5). This powerful
combination of chemistry and genetics has yielded new insights into AlP-induced
receptor activation.

Structural independence of tail and macrocycle
Endocyclic (within macrocycle) hydrophobic residues in AIP-II appear to be

important for receptor binding, whereas an exocylic residue (asparagine) is important

receptor activation. It was asked whether these two regions of the peptide are struct

independent. To address this idea, two-dimensional NMR studies of AIP-II, trAIP-II and
alanine-substituted analogs were performed. Fig. 2.19A shows a comparison of the
chemical shift differences (CSDs) of the backbone amide protons of AIP-II alanine
analogs (determined in 90% H2O/10% D20, pH 4.0) relative to the native AIP-II.

Substitution with alanine at any position slightly affects the CSDs surrounding the s
modification, without affecting other regions of the peptide backbone. The trend
exhibited for the amide protons also holds true for the alpha and beta protons (see
Appendix 1 for all NMR chemical shift assignments), thus suggesting that the side-

chains in the tail of AIP-II do not influence the backbone and sidechain structure of
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Figure 2.19.

Chemical shift comparisons of AIP analogs. A ) The backbone amide 'H

chemical shifts of AIP-II alanine analogs are depicted as chemical shift differences
(CSDs) relative to native AIP-II normalized to zero (performed in 9 0 % H2O/10% D20,
p H 4.0 at 298 K ) B ) The backbone amide 'H chemical shifts of trAIP-II thiolactone, AIPII lactam, trAIP-II lactam and the linear free acid version of AIP-II are depicted as
chemical shift differences (CSDs) relative to native AIP-II normalized to zero (performed
inDMSO-d6at298K).
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the macrocycle, and vice-versa. This idea is further supported by the comparison between
AIP-II and trAIP-II (performed in DMSO), which shows no significant CSDs between
the two peptides in the five amino acids that are common between them (Fig. 2.19B). In
these experiments, a CSD > 0.1 Appm was considered significant. These results
collectively suggest that the tail of AIP-E, containing the key asparagine at position 3,
does not stably interact with the macrocycle in solution.
A similar chemical shift comparison between AIP-II, trAIP-II and their lactam
analogs (performed in DMSO) reveals dramatic CSDs (»0.1 Appm) between the thiolactone
and lactam analogs in the amide, alpha, and beta protons of residues within the macrocycle
but not within residues of the tail (Fig. 2.19B, and Table 2.5 for AIPs synthesized), further
suggesting that the tail and macrocycle are structurally independent. Furthermore, these
results demonstrate that the lactam macrocycle has a very different conformation in solution
than the thiolactone, independent of whether the tail is present or not. This dramatic
difference in solution structure is correlated with the much weaker activity of the AIP-II
lactam for AgrC-II activation and the trAIP-II lactam for AgrC-II inhibition (Lyon et al.,
2002) (vide supra). Furthermore, the potent cross-inhibition of AgrC-I by the AIP-II lactam,
as compared to the relatively weak cross-inhibition by trAIP-II lactam, suggests that the tail
of AIP-II is particularly important for AgrC-I binding, especially in the context of a lactam
analog. This is supported by the decrease in potency of the thiolactone trAIP-II in
comparison to AIP-E for cross-group inhibition (see Table 2.6 for IC50 values).
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T a b l e 2.5. A I P s a n d derived analogs

AIPs

exocyclic1

endocyclic

AIP-I

y

S

T ':'' C2

AIP-I D 5 N

Y

s

T

AIP-IV

Y

S

AIP-IV Y5F

Y

AIP-I D 5 A
AIP-I M8I

mass expected

mass observed

D

F

I

M

961.1

960.9

}. c

N

F

I

M

960.1

959.9

T

c

Y

F

I

M

1009.2

1008.9

S

T

c

F

F

I

M

993.2

992.9

Y

S

T

c

A

F

I

M

917.1

916.9

Y

S

T

c

D

F

I

I

943.1

942.9

Acetyl-AIP-I

ac

Y

S

T

c

D

F

I

M

1003.2

1003.0

Biotinylated-AIP-I

bi

Y

S

T

c

D

F

I

M

1187.4

1186.9

Fluorescein-AIP-I

fl

Y

S

T

c

D

F

I

M

1319.4

1318.8

AIP-I linear free acid

•

Y

S

T

c

D

F

I

M

979.1

978.9

tr AIP-I

ac

c

D

F

I

M

651.8

652.0

tr AIP-IV

ac

c

Y

F

I

M

699.9

700.0

trAIP-I D 2 A

ac, ."' c

A

F

I

M

607.8

607.0

;; c

S

S

L

F

879.0

878.9

ac :' c

S

S

L

F

578.7

579.0

S

S

L

F

861.9

862.0

'.; c

S

S

L

F

897.0

896.4

AIP-II

G

V

tt'- A

trAIP-II

G

•v: N

a ,:: X3

AIP-II linear free acid G

v • N

A

AIP-II lactam

AIP-II/I

G

AIP-I/II

,v

•N

A ' ,c

D

F

I

M

951.1

951.0

Y

S\

T ' ;c

S

S

L

F

889.0

889.0

I

,N. '.' c

D

F

L

L

819.0

818.9

Y

1/ •N '; c

D

F

L

L

982.2

981.9

Y

I

N :"" c

D

F

L

L

1053.2

1052.9

AIP-III
AIP-III octapeptide
AIP-III nonapeptide

A

ac: acetylation; bi, biotinylated; fl, fluorescein-conjugated
'exocyclic residues are shaded in the table; 2.M1 of the peptides with a conserved cysteine contain a thiolactone
formed via the condensation of the a-carboxyl group of the AIPs with the sulfhydryl group, except for AIP-I
and -II linear free acid, which have a C-terminal carboxylic acid and a free thiol group;3 X=Dapa:
diaminopropionic acid
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Table 2.6. A I P activity o n the four agr groups of S. aureus

Activation (ECS0)
AIPs
AIP-I

AgrCI
30 nM

AgrCE

(20-50)

"

AgrCIII
~

Inhibition (IC50)

AgrCIV
26 uM
(23-29 \M)

AIP-I
D5N

90 nM
(60-130)

AIP-IV

62 nM
(50-75)

13 nM
(7-40)

10 nM
(1.5-30)

AIP-IV
Y5F

360 nM

30 n M
(20-45)

AcAIP-I

98 n M
(56-173)

trAIPIV

2nM

(7-24)

(1.5-3)

0.2 n M
(0.05-0.3)

30 nM

3nM

5nM

8nM

(3-7)

(4-17)

0.3 n M
(0.2-0.4)

13nM

8nM

(8-20)

(7-9)

60 n M
(50-70)

12 nM
(8-18)

540 n M
(500-590)

190 n M
(150-240)

4.5 u M
(3.5-6 puM)

47 n M
(40-55)

240 n M
(40-1200)

930 n M
(570-1521)

8nM
(6-10)

10 nM
(5-22)

4.1 (jM
(3-5.5 u M )

5nM

5nM

0.1 nM

5nM

(3-7)

(3-8)

(0.03-0.2)

(4-6)

InM

86 n M
(65-111)

730 n M
(640-820)

40 n M
(12-140)

trAIP-II

(0.7-2.6)

(2-5)

260 n M
(95-695)

230 n M
(190-270)

4nM
(3-5)

150 n M
(90-260)

510nM
(360-810)

70 n M
(33-147)

350 n M
(290-420)

9.9 u M
(6-16 u M )

10 nM
(6-15)

230 n M
(140-370)

0.3 n M
(0.2-0.4)

12 nM
(9-15)

70 n M
(30-150)

(5-6.5)

'

AIP-II/I

"
"

AIP-III

20 nM

14 nM

'

AgrCIV

(15-30)

InM

(10-90)

AIP-I/II

(2-5)

(0.5-3)

trAIP-I
D2A

Linear
AIP-II

(14-45)

(3-5)

5.8 u M
(3-10 u M )

AIP-II

AgrCIE
3nM

4nM

Linear
AIP-I
trAIP-I

AgrCE
25 nM
32 n M
(20-50)

(280-450)

AIP-I
D5A
AIP-I
M8I

AgrCI

26 n M
(22-31)

•

6nM

150 n M
(104-207)

The dash ( ) indicates n o activity at arly concentrat ion tested uj:) to at least 10 p M . It is worth
noting that AIPs that are full agonists cannot simultaneously be antagonists.
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Furthermore, chemical shift assignments (in D M S O ) of the linear free acid version of
AIP-II (see Table 2.5 sequence) reveals dramatic CSDs in comparison to AIP-II, thus
highlighting the necessity for the presence and appropriate structure of the AIP-II

macrocyle for potent agonist activity (Fig. 2.19B). Similarly large structural differ
were observed between the linear free acid version of AIP-I and native AIP-I (see
Appendix 1 for chemical shift assignments and Table 2.5 for peptide sequences).
Structural independence was also examined between the macrocycle and tail of AIP-I
and AIP-IV. Two-dimensional NMR was performed on full-length AIP-I and -IV and

compared to their truncated analogs, trAIP-I and trAIP-IV (see Table 2.5 and Appendix

1). The CSDs in the amide, alpha and beta protons were never any greater than 0.3 App

and were in most instances less than 0.1 Appm. This outcome is similar to the case of

AIP-II and trAIP-E, supporting the inference of structural independence. Furthermore,
acetylation of the N-terminus of AIP-I (Table 2.5) only results in local CSDs within
tail, as compared to AIP-I, without causing significant CSDs in the macrocycle.

Probing the Importance of the Macrocycle for Biological Activity
The linear free acid version of AIP-II was previously reported to be biologically

inactive on AgrC-I, -II, and -EI, utilizing the prior bioassay (Mayville et al., 1999)

this previous report, the sample of linear AIP-II was obtained by hydrolysis of a sma

quantity of AIP-E thiolactone, followed by RP-HPLC purification. As this procedure di

not yield enough material for 2D-NMR characterization, the peptide was re-synthesized
using standard Fmoc methods and characterized by NMR (vide supra). Furthemore,
linear AIP-E was re-tested on AgrC-I, -E, and -III, and tested for the first time on
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IV. In n o case w a s agr activation or inhibition observed, up to afinalconcentration of 55
uM, thus confirming and extending the prior results with the new reporter strains. Thus,
in the case of AIP-II, the macrocycle is critically important for biological activity.
It was initially assumed that this result would extend to all of the AIPs examined.
Upon synthesis and testing of linear AEP-I (Table 2.5, 2.6) it was found that this
molecule does not fully activate or inhibit AgrC-I and -IV up to a concentration of 69
uM. However, it does inhibit AgrC-II and -IE activation, with IC50 values in the submicromolar range (Table 2.6). These results indicate that linear AIP-I can bind to AgrCII and -III, most likely through the two C-terminal hydrophobic side-chains. However,
the ICS0 values for inhibition of AgrC-II and -IE by linear AIP-I are at least 20-fold
higher than those values observed for AIP-I thiolactone inhibition. It is very likely that
macrocylization in AIP-I serves the purpose of rigidifying the peptide backbone and
orienting the side-chains, thus increasing binding affinity to the receptor, perhaps through
a decrease in entropic costs incurred upon binding. It is also possible that, in an in vivo
infection, the concentration of hydrolyzed linear AIP-I does not reach concentrations high
enough to cross-inhibit other groups, as the reported concentration of AIPs in culture
supernatants is around 30 nM (Saenz et al., 2000). However, further testing is required to
verify the lack of activity of hydrolyzed linear AIP-I in wild-type strains during the
course of natural infections. In summary, the macrocycle of AIP-I and -E appears to play
an important (if not critical) role in the biologically relevant activity of the ABPs.
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Role of the N a n d C termini, using AIP-I
To probe the steric and electrostatic requirements of the N-terminus of AIP-I in
terms of receptor binding, a series of N-terminally modified analogs were synthesized. Nacetylated AIP-I activates AgrC-I and inhibits AgrC-II and -III with values comparable
to those obtained with native AIP-I (Table 2.6- unless otherwise listed, all activation and
inhibition results are presented in the table, including 95% confidence intervals). Nacetylated AIP-I does not activate or inhibit AgrC-IV at any concentration tested, which
is consistent with the fact that AIP-I only weakly cross-activates AgrC-IV (Table 2.6).
Relatively bulky fluorescein or biotin groups were attached to the free amino terminus of
AIP-I. These additions did not have any major effect on AIP-I function, as both
fluorescein-conjugated AIP-I and biotinylated AIP-I could activate AgrC-I and inhibit
AgrC-II at concentrations comparable to AIP-I in the nanomolar range, with an EC50
value for AgrC-I activation by fluorescein-conjugated AIP-I of 40 nM (22-74 nM, 95%
CI). Thus, the function of AIP-I is not dramatically affected by acetylation or the addition
of bulky groups on the N-terminus, suggesting that the ligand binding pocket can either
accommodate these bulky groups or, more likely, that the N-terminus is solvent exposed.
In other studies, it was tested whether the C-terminal hydrophobic amino acid,
methionine, in AIP-I could be replaced by another hydrophobic amino acid without
affecting function. Therefore, AIP-I with isoleucine replacing methionine at position 8
was synthesized. AIP-I M8I activates AgrC-I as well as native AIP-I (Table 2.6), and
similarly inhibits AgrC-II and -III, as compared to native AIP-I. AEM M8I activates
AgrC-IV more effectively than does AIP-I (730 nM vs. 26 uM), suggesting that this
substitution permits improved binding and/or ligand-induced receptor activation by this
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analog. Lastly, substitution of methionine with leucine in agrD by genetic methods

results in a bacterial strain that autoinduces in a manner similar to wild-type cells

and R.P.N, unpublished observations). These data collectively indicate that the thioe

linkage in methionine is not required for agonist activity, which is inconsistent wit
recent proposal from McDowell et al. that this linkage is critical (McDowell et al.,

Effect of tail length, using AIP-III
The chemical structures of various AIPs have been previously ascertained either

by preparation of synthetic peptides with demonstrated activity or by peptide sequenc
of AIPs purified from culture supernatants by RP-HPLC. The AIPs thus far examined by

these methods include: a heptapeptide from S. lugdunensis (ii et al., 1997), octapepti

from group IS. aureus (Ji et al., 1997), group IV S. aureus (see below), S. epidermidis

(Otto et al., 1999), and a nonapeptide from group IIS. aureus (Ji et al., 1997). The fo
method of synthetic peptide preparation was chosen to verify the sequence of AIP-IE.

Based on sequence similarities to AIP-I and the ability of AgrB from group I or III t

process the group I or EI AgrD propeptide in vivo, it was initially assumed that AIP-

would be an octapeptide (Ji et al., 1997). Accordingly, the octapeptide thiolactone wa

synthesized and shown to have cross-inhibitory activity toward group I cells. However

agr activation of AgrC-IE could not be demonstrated with this peptide (Mayville et al
1999). Indeed, the thiolactone octapeptide turns out to be an antagonist of AgrC-IE
activation by group EI agr+ supernatant, with an IC50 of 360 nM (300-430 nM, 95% CI)
(Fig. 2.20A). Therefore, the octapeptide is clearly not the native AIP-III. The group
thiolactone hepta- and nonapeptides were synthesized according to the group EI agrD
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Figure 2.20. AIP-III studies. A ) Group III cells were incubated with a constant amount
of group IE culture supernatant with varying [AIP-EI octapeptide]. B) Group III cells
were incubated with varying [AIP-III heptapeptide]. Data were collected as 6-lactamase
activity (V^, in mOD/min) and are shown at each concentration ± SEM. Unless otherwise
visible, error bars are contained within the confines of the symbol.
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amino acid sequence. T h e nonapeptide does not activate A g r C - E I up to a concentration
of 2.6 pM and instead inhibits AgrC-III activation by group EI agr+ supernatant, with an
IC50 of 790 nM (480-1310 nM, 95% CI). On the other hand, the thiolactone heptapeptide
is an activator of AgrC-EI, with an EC50 of 26 nM (Fig. 2.20B, Table 2.6). Furthermore,
no additive or inhibitory effects were observed when the heptapeptide was added with
group IE agr+ supernatant to the group EI cells, with the synthetic peptide at various
concentrations up to 60 uM. This suggests that the heptapeptide is likely to be the native
AIP-III.
Further analysis supports this hypothesis, as the heptapeptide mimics what has
been seen with group EI agr+ supernatants, as well as with supernatants from other
groups (Ji et al., 1997). It does not activate AgrC-I, II, or IV at any concentration tested
up to 30 pM and instead inhibits their activation (Table 2.6). Furthermore, AIP-I, -II, and
-IV inhibit AgrC-III activation by the heptapeptide (Table 2.6). The fact that the
thiolactone heptapeptide corresponds to the native AIP-EI is further supported by tandem
mass spectrometry analysis performed on group III culture supernatants indicating the
presence of the heptapeptide (vide infra). The fact that the addition of amino acids onto
the N-terminus of AIP-III abolishes activation of AgrC-EI, but that the addition of
functional groups onto the N-terminus of AIP-I has little effect on its activity, indicates
that the N-terminus plays different functional roles in the AIPs thus far examined. This is
indicated in Figure 2.21, where the N-terminus of AIP-IE is marked with an asterisk to
denote its importance for agr activation.
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AIP-I

AIP-II

AIP-III

AIP-IV

Figure 2.21. Structure and key determinants of the AIPs. Standard single letter codes
for amino acids are indicated. The sulfur atom of the cysteine and the carbonyl
contributed from the C-terminal amino acid are shown in a thioester linkage, which

closes the macrocycle. Exocyclic (tail) residues are represented in shaded grey circl

whereas endocyclic residues are represented in clear circles. Residues that are criti

receptor activation are marked with an asterisk (*). The N-terminus of AIP-III is mar

with an asterisk (*), to reflect the fact that additional amino acids on the N-termin
abolish receptor activation.

Activity of AIP-IV
Several laboratories have identified a new group of S. aureus strains, designated

group IV (vide supra) (Jarraud et al., 2000; McDowell et al., 2001; Otto et al., 2001)
Group IV agr+ supernatant activates RNAIE expression in group IV strains and the P3

promoter in a group IV reporter strain, while inhibiting agr expression in group E an
strains (vide supra). Furthermore, group IV agr+ supernatant activates group I cells

(Jarraud et al., 2000) and also activates to a similar extent a chimeric receptor, in
the sensor domain from AgrC-I is fused to the HK domain from AgrC-IV (vide supra)

and (Lyon et al., 2002). Such data indicate that AIP-rV is a cross-activator of AgrC-I

However, it has recently been reported that the synthetic octapeptide AIP-IV (sequenc
shown in Fig. 2.21) is an inhibitor of group I agr expression, with an IC50 of 7 uM,
than a cross-activator (McDowell et al., 2001). McDowell et al. suggested that the
difference in activity between the synthetic AIP-IV and bacterial supernatants could
accounted for by the presence in the supernatant of other components capable of
influencing agr expression. As there is no other known extracellular signal that has

reproducibly confirmed to activate the agr system (Novick, 2000), it would be importan

to confirm the existence of such a factor, if it does exist. Accordingly, the octapep
thiolactone AIP-rV was synthesized and assayed in the absence of group IV culture
supernatant.
Synthetic AIP-rV is an activator of AgrC-IV and -I, with EC50 values in the

nanomolar range (Table 2.6). Synthetic AIP-IV is, as expected, an antagonist of AgrC-

and -III activation. Conversely, both AIP-II and AIP-III inhibit AgrC-IV activation b

AIP-IV (Table 2.6). The above results mimic the activity previously seen with group I
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agr+ supernatant (Jarraud et al., 2000; L y o n et al., 2002), providing strong evidence that
the octapeptide thiolactone corresponds to the native AIP-IV. This is also consistent with
tandem mass spectrometry analysis performed on group IV culture supernatants, which
has indicated the presence of the octapeptide (vide infra). Since the activity of the
synthetic AIP-IV mimics that of culture supernatants, this strongly suggests that there is
no additional factor in group IV culture supernatants activating group I cells, and
confirms that AIP-F/ can cross activate AgrC-I. It is noteworthy that McDowell et al. did
not report whether their synthetic AIP-IV activates group IV cells (McDowell et al.,
2001). Furthermore, none of their peptides were characterized by two-dimensional NMR,
thus making it impossible to verify that their peptides are identical to the ones reported
herein. This is particularly important, as it is well-known that the synthetic methodology
utilized by McDowell et al. to prepare their AIPs can promote C-terminal epimerization
(Goodman and McGahren, 1967, Nakayama et al., 2001) (vide infra concerning synthesis
of lactone AIPs).

Probing the critical side-chain differences between AIP-I & -IV
AIP-I and AIP-IV differ by only one amino acid: an endocyclic aspartate versus
tyrosine in AIP-I and -IV, respectively (Figure 2.21). As shown above, the amino acid at
this position profoundly affects the properties of the peptide, as AIP-I strongly activates
AgrC-I but only weakly activates AgrC-IV, whereas AIP-IV strongly activates both. This
contrasts with AIP-II, where substitution of this position by alanine (AIP-II S6A) did not
result in any major change in bioactivity (Mayville et al., 1999). This prompted structureactivity relationship studies of this critical residue in AIP-I and -IV to determine what
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role it plays in ligand-receptor binding and/or activation (Fig. 2.22, Table 2.6). Initially,
this residue was replaced with alanine. This peptide, abbreviated AIP-I D5A, does not
activate AgrC-I or -IV at any concentration tested (up to 10 uM), and instead potently
inhibits activation of both receptors (Table 2.6). The inhibition of AgrC-I by this analog
is consistent with the results on group I cells obtained by McDowell et al. using the same
analog (McDowell et al., 2001). AIP-I D5A is also as potent as AIP-I and -IV in
inhibiting AgrC-II and -IE (Table 2.6), thus resulting in universal inhibition of all four
agr groups. Thus, replacing the relatively bulky side-chain at this position with an alanine
methyl group has little to no effect on receptor binding but switches the peptide from an
agonist into an antagonist.
To probe the role of this position further, more subtle modifications were
introduced. Substitution of the AIP-IV tyrosine with phenylalanine (Y5F) had no effect,
as the peptide was similar to native AIP-IV in its activation/inhibition activities (Table
2.6), suggesting that the polar hydroxyl in tyrosine at position 5 is not required for
bioactivity. In the case of AIP-I, the aspartate side chain is expected to be deprotonated at
physiological pH, thus generating a negative charge at this position. In order to test
whether a negative charge is required, we introduced an asparagine residue at this
position. AIP-I D5N activates AgrC-I with an EC50 value only slightly higher than that of
AIP-I (Table 2.6), thus demonstrating that the negative charge of the aspartate side-chain
is not essential for AgrC-I activation. In contrast to AIP-I, AIP-I D5N does not activate
AgrC-IV at any concentration up to 50 uM and instead inhibits AgrC-IV and AgrC-E
activation (Table 2.6). Remarkably, AIP-I D5N does not inhibit AgrC-III activation by
AIP-III, but rather activates group IE cells, with an EC50 of 360 nM (Table 2.6). This
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example is the only case to date of conversion of an inhibitory A I P into an activator. All
other previous substitutions have either inactivated the peptides or converted them from
activators into inhibitors.
AgrC-EI activation by AIP-I D5N was investigated further. As the functional
readout for AgrC-IE activation is comprised of the sensor domain of AgrC-IE fused to
the HK domain of AgrC-IV, upstream of AgrA-IV and including the P3-6/aZ reporter
gene cassette (see Methods and vide supra), it was important to confirm that the
activation by AIP-I D5N proceeds through this chimeric receptor. Therefore, in analogy
with earlier receptor-swapping experiments, the plasmid containing the chimeric AgrCIII and other elements was moved onto different genetic backgrounds. As shown in
Figure 2.23A, AgrC-III is activated by AIP-III and AIP-I D5N regardless of receptor
expression in different group-specific genetic backgrounds, with ADAIE acting as the
more potent agonist. However, the AIP-I D5N-mediated AgrC-IE activation is highly
resistant to inhibition by the known inhibitors of AIP-III mediated AgrC-EI activation,
e.g. AIP-I and AEMI (Figure 2.23B). Furthermore, the self-inhibitor, AIP-III
octapeptide, is also a very weak inhibitor of AgrC-III activation by AEM D5N, and it
furthermore appears that inhibition by all 3 AIPs occurs at approximately the same high
concentrations, which could represent non-specific inhibition. This profile is clearly
distinct from that observed with competitive inhibition of AIP-EI mediated AgrC-IE
activation, suggesting that activation of AgrC-IE by AEM D5N could be occurring
through a non-competitive mechanism. This activation most likely occurs through the
sensor domain of AgrC-IE, as it occurs regardless of the genetic background in which
AgrC-III is expressed and all AIPs thus far tested have acted through extracellular
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binding to the sensor domain of A g r C . However, further studies are needed to prove this
rigorously and to elucidate the mechanistic basis of activation by this analog.
Lastly, it was tested whether modification of the side-chains of AIP-I and AIP-IV
could affect the structure of the macrocycle, which might alter biological activity. Twodimensional NMR chemical shift assignments confirmed the presence of the correct
substitutions and demonstrated that the amide and alpha protons of AIP-IV Y5F and AIPID5N were not significantly different from those determined for AIP-IV and AIP-I,
respectively (< 0.1 Appm differences at all positions). In the case of AIP-I D5A,
comparison of the chemical shifts to those of AIP-I revealed no significant differences,
except at position 5, where local effects from the alanine substitution were observed.
Thus, these substitutions have little effect on the backbone structures of the peptides in
solution (see Appendix I for all chemical shift assignments).

Properties of trAIP-I & trAIP-IV
The endocyclic position 5 in AIP-I and -IV is a key determinant for AgrC-I and
-IV activation, respectively, whereas the exocyclic position 3 in AIP-E is a key
determinant for AgrC-II activation (Lyon et al., 2002). Removal of the tail of AIP-E and
thus removal of position 3 converted AIP-E into an antagonist (Lyon et al., 2000).
Therefore, removal of the tail in AIP-I might produce a peptide retaining activating
activity. Accordingly, an AIP-I derivative (trAIP-I) was synthesized, in which the tail
was replaced by an acetyl group (Table 2.5 and 2.6). This expectation seems to have
been realized, at least in part, as this peptide by itself activates AgrC-I very weakly at
high concentrations but also inhibits AgrC-I activation by AIP-I, with EC50 and IC50
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values that are not significantly different from one another (Table 2.6). This
concentration-dependent inhibition by trAIP-I reduces AgrC-I activation by AIP-I to the
maximal activation observed with trAIP-I alone (Fig. 2.24A). A ligand with decreased

efficacy of activation is defined as a partial agonist (Pliska, 1999), and it is the first time
that such a ligand has been characterized in a bacterial signaling system (to the
knowledge of this author).
TrAIP-I neither activates nor inhibits AgrC-IV at any concentration up to 44 uM,
indicating that it most likely does not bind AgrC-IV. Therefore, the very weak activity of
full-length AIP-I on group IV cells is abolished completely by removal of the tail. The
fact that trAIP-I is a partial agonist only at very high concentrations for AgrC-I and no
longer activates AgrC-IV at the highest concentration tested suggests that the tail
contributes to receptor binding and/or activation in both instances, but that the
macrocycle itself can partially activate AgrC-I. TrAIP-I inhibits AgrC-II with similar
potency to AIP-I (Table 2.6) and more weakly inhibits AgrC-EI as compared to AEM
(240 vs. 3 nM). Therefore, removal of the tail has little effect on cross-inhibition of
AgrC-E but does affect the potency of AgrC-III inhibition.
A truncated version of AIP-1 D5A was also tested to determine whether the loss
of activity by the substitution also resulted in a loss of partial agonism. This peptide,
abbreviated trAIP-I D2A, has no detectable AgrC activation activity and is a strong
inhibitor of activation of all four AgrC's (Table 2.6, and Fig. 2.24B for group IV
inhibition). This result underscores the key role of the amino acid at position 5 in AIP-I
for AgrC-I activation.
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Since the same critical activating residue occurs in AIP-IV, a truncated version of
this peptide was synthesized and tested. Activation by trAIP-IV (Table 2.5 and 2.6) was
undetectable up to its solubility limit (-10 uM) and it was a weak, though complete,
inhibitor of both AgrC-IV and -I, with IC50 values of 4.1 uM and 930 nM, respectively
(Fig. 2.24B, Table 2.6). Thus, partial agonism by trAIP-IV could not be detected and
seems unlikely since it inhibits AgrC activation completely. Lastly, trAIP-IV is an
inhibitor of AgrC-E and -EI activation in the low nanomolar range (Table 2.6),
suggesting that removal of the tail has little effect on cross-inhibition by trAIP-IV.
The partial agonism seen with trAIP-I again contrasts with a recent study, which
reported that trAIP-I is solely an inhibitor of AgrC-I (McDowell et al., 2001). This
discrepancy can be explained by the fact that McDowell et al. utilized a cell line
producing endogenous AIP-I for their bioassay, which might impede the observation of
partial agonism by trAIP-I.

Properties of chimeric AIPs
In an attempt to analyze further the remarkable differences between AIP-II and
-I/-IV with respect to critical residues, chimeric peptides were prepared in which the tail
of AIP-II was attached to the macrocycle of AIP-I and vice-versa. If the macrocyle from
AIP-I binds to AgrC-II in a similar orientation to that of AIP-II, then one might expect
that this chimeric peptide, designated AIP-E/I (Table 2.5) might be able to activate
AgrC-II. However, a different orientation of binding would most likely result in
inhibition of AgrC-II activation. This idea was tested, which yielded the latter result, as
AIP-II/I, inhibits AgrC-II activation (Table 2.6). Furthermore, AIP-E/I also contains the
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key endocyclic residue for AgrC-I activation, aspartate, within its macrocyle, and the
macrocyle alone (trAIP-I) is a partial agonist for AgrC-1. However, AIP-E/I does not
activate AgrC-I at concentrations up to 20 uM, and instead fully inhibits AgrC-I
activation (Table 2.6). Therefore, addition of the tail from AIP-II to the macrocycle of
AIP-I increases its inhibitory potency relative to trAIP-I and eliminates partial agonism
by this analog. Finally, AIP-II/I inhibited AgrC-EI and -IV activation, with IC50 values of
350 nM and 9.9 uM, respectively, which compares to IC50 values of 240 nM and > 44
uM for inhibition of AgrC-EI and -IV by trAIP-I. This outcome suggests that addition of
the AIP-II tail to the AIP-I macrocycle increases its affinity for binding to AgrC-IV while
having no effect on binding to AgrC-III.
The reciprocal chimera, AIP-I/II, in which the tail from AIP-I was fused to the
macrocyle of AIP-II (Table 2.5), inhibits AgrC-I, -II, -EI, and -IV activation (Table 2.6).
Comparing these IC50 values to those for trAIP-II (Table 2.6) suggests that the addition
of the tail of AIP-I to the AIP-E macrocycle increases affinity for AgrC-I, -IE, and -IV
relative to trAIP-II without increasing the affinity for AgrC-II. The lack of activation by
this analog was expected, as it possesses neither of the residues from AIP-I or -II critical
for activation.
Lastly, chemical shift mapping was utilized to determine whether the structure of
the swapped macrocycles and tails in the chimeric AIPs changed as a result of fusing two
different group-specific segments together. Two-dimensional NMR chemical shift
assignments demonstrated that the amide and alpha protons of the macrocycles of AIPI/II and AIP-E/I were not significantly different from those determined for AIP-II and
AIP-I, respectively (Figure 2.25). In addition, the amide and alpha protons of the tails of
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AIP-I/II and AIP-E/I were not significantly different from those determined for AIP-I and
AIP-II, respectively (Figure 2.25 and see Appendix 1 for chemical shift assignments).

This further supports the inference of structural independence of tail and macrocycle
suggests that the tails and macrocycles of the chimeric AIPs can assume similar
structures to the segment of the native AIPs from which they are derived.
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S e c t i o n 2.5 -- C h i m e r i c s e n s o r d o m a i n s

localize t h e A I P -

Binding Site (in collaboration with Jesse Wright)
The close homology and asymmetric cross-reactivity between AgrC-1 and AgrC4 for their cognate AIPs initially prompted an examination of sensor domain chimeras

between these two receptors. This is to be distinguished from previous experiments in
which entire sensor domains were swapped onto the same HK domain. A suggested

topology and homology model for AgrC, illustrating the breakpoint for construction of
the chimeras, is diagrammed in Fig. 2.26. The group IV HK domain is common to all
chimeric sensor domain receptors. Chimeras are therefore designated as N::C, where N
represents the N-terminal and C the C-terminal region of the sensor domain (and the
common group IV HK domain is left out of the nomenclature). Paranthetically, one

inspiration for the construction of chimeric receptors and their pharmacological anal
with various peptide analogs came from an extensive body of literature on hormonal
signaling via G-protein coupled receptors (GPCRs) ((Unson, 2002) and references
therein).

Localizing the Binding Site
Initial studies focused on chimeric sensor domains between AgrC-I and -IV, as

these receptors share 87% identity. The AgrC-IV::I chimera was activated upon additio

of either AIP-I or AIP-IV (Table 2.7, Fig. 2.27A,B). However, AIP-I was a more potent
activator than AIP-IV on the AgrC-IV::I chimera (Table 2.7). The AgrC-I::IV chimera
responded in an analogous but reverse fashion (Table 2.7). Again, both AIP-I and

95

identity
o
AgrC-I and IV

AgrC-I. Ill
and IV

o
AgrC-I arid III

o

AgrC-IV and III

chimeric Junction

outside

Q?9

signaling fl|7#
domain .—.w 7

Cytosolic side

signaling domain

T
N

blaZ

R
AgrC-l::IV

agrC
1 1
P
1A
sensor domain
IV
I

agrA
T
s

AgrC-IV: :l IV
AgrC-IV::ll. IV
AgrC-1 .III I
AgrC-III::! III
AgrC-lll::IV III
proximal
subdomain

distal
subdomain

Figure 2.26. Topology a n d H o m o l o g y m o d e l of A g r C . A ) T h e putative topology of A g r C
is shown, with six transmembrane helices as predicted by bioinformatics and sequence
alignment of multiple AgrCs. T h e highly conserved breakpoint (or chimeric junction) for the
construction of chimeric sensor domains is shown with an arrow. The conservation of amino
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unique between all three receptors are marked as such. B ) Cloning strategy. At top is a
diagram of the a g r C A reporter construct using blaZ transcriptionally fused to the P3
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each case, the recombinant a g r C gene was cloned to the reporter construct replacing the
receptor domain-encoding region of the native gene. Chimeras involving AgrC-II were also
constructed but were essentially inactive and are not presented.
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activity based upon 6-lactamase activity is shown as a plot of Viml (initial velocity
%Maximal Activation versus peptide concentration.
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Table 2.7 - A I P activity on chimeric sensor domain receptors
Activation (EC50)
AgrCI:IV
AIP-I

AIP-II

AgrCIV:I

AgrCIII.I

+
1220 nM

++
30 nM

+
1700 nM

(1050-1410)

(15-45)

(1500-1900)

i

-

-

+

— ';

— -'•

—

—

'..'••. ~: '"'.'

AgrCIII:IV

'

AIP-III

—

AIP-IV

++
6nM

340 nM

(5-7)

(290-410)

-'

—

AIP-I
D5N

Inhibition (IC50)

AgrCI:IV

AgrCIV:I

AgrCIII:I

+

+

+

+

++

++

AgrCIII:IV
+

++

+
120 n M
(110-125)

++
440 nM

.....'—'

++

++

++
"

(350-530)

trAIP-II

-

, -

+

++

+

++

++, low n M activity, +, low p M activity, , no activity up to at least 10 uM. The EC50
values are shaded grey. No IC50 values are given because different AIPs at different

concentrations were used as agonists for the chimeric receptors, thus making comparis
between them meaningless. This was done because some chimeric receptors, i.e. 111:1V

and ELI, require relatively high concentrations of agonist to activate them. In all c

the most potent agonist for a given chimeric receptor was used as the agonist in inhi
analysis.
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AIP-IV activated AgrC-I::IV, but AIP-IV was more potent than AIP-I (AIP-I in the u M

range and AIP-IV in the nM range). Thus, the potency for activation for both AIP-I & I

appeared to be associated with the C-terminal region of the sensor domain. Additional

the activation of AgrC-I::IV by AIP-I represents a gain of receptivity by the chimera

comparison to the native AgrC-IV. The AgrC-I sequence at the N-terminus is most likel

responsible for this effect. Interestingly, most of the sequence divergence between A

I and AgrC-IV lies in this N-terminal region, which leads to the conclusion that AIP-

must be interacting with both subdomains of AgrC-I::IV. Moreover, both AgrC-IV::I and
AgrC-I::IV were inhibited by the heterologous AIPs E & EI, as well as by trAD°-E, a

global inhibitor (Lyon et al. 2000), suggesting that these chimeric receptors retain t

functional characteristics and overall specificities of native AgrCs I & IV (Table 2.
To investigate further the location of the AIP binding site for AgrC-I and AgrCIV receptors, chimeras were constructed in which the N-terminal sensor subdomain was
replaced with that of the less closely related AgrC-IE receptor (AgrC-I and AgrC-IV
share approximately 54% identity with AgrC-III in the receptor domain). The AgrC-EL:I

chimera was activated only in response to AIP-I, and the AgrC-EL:IV chimera responded

positively only to AIP-rV (Table 2.7, Fig. 2.27E,F). These responses were inhibited b
AIP-II, and neither chimera was activated by AIP-IE (Table 2.7). Activation of AgrCIII::! and AgrC-IE::IV required rather high concentrations of AIP-I and AIP-IV

respectively (in the low uM range), as compared to AgrC-I, -IV and the -L:IV and -IV::I
chimeras (activation in the nM range). Moreover, neither AgrC-EI::I and AgrC-III::IV

showed cross-activation with the opposite AIP, i.e. AIP-IV and -I, respectively (Tabl

2.7, Fig. 2.27E, F). In fact, AIP-IV inhibited activation of the IE::I chimera by AIP-
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AIP-I inhibited activation of the EL.IV chimera by AIP-IV (Table 2.7). In other words,
the potency of activation by AIP-IV and AIP-I of AgrC-I::IV and AgrC-IV::I,
respectively, was greatly decreased by replacement of the N-terminal moiety with the
corresponding region of AgrC-IE, perhaps due to the loss or gain of binding contacts
with the N-terminal subdomain. Furthermore, the AgrC-III N-terminal subdomain either
directly or indirectly influences the binding orientation of AIP-I and AIP-IV on AgrCL:IV and AgrC-IV::I, respectively. This different binding orientation converts them into
inhibitors of receptor activation. These results confirm that the specific contacts
necessary for AIP-I & TV activation reside in the C-terminal half of the receptor sensor
domain, but suggest that the N-terminal sensor subdomain has an important functional
role.

Orientation of AIP binding to the receptor.
Since activation by AIPs I & IV is associated with sequences in the C-terminal
subdomain of the receptor, it is clear that this region plays the prominent role in
imparting potency for AIP I and IV activity. Moreover, the only difference between AIPI and AIP-rV is at position 5, located within the AIP ring. This variable position is
responsible for i) asymmetric activation of AgrC-I & IV, ii) differential activation of the
AgrC-IV::I and -L:IV chimeras by the two AIPs, and iii) specificity of activation of the
AgrC-III::I and -EL:IV chimeras. This suggests that the AIP moiety responsible for
interaction with the C-terminus of the receptor is the ring (or macrocycle) rather than the

linear tail.
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Further support for this concept was provided by an assessment of the activity of

the AIP-I D5N analog. This analog activates AgrC-I but is a potent inhibitor of AgrC-

rather than a weak activator, suggesting that the side chain at position 5 is crucial

determining cross-activation specificity for AgrC-IV (see above Results). When assesse

against the chimeric receptors, AgrC-L:IV and AgrC-IV::I, the activity of AIP-I D5N wa

identical to its activities with native AgrC-I and AgrC-IV: AIP-I D5N activated AgrCIV::I and inhibited AgrC-L.TV (Fig. 2.27C, D), again focusing attention on the

macrocycle :C-terminal sensor subdomain interaction as the determinant of AlP-recepto
specificity for AIPs I & IV. However, the N-terminal subdomain plays an important

accessory role in this activation, as neither of the chimeric receptors, AgrC-IE: :I a

AgrC-III: :IV, is activated by AIP-I D5N, but, rather, their activation by AIP-I and A
IV, respectively, is inhibited by AIP-I D5N. Therefore, AIP-I D5N binds to these
receptors but must fail to make specific contacts necessary for activation, and this

can be attributed to the N-terminal sensor subdomain of AgrC-IE. Failure to make thes

contacts could also be responsible for the relatively high concentrations of AIP-I an

AIP-IV required for activation of the AgrC-EI::I and AgrC-III: :IV chimeras, respectiv
The above results imply that both AIP-I D5N and AIPs I & IV can provide

activating contacts with the AgrC-IV::I chimera and the native AgrC-IV since the AgrC
IV N-terminal sensor subdomain is more closely related to that of AgrC-I than is the
terminal sensor subdomain of AgrC-IE. With the native AIPs I & IV, weakened contacts
with the AgrC-III: :I and AgrC-EI::LV chimeras can be compensated by high
concentrations of agonist; these weakened contacts are presumably not present upon
binding of AIP-I D5N, no matter how high the concentration. Instead, AIP-I D5N binds
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strongly to the AgrC-LLV, AgrC-EI::I and AgrC-III: :IV chimeras, but does so with a
binding orientation that does not provide activation contacts but rather competitively
antagonizes activation by known agonists. In any case, it seems that one or more of the
contacts necessary for activation of AgrC-IV::I & L:IV by AIPs I & IV must be missing
in the AgrC-IE: :I & IIL:IV chimeras. This is supported by the complete lack of agonist
activity of the AIP-I D5A alanine analog (not shown), which has been previously shown
to be a universal inhibitor of agr activation (Lyon et al. 2002). These observations lend
further support to the idea that the N-terminus of the receptor has an important role in
AIP binding for activation.
A comparison of AIPs I & IV with IE suggests that it is the tail moieties that are
responsible for the discrimination between these AIPs by the N-terminal sensor
subdomain of AgrC-EI. The AIP-EI tail is conspicuously different from that of AIPs I &
IV, containing only two residues, both of which differ from those of AIP I/TV. It has been
previously established that the AIP tail plays a significant role in receptor activation, as
addition of a single amino acid to the AIP-III tail converts this peptide into an AgrC-EI
inhibitor (see Section 2.4) The effect of the AgrC-IE N-terminal sequences and the
different length and amino acid requirements of the AIP-III tail for activation could
indicate that it is the tail sequences of AIPs I, IV, and D5N that fail to make effective
contacts with the N-terminal subdomain of the AgrC-IE::I and III:IV chimeras. With the
native peptides, the macrocycle contacts with the cognate C-terminal subdomains plus
higher AIP concentrations are presumably sufficient to activate the III::I or IE::IV
chimeric receptors in the absence of the putative tail contacts (activation of AgrC-III::I
with AIP-I and AgrC-EL:IV with AIP-P/); however, these contacts must not be
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sufficient when macrocycle contacts with the C-terminus of the receptor domain are
suboptimal or when these contacts change the binding orientation of the AIP so as to
break possible activating contacts, as with AIP-I D5N (Lyon et al. 2002).
The foregoing argument is clearly an oversimplification since it does not begin to

account for the inhibitory behavior of various AIPs and the general properties of sev

other chimeras. In particular, as shown in Table 2.7, AIP-IE is a strong inhibitor of
AgrC-III::I and AgrC-IV::I, a poor inhibitor of AgrC-IE::IV and has no detectable
activity on AgrC-L:IV up to a concentration tested of at least 10 pM. AIP-I D5N is a
potent inhibitor of AgrC L:IV, IE::IV and, as noted, EI::I. Additionally, D5A is a

universal inhibitor of AgrC activation, and an AIP-I analog without the tail (truncat
AIP-I) inhibits AgrC-I and AgrC-III but not AgrC-IV.
During the course of this study, other chimeras, L:EI, IV::EI, II::III, IE::E, L:II

and II: :I, were constructed using the same break junction. No activity could be dete

with the last three of this set of six; it is not known whether these are expressed a

inserted into the membrane. The other three were functional, but mostly in strikingly

unpredictable ways. The E::EI chimera was activated by AIP-II and AIP-rV at very high

concentrations, but not by AIP-IE or -I (not shown). Even more striking was the behavi
of the L:IE and IV::IE chimeras. As shown in Table 2.8, both of these chimeras were

strongly activated by most of the AIPs tested. This included not only AIP-III, but al

AIPs I, E, and IV, which are strong inhibitors of AgrC-EI (Mayville et al. 1999), AIPD5A and truncated AD°-E (trAIP-E), which are strong inhibitors of all four AgrCs

(Mayville et al. 1999, Lyon et al., 2000), and even linear AIPs I and II, which have n

103

Table 2.8 - A I P p r o m i s c u o u s activation of t w o chimeric sensor d o m a i n
receptors

Activation (EC50)

Inhibition (IC50)

AgrCi:ni

AgrCIV:III

AgrCI:III

AgrCIV:III

AIP-I

+

++

-

-

AIP-II

+

++

-

-

-

-

3.1
AIP-III

^M

640 n M

++

++

48 n M

4nM

AIP-IV

++

++

-

-

AIP-I D 5 N

++

++

-

-

AIP-I D 5 A

++

++

-

-

TrAIP-II

++

++

-

-

160 n M

50 n M

AIP-II F 9 A

-

-

ND

ND

Linear AIP-I

+

+

-

-

ND

ND

3.1
L i n e a r AIP-II

^M
-

6.7 fiM
+

++, low n M activity, +, low u M activity, , no activity up to at least 10 u M , N D , not
determined. EC50 values are listed in those instances where they were determined with
reasonable accuracy.
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been s h o w n before to activate agr. T h e important implication from these results is that
the mismatch between the sensor subdomains alters the structure of the receptor in such a
manner as to poise it for activation by any ligand that can bind that is, that activation
can occur without any of the putative group-specific contacts that are presumed to be
responsible for activation of the native receptors.
This observation prompted an examination of the AIP sequences. Overall, the
AIPs show a gradient of increasing hydrophobicity from their N- to C-termini, ending
generally with bulky hydrophobic amino acids (Fig. 2.28). With the exception of the
central cysteine, no other position in the AIPs is so strongly conserved. This analysis,
coupled with the behavior of the I::III and IV::EI chimeras, suggests an activation
mechanism in which the AIP binds to a hydrophobic pocket in the receptor, involving
one or both of the C-terminal hydrophobic residues, and then makes other site-specific

contacts that result in activation. According to this concept, the structural distortion of th
I::IE and IV::IE sensor domain chimeras bypasses the need for these other specific
contacts; all that is required for activation is binding. And if the two C-terminal
hydrophobic residues are required for binding, then replacing one or the other or both
with a neutral residue such as alanine is predicted to eliminate binding and thus to
eliminate activation of the I::EI and IV::EI chimeras. This prediction was confirmed as
shown in Table 2.8: the F9A variant of AIP-E, which had previously been shown to lack
activity with the four native AgrCs (Mayville et al, 1999) is totally inactive towards these
two chimeric receptors.
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Figure 2.28. A I P Alignment from the k n o w n agrD sequences. The conserved cysteine
(other than the S. intermedius serine-to be discussed later) is shaded and the conserved Cterminal hydrophobic amino acids are boxed. Hydrophobic amino acids are shaded in
yellow, while hydrophilic amino acids are shaded in blue. T h e asterisks indicate those
AIPs whose biologically active structures have been determined, with the exception of S.
lugdunenesis-ll, which is assumed to be a heptapeptide thiolactone, based on its strong
homology to S. lugdunenesis-l.
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S e c t i o n 2.6 -- A g r C is a p r o t o t y p i c a l receptor-histidine k i n a s e

Studies concerning the histidine kinase activity of AgrC were initiated with the

primary goal of confirming and extending prior results concerning an AlP-inducible MBP
AgrC protein lacking most of the AgrC sensor domain (Lina et al., 1998). These studies

included in vitro and in vivo analyses of the HK activity of AgrC, and, although the p

results (Lina et al., 1998) were not confirmed, important insights were gained and fut

avenues of research developed. These studies were in part inspired by extensive work o

other histidine kinases (Wright et al., 1993; Fisher et al., 1995; Qin et al., 2000; Z
2000; Marina et al., 2001; Zhu and Inouye, 2002).

Testing for Histidine Kinase activity in vitro
It has been reported that the HK domain of AgrC constitutively autophosphorylates
in vitro, when assayed in the context of an MBP-AgrC HK fusion protein (Lina et al.,
1998). This is consistent with bioinformatics studies of the HK domain of AgrC, which
have revealed with high certainty (E-value 4e-50 using SMART and PFAM search tools)
strong homology to the HATPase motif, commonly found in histidine kinases of known

structure such as EnvZ (Tanaka et al., 1998) and PhoQ (Marina et al., 2001). Furthermor

transmembrane histidine kinases function as preformed dimers (Dutta et al., 1999). Once

again, AgrC seems to fit this picture, as computer analysis has revealed that the link

spanning from the sensor domain to the kinase domain of AgrC has high helical propensi

and the potential to form a coiled coil, followed by a helix-turn-helix motif (Figure 2

This is consistent with structural studies on the E. coli osmosensor EnvZ, which has a
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AgrC-I Protein Sequence; two putative helices underlined
1-VELLNSYNFVLFVLTQMILMFTIPAIISGIKYSKLDYFFIIVISTLSLFLFKMFDS
ASLIILTSFIIIMYFVTCIKWYSILLIMTSQIILYCANYMYIVIYAYITKISDSIFVIF
PSFFWYVTISILFSYIINRVLKKISTPYLILNKGFLIVISTILLLTFSLFFFYSQIN
SDEAKVIRQYSFIFIGITIFLSILTFVISQFLLKEMKYKRNQEEIETYYEYTLKIE
AINNEMKKFRHDYVNILTTLSEYIREDDMPGLRDYFNKNIVPMKDNLQMNAIKLNGIE
NLKVREIKGLITAKILRAQEMNIPISIEIPDEVSSINLNMIDLSRSIGIILDNAIEAS
TEIDDPIIRVAFIESENSVTFIVMNKCADDIPRIHELFQESFSTKGEGRGLGLSTLKE
IADNADNVLLDTIIENGFFYSKS-42 5
Helix # 1

Helix # 2

Figure 2.29. Helical wheel analysis, performed on the linker region of AgrC using the
program, Protean, in the D N A S T A R package. The critical and conserved histidine residue
that is predicted to be phosphorylated is boxed and/or colored in red. A dotted circle
surrounds the hydrophobic residues in the two helices that are predicted to pack together to
form the four-helix bundle in a dimeric receptor.
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helix bundle dimerization motif formed from within the linker region (Tomomori et al.,
1999).
T h e above-mentioned study on A g r C (Lina et al., 1998) reported that fusion of the
last extracellular loop and transmembrane helix of the A g r C sensor domain to the H K
domain in an M B P fusion protein caused the kinase to only be active in the presence of
bacterial supernatants containing the activating AIP-I. This experiment was conducted in
vitro on fusion protein isolated from E. coli cells in the absence of detergents. This result
suggested to the authors that the last extracellular loop contains the A I P binding site
(Lina et al., 1998). It is perhaps m o r e likely that the last extracellular loop s o m e h o w
interferes with the histidine kinase activity of the receptor, and that this interference is
relieved by something in the bacterial supernatant or perhaps by A I P binding. This in
vitro result is very different from an in vivo situation where the transmembrane domain(s)
span the m e m b r a n e and is not solubilized by fusion to M B P .
A s the results with chimeric sensor domains suggest that the entire sensor domain
is important for A I P binding (vide supra), it became very important to reproduce the
above in vitro results. T o w a r d this end, the MBP-fusion plasmid constructs were obtained
from Gerard Lina and the proteins expressed and purified (see Methods). Initially, the
M B P - A g r C H K fusion protein (Figure 2.30A) was tested for constitutive kinase activity.
A s s h o w n in Figure 2.31, the M B P - A g r C H K fusion protein constitutively
autophosphorylates in vitro upon addition of ATT*f2P, reaching saturation by 30-60
minutes of incubation. These results confirm that the soluble H K domain of A g r C is a
kinase on its o w n without any portion of the sensor domain attached (Lina et al., 1998).
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A)

B)

H2N—CH-C—OH
I
CH2

W

.o
HO

X

3-phosphohistidine

3-thiophosphohistidine

Figure 2.30. Studies on the kinase domain of AgrC. A ) A schematic diagram of the
MBP-AgrC HK fusion protein, depicting the trans-autophosphorylating nature of

histidine kinase domains. B) The chemical structures of 3-phosphohistidine and 3-thio

phosphohistidine are shown. Histidine kinases autophosphorylate in the presence of ATP
yielding phosphohistidine derivatives.
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Figure 2.31. A g r C is a kinase. The M B P - A g r C H K fusion protein was phosphorylated
in vitro in the presence of ATPy32? or ATPy^S of approximately similar specific

activities. Different time-points were taken (10, 30, 60, and 90 minutes) and quenched
with SDS-PAGE buffer. Parallel SDS-PAGE gels were run, one for radioactive imaging
and the other for Coomassie Staining to verify equal protein loading.
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A s a control, A T P y ^ S , a pseudo-substrate competitive inhibitor, was tested in the
MBP-AgrC HK fusion protein kinase assay. Some labeling was observed (Figure 2.31),
indicative of thiophosphorylation of histidine in the protein (Figure 2.30B). Recently, it
has been shown that thiophosphorylated histidine is much more stable to acidic
conditions than phophorylated histidine, in the context of HK proteins (Lasker et al.,
1999). Furthermore, it has also been recently shown that thiophosphorylated proteins can
be selectively purified using a disulfide-capture resin and then modified with
photocleavable caging groups (Zou et al., 2002). Thus, the ability to obtain a pure, stably
thiophosphorylated HK domain of AgrC opens the door to a range of studies, including
binding assays between AgrC and AgrA, potential thiophosphate transfer to AgrA to
form a stably thiophosphorylated response regulator, and photoactivation of HK
phosphorylation in vitro or in vivo through deprotection of a caged thiophosphorylated
histidine.
The MBP^*1 loop-TM helix-AgrC HK protein (Figure 2.32A) was tested for
kinase activity in the presence or absence of AIP-I at 1 uM. In contrast to published

results, this protein autophosphorylates by itself in vitro, and this activity is unaffected by
the addition of synthetic AIP-I (Figure 2.32B). The activity of equimolar amounts of the
MBP-AgrC HK and the MBP-3rd loop-TM helix-AgrC HK proteins was not directly

compared, so it is not possible to state that they have equal activity. However, it is certain
that synthetic AIP-I had no effect on the activity of the MBP-3rd loop-TM helix-AgrC HK
protein, thus casting doubt on the previous claim that the third extracellular loop is
sufficient for AIP-I binding and HK activation (Lina et al., 1998). It is more likely that
the reported increased activity upon supernatant addition resulted from changes in pH or
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Figure 2.32. Kinase assay on MBP-3rd loop-TM helix-AgrC HK protein. A)
Schematic diagram of MBP-3rd loop-TM helix-AgrC H K protein. B)
Autophosphorylation of MBP-3rd loop-TM helix-AgrC H K protein in the presence or
absence (±) of AIP-I at 1 p M .
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osmolarity that affected kinase activity independently of AIP addition. These findings

are also more consistent with the observation that the entire sensor domain of AgrC i
necessary for potent activation by the AIPs (vide supra).
Extensive experimentation with Factor Xa cleavage of the MBP-AgrC HK, MBP3rd loop-TM helix-AgrC HK, and the 3A-2 and 4A-2 proteins (see below and Methods)

yielded poor results, both in terms of percent cleaved and percent recovered. The per
of the MBP fusion cleaved by Factor Xa never exceeded 50%, and the HK domain of
AgrC on its own tended to aggregate and disappear during gel filtration, RP-HPLC, or
ion-exchange chromatography (not shown). In the end, it was decided that efforts to
purify the HK domain on its own would be abandoned. For the future, it might be
worthwhile to demonstrate that the MBP-AgrC HK fusion protein is dimeric, either by

gel filtration or analytical ultracentrifugation, followed by site-directed mutagenes
putative dimerizing residues. Initial attempts to express His-tagged versions of the

HK domain failed, due to cloning difficulties (see Methods). His-tagging has been use
with great success to prove the dimeric nature of other RHKs, including EnvZ (Hidaka
al., 1997)
The 3A-2 and 4A-2 proteins (see Methods) are MBP-AgrC fusion proteins similar
to the MBP-AgrC HK and MBP-3rd loop-TM helix-AgrC HK proteins, respectively, with

two main differences. First, the number and composition of amino acids at the junctio
between MBP and AgrC differ between the proteins (Methods); and, second, both

proteins lack a signal sequence in MBP, thus directing their expression to the cytopl

rather than the periplasm (see Methods). Surprisingly, the 3A-2 and 4A-2 proteins wer

completely devoid of kinase activity. It is well known that the linker domain connect
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the sensor domain of R H K ' s to the H K domain is crucially important for proper function,
including the proper topological arrangement of the HK domain in relation to the
histidine-containing 4-helix bundle (Park and Inouye, 1997, Singh, 1998 #745), and it

also well known that bacterial chaperones in the periplasm can assist in proper prote

folding (Gilbert, 1994; Rizzitello et al., 2001). As experiments with osmotic shock wi

the MBP-AgrC HK protein did not release significant amounts of protein, even though a
large amount of protein was subsequently recovered after cell lysis, it seems likely
the vast majority of the functional protein was en route to the periplasm or simply

expressed in the cytosol. Furthermore, there is very little (if anything) known conce
folding of histidine kinases in the periplasm of E. coli (B. Wanner, personal

communication). Therefore, it appears more likely that modification of the linker reg

between MBP and the HK domain abolishes kinase activity, although further experiments

are necessary to differentiate between the "linker" hypothesis and the "improper fold

hypothesis. In any case, as neither protein was active as a kinase, further experimen
using them were abandoned, other than as reagents to test anti-AgrC antibodies in
Western blotting (vide infra).

Expressing the AgrC HK domain in vivo
As it has been shown that MBP-AgrC HK protein is an active kinase in vitro, it
was thought that expression of this protein in vivo would result in agr activation

independent of AIP addition. Toward this end, the shuttle vector, pRN7035, previously

used to make the group I, II and IV reporter strains, was utilized to express truncat

version of AgrC along with full-length AgrA. A ribosome-binding site was incorporated
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directly upstream of the start codon to ensure proper translation of these N-terminally

truncated proteins. Unfortunately, the cloning of the AgrC HK domain into the S. aure

vector occurred prior to the knowledge that linker length and composition might be of

critical importance to AgrC HK activity. Therefore, the construct lacks 3 amino acids
(SQF) from AgrC that were present in the MBP-AgrC HK protein, i.e.
MLLKEMKYK.. .cont... versus MBP-SOFLLKEMKYK.. .cont... (see Methods).
Upon testing three independent clones (6A, B, C) of the AgrC HK domain in S.
aureus, no detectable uninduced or AlP-inducible agr activation was detected (Figure

2.33A), leading to the conclusion that this protein was not a consitutive kinase in vi
Other constructs with N-terminal portions of AgrC appended onto the kinase
(TM3TMHK and 3TMHK - see Methods) were also inactive in vivo (Figure 2.33A).
However, the inclusion of transmembrane helices in these segments made it uncertain

about the correct incorporation of AgrC into the membrane and/or possible aggregation

of AgrC, and attempts to detect their expression with an anti-AgrC antibody on Wester

blots failed due to the fact that the antibody itself did not recognize AgrC (vide in
As one final means of confirming expression from these construct in vivo, the
plasmids were introduced into the agr+ strain, RN6734, and checked for a possible
dominant-negative effect on native agr signaling. In fact, the strains containing 3

independent clones of the AgrC HK construct produced significantly less agr activatio
as assessed by transcription from the P3-blaZ promoter on the plasmid and also by
transcription of RNAEI from the chromosome and subsequent translation of 8-toxin
(Figure 2.33B&C). The 3TMHK construct exerted a similar effect (in two independent
clones), whereas the TM3TMHK construct did not (in two independent clones) (data not
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Figure 2.33. Expressing° truncated
version of A g r C in vivo. A ) Independent clones
500-

from the 3 truncated versions of A g r C (see Results and Methods) were tested for agr
activation by the P-lactamase assay, with or without AIP-I at 1 u M . T h e group I reporter
strain, R N 9 2 2 2 , is the positive control. B ) T h e A g r C H K domain w a s checked for a
dominant negative effect in the agr+ strain, R N 6 7 3 4 , by the (3-lactamase assay. Each
clone exhibited this effect, so the data were combined to generate the S E M error bars
associated with possible plasmid copy n u m b e r differences. C ) A similar result w a s
obtained with the 5-toxin assay.
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shown). Therefore, the H K and 3 T M H K proteins are being expressed in vivo, but, instead

of being constitutively active as kinases, they are exerting a dominant negative effe
The dominant-negative effect could result from several different possibilities (see
(Wright et al., 2000; Wright and Kadner, 2001) for a discussion and analysis of such
effects). The one most favored at this time is the possibility that the HK domain of
dimerizes with the transmembrane native AgrC via four-helix bundle formation, thus

disrupting signaling through a normally dimeric transmembrane receptor. However, it i
also possible that the HK domain of AgrC on its own has phosphatase activity instead

kinase activity in vivo, as has been suggested from in vitro work in other HK signali
systems (Wright et al., 2000; Zhu et al., 2000).

Attempts to Develop an Anti-AgrC Antibody
During the course of this work, attempts were made to develop an anti-AgrC

antibody, as this reagent would obviate the need for epitope-tagging of AgrC and woul

provide a readout for AgrC expression levels. Toward this end, a peptide from the 3rd
extracellular loop of AgrC-I was synthesized, conjugated to Keyhole Limpet
Hemocyanin (KLH), and injected into rabbits for polyclonal antibody development
(assisted by Brenda Ayers). The amino acid sequence of this peptide was: C-AhxINSDEAKVIRQY, where a cysteine amino acid was added, N-terminal to an
aminohexanoic acid (Ahx) spacer, for KLH conjugation (see Methods). Sera from two

rabbits recognized the peptide epitope, containing the aminohexanoic acid (Ahx) space
on dot blots, and the same peptide (minus KLH) was used for affinity purification,
resulting in substantial concentration of reactive antibodies (Methods).
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However, extensive experimentation with Western blotting of whole cell lysates
and/or membrane preparations from various agr± strains, including strains lacking
protein A (known to bind strongly to the Fc region of IgGs, used for primary and

secondary detection), never revealed a reactive band of the approximate molecular wei

of intact AgrC (-50 kDa) (not shown). In addition, this antibody did not react with th
purified MBP-3rd loop-TM helix-AgrC HK protein, containing most of the epitope
sequence (SDEAKVIRQY), nor did it react with MBP fusion proteins constructed to
contain the entire epitope (INSDEAKVIRQY) (see Methods). In the end, it was

concluded that inclusion of the aminohexanoic acid spacer in the injected peptide bia

the immune system to produce antibodies against this unnatural amino acid. In the fut
the peptide, CINSDEAKVIRQY, should be synthesized and used to affinity-purify any

reactive antibodies from the original rabbit serum. If anti-AgrC antibodies cannot be

obtained in this fashion, then rabbits will need to be immunized with the peptide wit

Ahx, or else with a recombinantly expressed fragment of AgrC. It would be far superio
to use chickens as the antibody producer, as it is known that, unlike mammalian IgG,
neither the Fc region nor the Fab region of chicken IgY (IgG) reacts with protein A

(Langone et al., 1983). However, unless the primary antibody is directly conjugated to
alkaline phosphatase, this does not circumvent the problem that the Fc region of the
chicken secondary antibody (conjugated to alkaline phosphatase and presumably raised
rabbit or mouse) would also still bind to protein A. To get around this problem, the

chicken anti-protein A antibodies is a viable option for blocking all protein A bindi

sites (Hoffman et al., 1996). Even with this, it is noteworthy that other secondary Ig

binding proteins have recently been characterized in S. aureus (Zhang et al., 1998; Z
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et al., 1999; Zhang et al., 2000). Even in agr-null, protein A-null strains, proteins of -50

kDa in MW were observed to react with the anti-rabbit secondary antibody, so one must

exercise caution in this molecular weight range when attempting to attribute a Wester
blot band to the primary antibody.
Regarding immunization with a recombinantly expressed fragment of AgrC, it is
important to note that the MBP-AgrC HK protein discussed above has been used to

generate an anti-AgrC antibody, which was reported to recognize an autophosphorylated

AgrC, thus confirming AIP-induced AgrC autophosphorylation in vitro and in vivo (Lina
et al., 1998). However, it is noteworthy that these authors did not check for whether
anti-AgrC antibody recognized the AgrC HK domain after removal of the highly
antigenic MBP by Factor Xa cleavage. Therefore, this antibody (kindly provided by
Gerard Lina) was checked for AgrC HK binding after Factor Xa cleavage of the MBPAgrC HK protein (Fig. 2.34). Although the cleaved HK domain was relatively unstable
after removal of MBP (thus making it hard to visualize on Commassie staining, Fig.

2.34A), radioactive kinase assays demonstrated its presence in the cleavage mixture (
2.34B). However, the antibody did not recognize the HK domain of AgrC, and instead

only recognized MBP, thus leading one to question its validity as an anti-AgrC antibo

(Fig. 2.34C). In the future, antibodies raised against MBP-fusion proteins should eit
be affinity-purified with some version of AgrC and/or immuno-depleted of MBP-

recognizing antibodies. Unfortunately, these results raise uncertainty concerning the
published data on autophosphorylation of AgrC in vivo in response to culture

supernatants (Lina et al., 1998), as it is possible that the "reactive bands" resulted

IgG-binding proteins in S. aureus (vide supra). It is most likely the case that the o
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Figure 2.34. Testing of G. Lina Anti-AgrC Antibody. A ) The MBP-3rd loop-TM helix
AgrC H K protein was proteolyzed with Factor X a to remove M B P , as demonstrated by
Coomassie staining. The H K domain of AgrC is unstable on its own and is thus only
faintly visible on the Coomassie gel. B ) However, a radioactive kinase assay
demonstrates the presence of the H K domain after Factor X a cleavage. C ) Under these
conditions, the anti-AgrC antibody appears to bind M B P but does not bind the H K
domain.

12]

radioactive band at -50 kDa was indeed AgrC, but the proof of this provided in the form

of an anti-AgrC Western blot is uncertain at this time. Perhaps, an epitope-tagged Ag

can be (over)expressed in vivo, and its AlP-induced phosphorylation can be proven wit
certainty using commercially available anti-epitope antibodies.

Section 2.7 -- Hypothesis-driven MSn analysis of Staphylococcal AIPs.

(in collaboration with Markus Kalkum and Brian Chait)
Assays that provide information on specific peptides that are secreted by living
cells (e.g., toxins, pheromones, virulence factors, quorum sensing peptides) can be
valuable as diagnostic aids. For example, the presence and identity of a specific

microorganism may be inferred by detection of characteristic secreted peptides, which

may also be used to distinguish between subtypes of a given strain. Several authors h
described the use of MS to identify microorganisms based on fingerprint masses of

protein constituents as well as secreted peptides and proteins (Fenselau and Demirev,

2001). Recently, electrospray ionization-Fourier transform tandem MS of intact protein

has been applied for the characterization of biomarkers from Bacillus cereus T spores

(Demirev et al., 2001) and a combined approach of single-stage and tandem MS was used

to identify proteins secreted from adipocytes (Kratchmarova et al., 2002). Because the
methods rely on the initial detection by single-stage MS of intact peptide ions from
highly complex milieu, it may be difficult to detect trace amounts of the secreted
peptides. In addition to limitations imposed by dynamic range and signal suppression

effects, low-level signals of interest tend to disappear into the "chemical noise" (B
et al., 2002; Krutchinsky and Chait, 2002). Here, a method, developed by M. Kalkum and
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B . Chait and applied herein to a biological problem, is presented for the rapid,
unambiguous detection of trace amounts of peptides secreted from microorganisms,
utilizing multi-stage MS (MS2 and MS3) analysis of crude supernatant mixtures with a
novel MALDI-quadrupole ion trap mass spectrometer (Krutchinsky et al., 2001). In this
procedure, secreted peptide ions that are hypothesized to be present in the supernatant,
but that are not sufficiently abundant to be observed in the regular single-stage mass
spectra, are subjected to multi-stage MS. Highly specific fragmentation signatures enable
unambiguous identification of the peptides of interest and differentiation of the signals
from the background.
This method, termed hypothesis-driven multistage mass spectrometry (HMS-MS),
is based on the ability of MALDI-ion trap mass spectrometry to separate specified
peptide ions from a complex and noisy mixture and to convert these selected peptide ions
into a few informative fragment species with low noise background. Resonant excitation
within the ion trap provides an efficient method to cleave peptide bonds at preferred
positions, leading to relatively simple fragmentation signatures with high signal-to-noise
ratios. Key to the success of the approach is the very small fraction of the total sample
that is consumed to obtain each multi-stage mass spectrum. Consequently, one can test a
large number of different hypotheses on a given sample before it is depleted. In contrast
to HPLC-coupled-MS, this method has no significant time limits on obtaining this
information.
This method was used for the rapid detection and structural characterization of the
autoinducing peptides (AIPs) of Staphylococcus aureus. Concentration or desalting steps
were useful for the analysis of staphylococcal AIPs from bacterial culture supernatants. A
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fast (~ 1 min) and simple purification procedure performed with small culture volumes

(0.01-1 ml) was adequate. Despite this, it was not generally possible to decide on th

presence or absence of AIPs based on single stage MS spectra (Fig. 2.35, top left han
panels of I, II, II and IV). Indeed, it was necessary to perform both double-stage

(MS/MS) and triple-stage (MS3) experiments on synthetic AIPs to assess the most inten

fragment-ions that should be expected when analyzing the naturally occurring AIPs fro

supernatants. For example, the fragmentation of synthetic AIP-I ions yields an intens
ion peak at m/z 711.5 and less intense y5 and y7 ion peaks at m/z 610.6 and 798.5,

respectively (Fig. 2.35,1). However, only the intense y5 ion can be distinguished from
background noise in the MS/MS spectrum of natural group-I AIP supernatants. Indeed,
due to residual background in the MS/MS spectrum, it proved necessary to perform a

triple-stage MS experiment (MS3) to test whether the peak at m/z 711.5 from the MS/MS

experiment can be attributed with high confidence to AIP-I. The MS3 experiment with t

supernatant sample of AIP-I revealed essentially the same fragmentation pattern as th

obtained with the corresponding synthetic peptide. In general, MS/MS fragmentation of

groups I, EI, and IV AE>s lead to fragment ions that retain the cyclic component of t

intact peptides. Since two cleavages are necessary to obtain observable fragments fro
ring, such fragment ions were first detected in the MS3 experiments (Fig. 2.35).
A deviation from this scheme was observed for AIP-E. This peptide was
predominantly desorbed as the singly natriated ion (M+Na+) rather than the more
commonly observed protonated form (M+H+) (Fig. 2.35, II, synthetic), even though the

sample is prepared at low pH. Loss of phenylalanine in the MS/MS experiment indicates

dissociation of the ring (Fig. 2.35, II, ion peak at m/z 754.5), which was not observe
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F i g u r e 2.35. Hypothesis-driven M S " analysis of groups I to I V autoinducing peptides
( A I P s ) f r o m S. a u r e u s culture supernatants (natural) a n d c o m p a r i s o n with M S n spectra of
synthetic A I P s . O n l y the m o s t a b u n d a n t fragmentation p a t h w a y s of these lariat-like
peptides are indicated using the sequences o n the left for each M S stage. N o t e that
M S / M S a n d M S 3 experiments for AIP-II w e r e p e r f o r m e d o n the m o r e abundant natriated
ions ( M + N a + ) , all other spectra are those of protonated ions a n d their fragments. T h e tip
of the beige b a c k g r o u n d underlying the M S / M S spectra points to the parent ion. M S 3
spectra are m a r k e d in blue for parental-y ions a n d in purple w h e n derived f r o m parental
b-ions. This experiment w a s p e r f o r m e d b y M a r k u s K a l k u m .
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w h e n fragmenting the protonated synthetic peptide (data not shown). In this case, the
polar serine residues in the ring appeared to chelate the sodium cation, thus altering the
fragmentation behavior. When it was assumed that the hypothetical parent ion mass of
AIP-II is natriated, identical MS/MS and MS3 fragment ions from the peptide in the
culture supernatant and from the synthetic AIP-II were obtained (Fig. 2.35, II, natural).
Only the most intense MS/MS peaks can be used with confidence in order to
verify the presence of AIP peptides in the supernatants; hence, only their m/zs were
chosen for the MS3 experiments. The MS3 experiment was particularly necessary to
unambiguously verify the presence of native AIP-III because its diagnostic y6 fragment is
of relatively low intensity (Fig. 2.35, III, natural). In addition, the spectra indicate that
AIP-III is a heptapeptide and not an octapeptide, as previously assumed (Ji et al., 1997).
This observation corresponds well to other findings, which demonstrate that only the
synthetic heptapeptide, and not the octapeptide or nonapeptide, activates agr group-Ill
cells (vide supra).

HMS-MS demonstrates that the AIP of Staphylococcus intermedius is a Lactone
Five-fold concentrated, desalted culture supernatant of Staphylococcus
intermedius gave a clearly discernable signal at m/z 1007.8 in the single-stage MS mode
(Fig. 2.36). It would be possible to assign this signal to the AIP of S. intermedius if one
assumes that the AIP is a nonapeptide and that cyclization is accomplished via a lactone
bond rather than as a thiolactone (because the S. intermedius AIP contains a serine
instead of a conserved cysteine residue at the corresponding position in all other AIPs
examined). In order to test this hypothesis, multistage MS experiments were performed
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on the ions at m/z 1007.8 and on fragments thereof (Fig. 2.36). Three fragments (y8, y7
and b4) were obtained in the MS/MS experiment. None of these fragmentations occurs
within the presumed cyclic part of the peptide, a characteristic that corresponds to
observations made when studying MS/MS fragmentation of protonated S. aureus AIPs.
The b4 ion at m/z 468.3 results from fragmentation of the peptide bond C-terminal to the
threonine, which is the first residue outside the ring. The identity of the b4 ion was
verified by a MS3 experiment that yielded b2 ions (Fig. 2.36). The y7 ion at m/z 738.5,
observed in the MS/MS experiment, results from a preferred fragmentation of the peptide
bond on the N-terminal side of proline that is also responsible for generating b2 ions in
the MS3 experiment on b4 ions. The y7 ion comprises the cyclic portion of the peptide,
making it 18 Da lighter then its theoretical linear counterpart. Subsequent fragmentation
of the y7 ion in an MS3 experiment leads to y5 and y6 ions (m/z 540.3 and 641.2) that also
originate from bond dissociations outside the ring. These spectra provide strong evidence
that the S. intermedius AIP is indeed a nonapeptide with a cyclized portion comprised of
a lactone.
Hypothetical masses that form the basis for any HMS-MS experiment have to be
assessed carefully as the example of the natriated AIP-E ions demonstrates. Although no
synthetic form of the S. intermedius AIP was available for analysis, the MS2 and MS3
experiments of the natural AIP (Fig. 2.36) unambiguously characterize it as a
nonapeptide lactone, which is the first such peptide characterized in agr signaling. This
finding has important implications for understanding the detailed interaction of AIPs with
their receptor (vide infra). The use of lactone peptides for quorum-sensing was also
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recently shown in the gram-positive bacterium, Enterococcus faecalis (Nakayama et al.,
2001).

Lactone AIPs - Implications for AlP-receptor interaction
The detection and characterization of a lactone AIP from S. intermedius has

important implications for agr signaling, as an ester linkage is far less reactive th

thioester linkage to nucleophilic attack by a residue in AgrC. Therefore, signaling b
AIP would most likely proceed through a non-covalent interaction, thus making it

unlikely that AlP-induced AgrC signaling occurs through any sort of covalent interact
in the entire agr system. However, one must first demonstrate that this AIP indeed

activates its corresponding AgrC. Northern blot analysis in the laboratory of G. Lina
revealed up-regulation of RNAIII expression in pre-exponential cultures of RN9423
treated with stationary phase supernatants from the same strain (Figure 2.37-kindly

provided by G. Lina), thus indicating that the lactone AIP most likely activates AgrC

from this strain. The complete DNA sequence for the agr operon in this S. intermedius

strain, RN9423, including the sequence of RNAEI, has been obtained. These data reveal
that RNAEI includes what appears to be a viable 6-toxin sequence of:
MAGDIISTIVDFIKLIAETVKKFTK. However, all efforts to detect 8-toxin production

by RP-HPLC analysis of post-exponential or stationary phase bacterial cultures from t

strain have failed (data not shown). Yet, blood plate analysis reveals a large cleari

surrounding the streaked strain, consistent with the production of a very active hemo
component (although it is unknown if this component is agr-regulated). Genomic DNA
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Figure 2.37. S. intermedius (RN9423) supernatant activates agr in S. intermedius
(RN9423) cells . A ) Northern blot analysis. One-tenth volume of post-exponential
RN9423 supernatant (+ S. intermedius) or broth (+BH) was added to an earlyexponential phase culture of RN9423 and samples were taken every 30 minutes for
Northern blot hybridization analysis using an RNAIII-specific probe. RNAIII expression
increased earlier in the culture induced by S. intermedius AIP lactone. B) Cell density
was monitored over the course of the experiment, indicating that addition of 5.
intermedius supernatant had only a mild effect on growth of the cells. This experiment
was performed by Yvonne Benito and Gerard Lina.
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has been prepared from this strain, and experiments are underway to develop a 0lactamase reporter assay to monitor agr activation more easily.
As the S. intermedius lactone AIP is an activator of agr, it was asked whether the
lactone versions of other AIPs activate their respective receptors. Two groups have
synthesized different lactone AIPs, one for AIP-II (Mayville et al., 1999) and the other
for the S. epidermidis AIP (Otto et al., 1999), and have published that neither of these
lactone versions activates their respective receptors at concentrations up to -5 uM. In
addition, the lactone AIP-II is a potent cross-inhibitor of group I, but is not a selfinhibitor, similar to the case with AIP-II lactam (Mayville et al., 1999). As was also seen
with AIP-II lactam, there are significant chemical shift differences (CSDs) between AIPII lactone versus AIP-E thiolactone (Figure 2.38), thus suggesting structural difference
between them in solution.
There are at least two possible explanations for the large difference in agonist activity
between the lactam/lactone and thiolactone peptides. The first reason could be one of a
chemical nature, including steric and electronic differences between the peptides. In the case
of the lactam analog, the amide bond has significant double-bond character, thus imposing a

rigid planarity on it. This might impinge significantly upon the ability of the ligand to bind to
and activate the receptor, as the energetic cost for adopting an active conformation could be
too high. In the case of the lactone analog, there are subtle electronic and stereochemical
differences between sulfur and oxygen in the context of a thiolactone versus a lactone linkage,
which could collectively account for the difference in activity between them. Some of these
differences are: 1) Sulfur is a nonpolar atom relative to oxygen and more polarizable; 2) sulfur
has a larger radius than oxygen, 2.0 A vs 1.72 A; and 3) the bond angle around a sulfur atom
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F i g u r e 2.38. C h e m i c a l Shift Difference ( C S D ) M a p p i n g of the L a c t o n e A I P - I I relative to
AIP-II thiolactone, AIP-II lactam, a n d AIP-II linear thioester. T w o - d i m e n s i o n a l N M R
assignmetns of each peptide in d D 2 0 at 2 9 8 K allowed for c o m p a r i s o n b e t w e e n t h e m ,
revealing significant a m i d e a n d alpha ' H differences b e t w e e n the lactone AIP-II and the
thiolactone AIP-II, c o m p a r a b l e in m a g n i t u d e to the difference seen with AIP-II lactam or
AIP-II linear thioester.
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is generally more acute than around an oxygen atom. X-ray crystallography, N M R and

molecular modeling studies of the AIPs and analogs derived thereof should delineate suc
differences in a detailed manner.
The second formal possibility is that the AIPs could be forming a transient covalent

linkage with AgrC, through any number of potential nucleophiles, such as the side-chain
serine, aspartate, glutamate, tyrosine, cysteine (although this last amino acid is not

the Group II AgrC, but is present in a conserved position in the Group I, III, and IV A

and histidine (although not possible in this case because histidine is not found in the
domain of AgrC from Groups I-IV). Such a model would predict that transient covalent

binding serves the purpose of increasing the affinity of the ligand for the binding poc

AgrC. However, this mechanism would be feasible only if release of the covalently bound

AIP occurs with rapid kinetics, as slow release of the AIP or of trAIP-II should lead t
pseudoirreversible activation or inhibition, respectively, which has not been observed

supra). As this putative release would most likely involve hydrolysis of the AlP-recept
adduct, rather than re-formation of the thiolactone peptide, HMS-MS was used to detect
linearized forms of any AIP in groups I-IV culture supernatants. No such peptides were
detected (not shown, M. Kalkum), thus rendering this possibility more unlikely.

Section 2.8 -- Peptidomimetic Design to develop more stable

and potent universal agr inhibitors

There are several methods available to develop more stable and potent agr

inhibitors, based on the lead compound, trAIP-II thiolactone, which has been shown to b

a global inhibitor of agr activation (vide supra). Alternatively, high throughput scree
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of small molecule libraries can lead to compounds radically different from trAIP-E, but
with enhanced stability and/or potency. Both of these approaches are currently being
applied in the laboratory.
Toward the first goal of converting trAIP-II thiolactone to a peptidomimetic,
efforts have been initiated along the lines illustrated in Figure 2.39. The methods
illustrated are by no means comprehensive, and there is a large body of literature relating
to the art of peptidomimetic design (al-Obeidi et al., 1998; Steer et al., 2002).
As already discussed, trAIP-II lactam was synthesized and tested, and although it
is a much more stable compound, it has a dramatic (~ 100-fold) loss in potency (vide
supra). This loss in potency has been explained by structural differences between the
lactam and thiolactone AIPs in solution. Paranthetically, it is noteworthy that the
synthesis of trAIP-II lactam included macrocyclic ring closure mediated via
intramolecular aminolysis of a linear thioester precursor, which resulted in one
stereochemically correct product (see Methods). It is worth noting here that a recent
paper detailing the synthesis of quorum-sensing lactone peptides via the different method
of macrolactonization of protected peptide active esters in DMF reported racemization of
the C-terminal amino acid during the procedure, as evidenced by chiral amino-acid
analysis (Nakayama et al., 2001). Mechanistic studies of oxazolone-mediated
racemization of peptide active esters are well-documented (Goodman and McGahren,
1967), and it is very likely that such a process can occur with synthetic strategies using
cyclization of protected peptides in solution, as was done by other groups to sythesize the
AIPs (Otto et al., 1998; Otto et al., 1999; McDowell et al., 2001) and by this group for the
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Figure 2.39. TrAIP-II Peptidomimetic Design. A diagram illustrates some of the many
possible approaches to developing a proteolytically and pH-stable global inhibitor of
virulence. Such approaches focus on stabilization of the base-labile thioester linkage,
followed by efforts to minimize proteolytic cleavage of amide bonds by endopeptidases.
Varying key side-chains and the peptide backbone of the AIPs, including the construction
of smaller and larger macrocycles, promises to yield much insight into the sequence and
structural requirements for AlP-induced AgrC activation or inhibition.
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lactam and lactone AIP-II (Mayville et al., 1999). In the future, any A I P m a d e by this
latter method should be fully characterized to establish with certainty the stereochemical
integrity of every stereogenic center. This could include the use of chiral amino acid
analysis or other methods (Hayashi and Sasagawa, 1993; Vandenabeele-Trambouze et
al., 2000).
To allow more flexibility in the thioester-replacing linkage without sacrificing
stability considerations, a thioether AIP was envisioned. A synthetic strategy was
devised, which commenced with conversion of protected linear trAIP-II thioester to a
primary alcohol in solution with NaBH4-mediated reduction in the presence of thiols.
The inclusion of thiols ensured deprotection of the cysteine residue, which was protected
with a thiosulfonate protecting group, while leaving the serine protecting groups (OBenzyl) intact. The key step of the synthesis was to include a thiol-mediated Mitsunobu
condensation with the C-terminal primary alcohol to form the thioether linkage. This was
inspired by recent work demonstrating alkyl thioether synthesis via imidazole mediated
Mitsunobu condensation (Falck, 1999).
After considerable optimization, the pure primary alcohol was obtained from the
linear thioester starting material in an overall yield of 24% (not shown). However,
extensive experimentation with Mitsunobu chemistry never resulted in thiol-mediated
macrocyclization, as evidenced by RP-HPLC and MS. Although disappointing, this was
not entirely unexpected, as the one paper concerning this key Mitsunobu step only
formed highly favored 5- and 6-membered rings, using small molecules and not peptides
(Falck, 1999). Two recent papers concerning the synthesis of cyclic lanthionine
enkephalin analogues (Rew, 2002) and cyclic melanocortin receptor agonists
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(Bondebjerg et al., 2002) suggest alternative schemes for the synthesis of trAIP-II
thioether, which are actively being explored.
An alternative molecule to the trAIP-II thioether is the trAIP-II lactone (Figure
2.39). This molecule contains an ester linkage, which is much more stable than the
corresponding thioester, and which has the advantage of flexibility that a lactam linkage
does not possess. However, the results with full-length AIP-II lactone, including the
dramatic CSDs observed in comparison to AIP-E thiolactone, raise doubts concerning the
potency of self-inhibition by trAIP-II lactone, although it is important to assay a lactone
molecule that has been fully characterized chemically with regard to stereochemistry.
Therefore, efforts were undertaken to synthesize trAIP-E lactone (see Methods). The
reaction resulted in formation of two products of identical mass, with the major product
(presumably the unracemized L-version) eluting earlier on RP-HPLC as the more
hydrophilic species. Unfortunately, the mass of these products did not correspond to that
of trAIP-II lactone, but rather to that of a side-product brought about by reaction of trace
pyrrolidine amines in the PYBOP with the activated ester in the linear trAIP-E starting
material. Nonetheless, these results lend support to the possibility of racemization during
cyclization of protected peptides in DMF with ester-activating reagents, such as PYBOP
or HBTU, and catalytic DMAP.
Ongoing work in the laboratory, in collaboration with a graduate student, Jane
Chao, is focused on the synthesis of AIPs incorporating B-amino acids, N-methyl amino
acids, and D-amino acids. In fact, one group has already begun D-amino acid scanning in
the AIPs, although quantitative EC50 and IC50 values were not reported (McDowell et al.,
2001). Preliminary results thus far have shown that the macrocyclization kinetics of the
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AIPs in solution are dramatically slowed by peptide backbone modification, thus
supporting the notion of structurally-assisted macrocyclization and thereby accounting
for the extremely rapid and quantitative ring-closure of the AIPs in solution (on average,
>95% complete in < 2 hours). This stands in dramatic contrast to the extremely slow and
low-yielding macrocyclization of protected thiolactone AIPs in solution (McDowell et
al., 2001).
Recently, Rockefeller University has established a high-throughput screening
facility for the identification and analysis of small molecule agonists and antagonists. The
agr project was used initially as a pilot project in the center. The normal 96-well assay
format was converted to a 384-well format, and -7000 compounds were screened for
agonist activity and -2000 for antagonist activity. This pilot project demonstrated that a
384-well format was suitable and efficient for high-throughput analysis in the agr system,
and further demonstrated that the best signal-to-noise ratio was obtained when the
bacteria were grown at 37°C, rather than at the somewhat more convenient room
temperature. Several molecules were identified that appear to have agonist or antagonist
activity, and efforts are currently underway to confirm these "hits". In the future, -20,000
compounds will be screened for agonist and antagonist activity using the optimized assay
format. This will hopefully lead to stable and potent agr-active compounds that can then
be assessed for activity in mouse models of infection.
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C h a p t e r 3 - Discussion

General Significance of the agr System
Two-component systems are the major means by which bacteria sense

environmental stimuli. In most cases, the activating ligands for the receptors are un
(Hoch, 2000). The agr system is one of a few cases where the ligands have been
chemically characterized, as thiolactone peptides (AEPs), and the system is unique in
AIPs from heterologous strains are naturally occurring inhibitors of agr signaling.

Herein, the mechanism by which naturally-occurring AIP sequence variants activate and

inhibit agr has been investigated. Although the agr locus is conserved throughout the

staphylococci, the agr autoinducing peptides and their cognate receptors have radical
diverged, generating at least four autoinduction specificity groups in S. aureus. In

general, AIPs activate agr expression in strains belonging to the same agr group as t

producer strain, and inhibit agr expression in organisms belonging to any other group
is very possible that this divergence causes intergroup interference, leading to
environmental isolation, and is at least partially responsible for speciation within

staphylococci. Similar divergence within the structurally similar comAP locus, requir
for competence in bacilli, is also thought to be responsible for speciation in these
organisms (Tortosa and Dubnau, 1999).

The AIPs Activate and Inhibit agr Signaling through AgrC
It was previously hypothesized that activation and inhibition by native AIPs might
involve different mechanisms - either different modes of interaction with the AIP

receptor, AgrC, or interaction with cellular components other than AgrC - e. g., AgrB
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(Mayville et al., 1999). This latter possibility w a s clearly ruled out by means of plasmid
constructs containing a 6-lactamase reporter driven by the (conserved) agr P3 promoter
and including the P2 driven agrA+C modules from different specificity groups.
Placement of these plasmids in agr-null derivatives of the agr specificity group
corresponding either to that of the cloned module or to that of other groups, enabled the
direct in vivo analysis of AlP-specific activation/inhibition in the absence of AgrB or of
any endogenous AIP. Since these tests demonstrated the predicted cross-group
inhibition, it is clear that AgrB is not the site of inhibition. Since these tests also
demonstrated that cross-group inhibition occurs independently of host background, and
with similar dose responses, it is also clear that the only determinant of agr group
specificity is the AgrA+C module. Although AgrA and C were not tested independently,
AgrA is identical between the S. aureus agr specificity groups, whereas the sensor
domain of AgrC is highly variable; thus there is little doubt that AgrC is the key
determinant. This was confirmed through sensor domain swapping, in which it was
shown that activation and inhibition follow with the sensor domain of the respective AIP
receptors. Although there are certainly other cellular factors involved in agr signaling, the
results indicate that none of these determines group-specificity.

AIP-Receptor Interaction is Reversible and Competitive
A primary focus of this work has been on the reversibility (or irreversibility) of
the agr AlP-receptor interaction. The theoretical basis for this focus was the possibility
that the AIPs, with their highly reactive thiolactone bond, unique for signaling peptides,
might act by acylating their receptor, leading to irreversible activation. This was initially
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supported by experiments in which it w a s not possible to eliminate AlP-induced signaling
completely by extensive washing. However, a definitive test for reversibility was enabled
by the natural antagonism among variant AIPs produced by strains belonging to different
agr specificity groups. In these experiments, AIP-I and -II and their synthetic analogs
were tested versus reporter strains belonging to either group. Using several different
experimental protocols, it was shown clearly that AlP-receptor binding/activation is
completely reversed by the addition of an antagonist AIP. Thus the residual activity
remaining after extensive washing was eliminated by treatment of the cells with an
antagonist, and only the relative concentrations of agonist and antagonist but not the
order of their addition determined the outcome of an experiment. Furthermore, an
extracellular site of action for the AIPs is supported by the sensor domain swapping
results as well as by the washout data. Although these data and the activation seen with
the lactam analog rule out a stable covalent linkage between the AIPs and the receptor, a
transient covalent linkage formed between the AIP and receptor cannot be completely
ruled out.
Pharmacological experiments were performed in which agonist concentrationresponse curves were measured in the presence of increasing concentrations of antagonist
AIP. In all cases examined, the agonist and antagonist curves shifted in a parallel, dextral
fashion with no depression of the agonist maximal response. Qualitatively, these
observations are consistent with a simple competitive interaction in which the agonist and
antagonist AIPs compete for the same binding site on the receptor, AgrC. The data sets
were also analyzed using the non-linear regression method of Lew and Angus (Lew and
Angus, 1995). The calculated Schild slopes were all considerably less than unity.
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Surprisingly, this does not conform to a simple 1:1 competitive interaction, which
predicts a Schild slope of one. It should be noted, however, that because the assays in the
current study quantified downstream transcriptional effects, mechanistic interpretations
of the Schild slope factors and pA2 values remain speculative until future (direct binding)
experiments can determine such values more directly. This caveat aside, the results do
raise the possibility that the receptor-ligand interaction occurs through some more subtle
mechanism. In this regard, it is worth noting that bacterial RHKs are generally thought to
be dimeric (Stock et al., 2000), raising at least the possibility of cooperativity between
two AIP binding sites. Although this is an intriguing idea, additional experiments along
the lines of a direct binding assay will be required to test this hypothesis.

The Thioester linkage is Not Required for agr Activation
The lactam analogs of AIP-I (McDowell et al., 2001) and AIP-II can activate their
cognate receptors, but only at very high concentrations. The finding that this activation is
competitively blocked by a native heterologous AIP suggests that the lactam analog binds
its cognate receptor on the same site as the native thiolactone but only very weakly.
Furthermore, this suggests that the highly reactive thiolactone linkage is not absolutely
required for activation of the receptor, although this linkage does confer much increased
affinity to the AIP. The difference in affinity between the lactam and thiolactone AIPs is
explained by their different conformations in solution, as determined by two-dimensional
NMR analysis, which further demonstrated that the trAIP-II lactam and trAIP-II
thiolactone have very similar conformations to their corresponding full-length analogs
(see Results). It is very likely that the lactam analogs of the AIPs (full-length and
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truncated) have a conformation in solution that is very different from the receptor-bound
conformation of the signaling AIP. There are two possible reasons to explain why it
might be thermodynamically more costly for the AIP lactams to assume a receptor-bound
conformation. First, the lactam analogs have a hydrogen bond donor in the form of an
amide proton that does not exist in the thiolactone peptides, which could result in a
different hydrogen bonding network. Second, the activation energy barrier for rotation
around an amide linkage is much higher than for rotation around a thioester linkage.
Therefore, a thermodynamic penalty is incurred when the lactam analogs bind to AgrC,
thus decreasing affinity.
Cross-inhibition by the AIP-II lactam analog is similar in potency to crossinhibition by the native AIP-II, suggesting that the lactam binds the heterologous receptor
with similar affinity as the native peptide. Thus, the cross-inhibitory action of the AIPs
involves an interaction with the heterologous receptor that is different from binding to the
cognate receptor. This cross-inhibitory binding is also very permissive with respect to the
AIP amino acid sequence, since many variant AIPs so far tested are strong antagonists
though their sequences are highly divergent (Ji et al., 1997; Otto et al., 1998; Jarraud et
al., 2000). However, the C-terminal hydrophobic amino acids in the AIPs appear to be
critical for receptor binding and subsequent inhibition (discussed further below).

Key Determinants of Receptor Binding and Activation in the AIPs
Extensive structure-activity relationship (SAR) studies have been performed on
the AIPs (Otto et al., 1998; Mayville et al., 1999; Otto et al., 1999; Lyon et al, 2000;
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McDowell et al., 2001; Otto et al., 2001; Lyon et al., 2002; Lyon et al., 2002), and have
shown:
i) The length of the AIPs varies from 7-9 amino acids in length, with an
invariant cysteine located five amino acids from the C-terminus, which is
fixed based on the absolute conservation of a presumed AgrD processing
motif (DE) directly following it in over 30 different AgrDs (Dufour et al.,
2002).
ii) The AIPs contain a thiolactone that is formed from the condensation of the cccarboxyl group of the peptide with the sulfhydryl group of the conserved
cysteine
iii) The macrocycle is required for agonist activity (residues contained within the
macrocycle are referred to as endocyclic, whereas residues N-terminal to the
conserved cysteine and therefore outside of the macrocycle are referred to as
the "tail" or exocyclic.
iv) The nature of the linkage forming the macrocycle, comprised of a thioester
bond, is critical for certain aspects of biological activity, as the lactam analogs
of AIP-I and AIP-E are potent cross-group inhibitors but activate receptors
within their group only at very high concentrations (McDowell et al., 2001;
Lyon et al., 2002).
v) In the case of AIP-E, the tail is necessary for AgrC-E activation but not for
AgrC-I inhibition (Mayville et al., 1999) and substitution of asparagine for
alanine at position 3 in the tail of AIP-E converts an agonist into an antagonist
of AgrC-E activation (Lyon et al., 2002).
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vi)

T h e C-terminal three and two residues in AIP-I and - E , respectively, are

hydrophobic, and substitution of these residues by alanine decreases activation
and cross-inhibition dramatically, thus leading to the conclusion that these
residues are critical for AIP binding to AgrC (Mayville et al., 1999;
McDowell et al., 2001).
vii) Subsitution of the endocyclic aspartate by alanine at position 5 in AIP-I
converts it from an agonist into an antagonist of AgrC-I activation (McDowell
et al., 2001).
In addition, characterization of the AIPs from the four known S. aureus agr
groups with respect to their activating and inhibiting activities has been completed.
Several analogs of the AIPs demonstrate further that certain residues in the AIPs are
critical for receptor activation. These key residues are not all located at corresponding
positions, being endocyclic in some peptides and exocyclic in at least one (AIP-E).
Furthermore, the interaction of these key residues with the receptor is critically dependent
on the composition of the rest of the peptide. Moreover, the presence and composition of
the tail exerts profound effects on the function of the AIP, even though it has little to no
impact on the structure of the macrocycle, as determined by two-dimensional 'H NMR.
While AIP agonist activity is very sensitive to amino acid side chain and
structural changes, cross-inhibition by the AIPs seems to be more tolerant of sequence
and structural diversity, as the AIP-E lactam and several alanine-substituted analogs have
potent antagonist activity (Mayville et al., 1999; McDowell et al., 2001). This
observation has led to the suggestion that cross-inhibition by the AIPs involves a binding
interaction that is different from that of agonist AIP binding, although the inhibition is

145

competitive (Lyon et al., 2002) (illustrated schematically in Fig. 3.1). This hypothesis is
supported by experiments performed with chimeric AIPs, in which it was shown that a

peptide possessing both of the residues in AIP-I and -II critical for agonist activity did not
activate and instead universally inhibited AgrC activation (Table 2.6). Therefore, in the
chimeric AIPs, these critical residues are not presented in the proper orientation within
the ligand binding pocket of the receptor (Fig. 3.1). This result provides a sharper focus
on the general phenomenon of cross-inhibition by native AIPs, which usually differ from
the group-specific AIP agonists at many positions. This means that particular residues in
the tail and macrocycle must match in order for the AIP to bind in the correct orientation
to activate the corresponding receptor; otherwise, competitive inhibition results.
The apparent difference in the roles of the ring and tail moieties of AIP-E could
be interpreted to mean that the ring structure is responsible for recognition of and binding
to the putative ligand pocket of the receptor, and that the tail region is responsible for
initiating the signaling process. It was reasoned that removal of the tail region might
render a ligand which should be unable to activate AgrC signaling but should be a strong
inhibitor of its cognate AgrC as well as of the heterologous AgrCs. This was confirmed
using a truncated AIP-E (trAIP-E) lacking the tail but retaining the thiolactone structure.
This peptide inhibited not only AgrC-II, but also AgrC-I, EI, and IV (which, based upon
the current understanding of agr grouping, represents global agr inhibition in S. aureus).
Furthermore, trAIP-II weakly inhibited 8-toxin production in the S. epidermidis strain,
RN2375, and strongly inhibited 5-toxin production in the S. warnerii strain, RN3178.
These results suggest that trAIP-II may serve as a model for a global inhibitor of
staphylococcal agr activation, which may be of therapeutic relevance. Furthermore, the
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Figure 3.1. Model of receptor binding modes - AIP-I, AIP-II, and the chimeric
peptide, ATP-H/T, are depicted schematically as bound to the ligand binding pocket of
AgrC-I and -II. The key endocyclic residue (D5) of AIP-I and the key exocyclic residue
(N3) of AIP-E insert into hypothetical grooves of AgrC-I and -II, respectively, triggering
receptor activation, as illustrated by +++++. Cross-inhibition most likely involves
different orientations of binding to the heterologous receptor, as depicted by the tilt of the
ligands in the binding pockets of AgrC-I and - E . The chimeric peptide, AIP-E/I, does not
activate and instead inhibits AgrC-I and - E because it also binds in a different
orientation, thus preventing the key residues from activating their respective receptor.
This is a highly schematic model for the sole purpose of illustrating different modes of
binding, and there is currently no information available concerning the ligand binding
pocket within the sensor domain of AgrC.
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observation that an A I P agonist of the agr response (i.e. the intra-group A I P ) can be
converted into an antagonist of that response by removing the tail (i.e. trAIP-II) or by
substitution of asparagine for alanine in AIP-II N3 A, provides further, compelling
evidence that AgrC is the molecular locus of activation and inhibition. Ongoing studies
are focused on the design and/or discovery of peptidomimetic or small molecule agonists
or antagonists of agr signaling.
Two-dimensional NMR studies did not reveal any significant chemical shift
differences in the backbone protons of the truncated analogs versus their respective fulllength AIPs, suggesting that the backbone structure of each macrocycle is not
dramatically altered upon removal of the tail. However, the large difference in bioactivity
between these analogs, with EC50 values in the nanomolar range for agonists and
substantially higher IC50 values for truncated antagonists (Table 2.6), suggests that
removal of the tail usually, but not always, results in decreased affinity of the ligands for
the receptors. In the case of AIP-I and -IV, affinity can be regained through modification
of the ligand, since trAIP-I D2A inhibits receptor activation in the nanomolar range.
Another way in which affinity can be restored is by adding the tail from a different AIP.
As the heterologous tail does not materially affect the structure of the macrocycle, it is
likely to exert its effect through increased interactions with the receptor. For example, the
chimeric peptide, AIP-I/II, inhibits AgrC-I, -III and -IV activation with IC50 values that
are substantially lower than those seen with trAIP-E. In addition, AIP-E/I inhibits AgrC-I
at nanomolar concentrations, in contrast to the inhibition in the micromolar range by
trAIP-I (Table 2.6). This is not the whole story, however, since trAIP-I and -IV are only
marginally less potent as inhibitors of AgrC-E than are the corresponding native AIPs.
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Structure-activity studies of the endocyclic residue at position 5 in AIP-I and -IV
revealed several significant features of the peptide-receptor interaction. Substitution of
asparagine for aspartate in AIP-I converted a weak activator of AgrC-IV to a potent
inhibitor, suggesting that the negative charge of the aspartate residue in AIP-I cannot be
readily accommodated in the binding pocket of AgrC-IV. In contrast, the electrically
neutral asparagine binds with relative ease in the AIP-rV binding pocket, though this does
not result in AgrC-IV activation. The mechanistic basis for weak activation by AIP-I and
inhibition by AIP-I D5N will only be fully understood once the ligand binding pocket in
AgrC-IV has been characterized.
Activation of AgrC-I by AIP-I, AIP-IV, AIP-I D5N, AIP-IV Y5F and inhibition
by AIP-I D5A suggests that a single side-chain methyl group at position 5 (i.e. AIP-I
D5A) is insufficient for AgrC-I activation, but that bulkier groups will do, with the
exception that positively charged side-chains have not been tested. Furthermore, the
partial agonism of AgrC-I by trAIP-I but not by trAIP-I D2A suggests that the key
aspartate residue confers activating properties on the macrocycle in the absence of the
tail. Lastly, in the course of testing the various analogs, it was found that AIP-I D5N
activates agr signaling in group EI cells. This activation is surprising, as native AIP-I and
AIP-III are cross-inhibitors of AgrC-EI and -I, respectively, and both AIP-I and AIP-IE
share a common endocyclic aspartate residue that has been shown to be critical for AgrCI activation by AIP-I. Initial studies of this activation of AgrC-EI by AIP-I D5N have
indicated that it might be proceeding through a non-competitive mechanism at the level
of AgrC. Future studies should attempt to localize this non-competitive activation to the
sensor domain of AgrC-III, as it is possible that activation by this analog might be
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occurring through s o m e other mechanism other than binding to the AIP-IE binding
pocket of AgrC-EI.
The native AIP-III is a heptapeptide, as determined by synthetic means and by
HMS-MS. The addition of extra residues on the N-terminus of AIP-EI switches it from
an agonist into an antagonist, and the addition of an N-terminal glycine to the S.
epidermidis AIP inactivates the peptide (Otto et al., 1999). In contrast, N-acetylation or
the addition of relatively bulky groups (such as fluorescein or biotin) to the N-terminus of
AIP-I does not affect its activity. These contrasting results suggest that the effect of Nterminal modification varies for different AIPs. Furthermore, the contrasting lengths of
the AIPs (7, 8, or 9-mers), along with the complete lack of detection by HMS-MS of any
other shorter or longer forms in bacterial superatants of the respective agr groups,
suggests that the processing enzyme, AgrB, specifies the length of the corresponding
AIPs relative to the conserved C-terminal (DE) motif in the AgrD propeptide. The
mechanistic basis by which this is achieved remains a complete mystery.
An enduring question is why evolution has favored the use of a thioester linkage
in the AIPs, which has not been described in any other receptor-ligand based signaling
system. If the thioester linkage is not involved in acylation of the receptor, then other
theories must be invoked to explain its presence. One possibility is that enzymatic
formation of these peptides by the protein, AgrB, utilizes the relatively reactive thiolate
anion of the cysteine side chain for cleavage of the pro-peptide sequence. Alternatively, it
is possible that the transient nature of a thioester linkage at physiological pH could
provide a means for the signal to be abolished in a relatively short time period. This
might be advantageous for the bacteria in allowing them to modulate their own virulence
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by continual synthesis of the A I P in settings where virulence genes need to remain on and
to stop synthesis in settings where virulence genes need to be switched off rapidly.

Localization of Binding Determinants in AgrC for the AIPs
The identification of a peptide ligand recognition site in AgrC and the ligand
orientation has been established through the construction and assessment of chimeric
sensor domain receptors. Obviously, the architecture of the ligand-receptor complex can
be confirmed only by structural analysis of an AgrC receptor-AIP co-crystal.
Nevertheless, significant progress has been made through the study of receptor sensor
domain chimeras and their interactions with native and variant peptide ligands. The agr
system is especially amenable to this type of analysis because the respective protein
homologues are closely related and have the same function. The site of segment exchange
was chosen with a view toward localizing the determinant of receptor specificity for the
two most closely related agr loci in S. aureus, those of specificity groups I and IV.
Because the site was within a set of 8 amino acid residues that are absolutely conserved
between AgrC-I and IV, it was considered unlikely that the exchange would disrupt the
putative recognition site.
Two important features of the Agr quorum sensing system have been identified
which emphasize the relative location and probable orientation of the AIP on the AgrC
receptor: i) The potency for binding and activation resides in the C-terminal half of the
AgrC sensor domain. This is supported by the observation that activation follows with the
C-terminal region of the sensor domain. Hence, AgrC-I:IV and AgrC-ELIV are
preferentially activated by AIP-IV, and AgrC-IV:I and AgrC-IE:I are preferentially
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activated by AIP-I. ii) The AIP ring makes contacts necessary for activation with the Cterminal region of the AgrC sensor domain. Activation follows the presentation of a
critical activating residue in the AIP-I ring. This is demonstrated by the action of

ID5N analog, which can activate AgrC-IV:I but is now inhibitory towards AgrC-I:IV. It
is also noteworthy that the C-terminal region of the sensor domain, which confers

potency for activation, is also the region boundary closest to the intracellular sign

domain. Thus, conformational changes, induced by AIP binding to the C-terminus of the
receptor domain, may be communicated directly to activate HK autophosphorylation and
the signaling cascade in a manner functionally similar to two-transmembrane sensorHKs.
Perhaps most remarkably, there was a dramatic broadening of AIP recognition

specificity seen with the I::EI and IV::EI chimeras. This does not mean simply that t

N-terminal contribution to AIP recognition was responsible, since if that were the ca

the broadening would have included only AIPs I and IV. Since it included AIPs, such a

AIP-II, that are strong inhibitors of all three of the native AgrCs, the broadening o
specificity must reflect a profound change in the structure of the receptor, a re-

organization of the binding pocket enabling it to accommodate and be activated by a w

variety of ligands, without simply eliminating the need for a ligand. That is, the ov
structure of the receptor must determine in a large measure the outcome of any AIP-

receptor interaction. Incidentally, the I::E and E:.T chimeras are non-functional, as
IE::E (data not shown - it has not been confirmed that these molecules are expressed
emplaced correctly in the membrane). It would seem that exchanging intradomain

segments between AgxC-l/TV and IE is probably as far afield as one may go and still h
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a functional receptor. Whereas the results with AIPs I & IV and their interactions with the
AgrC-I/IV sensor domain chimeras support the hypothesis that site-specific ligandreceptor recognition underlies the activation mechanism, this hypothesis is fundamentally
inadequate to explain the very broad range of results presented with the other functional
chimeras.
On the basis of the strong hydrophobicity of all 27 staphylococcal AIPs of known
sequence, it is suggested that the AgrC receptor domain forms a hydrophobic pocket into
which various AIPs and their analogs can be inserted. AIP interactions with the receptor
would then occur in two stages: the first would be entry into this pocket, driven
energetically by the potential for hydrophobic interactions between ligand and receptor.
The second would be sequence-specific, presumably hydrophilic, interactions with
correctly positioned residues in the receptor, thus triggering activation through a series of
receptor isomerization steps. It will be recalled that the ultimate and penultimate residues
in 26 of the 27 known AIPs are bulky hydrophobic amino acids (Dufour et al., 2002) and
that replacement of either of these, in AIP-II, with alanine abolished all activity of the
peptide (both activation and cross-inhibition), up to the maximum concentration tested of
10 uM (Mayville et al. 1999) and in AIP-I virtually eliminated activity (McDowell et al.,
2001). This predicts that peptides with these alanine replacements would enter the pocket
very poorly, if at all; i.e., would not bind the receptor. According to this model, entry into
the pocket would require hydrophobic interactions involving these two residues and
activation would require additional specific contacts. The greatly broadened activation
specificity of the I-EI and IV-EI chimeras could mean that the chimeric receptors are
structured in such a way as to be poised for activation by almost anything that can occupy
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their putative hydrophobic pocket, obviating the need for any specific hydrophilic
contact. This is supported by the lack of activation by AIP-II F9A, which lacks a key
hydrophobic contact, on these chimeras. Furthermore, the failure of AIP-I to activate the
I::IE chimera could mean that the negatively charged aspartate residue at position 5
interferes with the formation of an intimate hydrophobic complex. Consistent with this is
activation of the chimeras by the D5N and D5A analogs, which are electrically neutral at
this position.
Inhibition has been viewed as the result of occupation of the ligand binding
pocket by the inhibitor; according to the present view, inhibition would result when a
peptide is able bind in the putative pocket but is unable to make specific activating
contacts with the receptor. This is consistent with the very wide range of inhibitory
peptides, all of which contain C-terminal hydrophobic amino acids. However, the
conformation in solution of these hydrophobic amino acids can be quite important, as the
linear AIP-E cannot activate or inhibit any receptor, while the AIP-II lactam is a potent
cross-inhibitor (but a very weak self-activator). On the other hand, the linear AIP-I
peptide can inhibit AgrC-II and -IE but cannot activate or inhibit AgrC-I or -IV. while
the AIP-I lactam is a weak self-activator and it was not tested for cross-inhibiton
(McDowell et al., 2001). These results collectively suggest that the content and
conformation of the AIPs plays a critical role in the process of inhibition.
Several transmembrane signal receptors for which peptides serve as activating
ligands have been described in Gram-positive bacteria. Unlike their counterparts in
Gram-negative bacteria, which do not have peptide ligands and usually have one or two
transmembrane helices, each of these has 4-6 transmembrane helices. Data presented in

154

this study suggest that in the staphylococcal agr system the entire complex polytopic
receptor domain may be involved in the receptor-ligand interaction, which seems to be
based largely on hydrophobic interactions followed by other specific activation contacts.

Conclusions
Staphylococcus aureus is an important nosocomial pathogen that has developed
resistance to most antibiotics and has lately become the focus of novel therapeutic
initiatives. The possibility of identifying agents that block the expression of virulence
factors represents one such initiative. In previous studies, it has been shown that this

initiative is valid in principle, as interference with agr expression in vivo can attenuate an
experimental S. aureus infection (Mayville et al., 1999). Furthermore, global inhibitors of
the agr response have been developed, which provide initial leads for drug optimization.
The data described herein have demonstrated that the mechanism of interference
proceeds through reversible and specific extracellular antagonism of signaling through
the sensor domain of the RHK, AgrC. It has been recently demonstrated that the wellcharacterized peptide-based competence induction system in Streptococcus pneumoniae
is required for virulence in a mouse model of infection (Lau et al., 2001) and that a
lactone-containing peptide in Enterococcus faecalis activates expression of virulence
factors (Nakayama et al., 2001; Qin et al., 2001). By analogy, these systems and many
other RHK-based systems in bacteria, plants and other species will be amenable to this
type of antagonism. Therefore, the design of molecules that compete (reversibly or
irreversibly) with naturally occurring agonists for binding at RHK sensor domains could
represent a generally applicable approach to the inhibition of RHK signaling.
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C h a p t e r 4 - Materials a n d

Methods

General Methods
All amino acid derivatives and resins were purchased from Novabiochem (San

Diego, CA) and Peninsula Laboratories (Belmont, CA). All other chemical reagents were
purchased from Aldrich Chemical Co. Restriction enzymes were purchased from New
England Biolabs (Beverly, MA) unless otherwise specified. Dimethyl-dg sulfoxide was
purchased from Isotec Inc. (Miamisburg, OH), and nitrocefin was purchased from
Becton-Dickinson (Franklin Lakes, NJ). Analytical gradient reversed-phase HPLC was
performed on a Hewlett-Packard 1100 series instrument with diode array detection.
Analytical HPLC was performed on a Vydac C18 column (5 micron, 4.6 x 150 mm) at a
flow rate of 1 mL/min. Preparative HPLC was routinely performed on a Waters
DeltaPrep 4000 system fitted with a Waters 486 tunable absorbance detector using a
Vydac C18 column (15-20 micron, 50 x 250 mm) at a flow rate of 30 mL/min. All runs
used linear gradients of 0.1% aqueous TFA (solvent A) vs. 90% acetonitrile plus 0.1%
TFA (solvent B). Mass spectrometric analysis was routinely applied to all synthetic
peptides and components of reaction mixtures. ESMS was performed on a Sciex API100 single quadrupole electrospray mass spectrometer.

Bacterial strains and growth conditions
Staphylococcal strains are derivatives of NTCC8325, and Esherichichia coli

strains JM109 or DH5a were used for cloning. RN6734 is our standard laboratory strain
and is agr group I. RN7206 is a derivative of RN6734 in which the agr locus has been
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replaced by tetM [Novick et al. 1993). R N 4 2 2 0 is a heavily mutagenized derivative of
S.aureus that readily accepts foreign DNA (Novick et al. 1991). S. aureus cells were
grown in CYGP broth (Novick, 1991) with shaking at 37°C. Overnight cultures on GL
plates (Novick, 1991) were routinely used as inocula. Cell growth was monitored with

Klett-Summerson colorimeter with a green (540 nm) filter (Klett, Long Island City, NY

Antibiotics used were erythromycin (10 pg/ml) and tetracycline (5 pg/ml). Biotyping of
staphylococci was performed at the Tisch Clinical Microbiology Lab, which confirmed
the species classification of the non-aureus strains.

Construction of strains and plasmids
A shuttle vector, pRN7035, was used which carries a V3:blaZ reporter, an ori
from pT181 (for replication in S.aureus), the ermC gene from pE194 (for selection in
S.aureus), and an ampicillin/ColEl ori fragment from pUC19 (for replication and

selection in E.coli). This plasmid was constructed by cloning a polymerase chain reac
(PCR) product containing the 180 nucleotide agr P2P3 region into the pUC polylinker
site of plasmid, pRN7034. Plasmids pRN7062, pRN7105, and pRN7107 were
constructed by cloning PCR fragments, containing agrC, agrA, and downstream

termination signals amplified from the genomic DNA of various prototypical agr groups

into the PstI or Pstl/SphI sites of the pUC polylinker of pRN7035. The following PAGE
purified primers (Integrated DNA Technologies, Inc.) were used in the PCR reactions:
group I pRN7062, forward primer, 5'CCAACTGCAGGAAGTACCAAAAGAATTAACACAA (PstI site underlined), reverse
primer, 5'-TTATACTGCAGACGTTTGCCAACATTACAAGAGG (PstI site

157

underlined), for group E pRN7105, forward primer, 5'TTTGAACTGCAGAAAGTACCCGCTGAATTAACG (PstI site underlined), reverse
primer, 5'GGTGAAGCATGCAGTTTGCCA ACATTAC A AGAGGTTG A AC A AGC ATTTT A A
(SphI site underlined), for group IV pRN7107, forward primer, 5'
TCTTAACTGCAGAAGTTGAAATACCTAAAGAATTAA CTCAATTACACG (PstI
site underlined), reverse primer, 5'-GGTGAAGCATGCAGTTTGCCAACATTACA
AGAGGTTGAACAAGCATTTTAA, (SphI site underlined). Plasmid DNA from the
corresponding E. coli DH5oc derivative was introduced into the restriction-defective
aureus strain, RN4220, by the protoplast method (Novick et al. 1991). Plasmids were
then moved onto various genetic backgrounds by phage transduction to develop new
strains, such as RN9222 (CAM), RN9372 (CA2-E), and RN9371 (CA4-IV), which are

referred to as group I, II or IV or AgrC-I, -II or -IV, respectively (Novick, 1991). No

RN9365 (CAI-I) is an additional strain with Group I agrC and agrA in a different grou

agr-null background, RN7206. This strain was tested and the results for RN9222 (CA1-1
were reproduced in this strain.

Group I, II, and III chimeric receptor construction
Chimeric receptors were assembled by Jesse Wright by fusing the N-terminal
sensor domain of the Group I and Group II agrC coding sequence to the Group IV agrC
HK - agrA coding region in the reporter construct pRN7107. The Quik Change
Mutagenesis kit (Stratagene) was used to introduce an Afl E restriction site at the

probable junction between the (N-terminal) sensor and (C-terminal) HK domains in agrC
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(JSW1 and J S W 2 ) creating pRN7128. The Group I and Group II sensor domains were
amplified from pRN7062 and pRN7105 with Pwo polymerase (Roche) using a common
upstream primer (JSW5) and downstream primers complementary to either Group I
(JSW2) or Group E (JSW7) incorporating the new Afl II site. The PCR products were

digested with Pst I and Afl II and ligated into pRN7128 digested with the same enzyme
to create the chimeric reporters pRN7107-2-GI and pRN7107-2-G2 (referred to in the
text as Group I chimera and Group II chimera). Plasmid inserts were identified by
restriction analysis and DNA sequencing. Primer sequences — complementary primers:
JSW1 5' - CAATTTCTCCTTAAGGAGATGAAATA - 3'
JSW2 5' - TATTTCATCTCCTTAAGGAGAAATTG - 3'
upstream primer: JSW5 - 5' - GCACATGGTGCACATGCACCT - 3'
downstream primers: JSW2 (for Group I),
JSW7- 5' - TATTTCATCTCCTTAAGGGTGAAAAG - 3' (for Group II)
The group IE sensor domain was amplified from chromosomal DNA isolated
from group EI strain RN8465 with Pwo polymerase (Roche) using the 5' oligonucleotide
JSW9 5'-GGCGCCTGCAGGAAGTACCAAAAGAATTAACTC (PstI site in bold) and
3' oligonucleotide JSW8 5'- TATTTCATTTCCTTAAGAGTAAATTG (Aflll site in

bold). The PCR product was digested with PstI and Aflll and ligated into pRN7128 with
the same enzymes to create the reporter pRN7131. The introduced sequence was
confirmed by DNA sequencing. Plasmid DNA from the corresponding E. coli

DH5a derivative was introduced into the restriction-defective S. aureus strain, RN422
by the protoplast method (Novick, 1991). Plasmids were then moved into the Group I
agr-null cell line, RN6911, by phage transduction (Novick, 1991).
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The new group III reporter strain, RN9532, uses B-lactamase production from a

P3-blaZ fusion to monitor group III activation and lacks any endogenous AIP-EI. Group

III cells are induced for B-lactamase activity by culture supernatants of group EI s

but not of group I, II or IV strains, and synthetic AIP-I, -II and -IV do not activate
cell line at concentrations up to 10 pM. Group EI culture supernatants were filtered

through a 10 kDa-cutoff Centricon filter to remove B-lactamase, which is endogenously

produced by all group III strains in our collection, as tested by the nitrocefin meth

Construction of chimeric sensor domain receptors
Plasmid pRN7128 served as the vector for expression of the receptor chimeras in
RN7206. Plasmid pRN7128 has a unique Aflll restriction site at the boundary between
the receptor and the HK motifs in agrC. Two-step PCR (Higuchi et al., 1988) with

appropriate primers and receptor templates was used to construct the chimeric fusions
(performed by Jesse Wright). The PCR fragments were then ligated back into pRN7128

using an upstream PstI site and the Aflll site. Sequences of the chimeras were confir
by dye terminator DNA sequencing chemistry (Skirball DNA Sequencing Core Facility).
pRN7128 derivatives were electroporated into S.aureus RN4220 and moved into an agr-

null strain, RN7206, by phage transduction to eliminate the effects of endogenous AIP
on function. The AgrC RHKs are referred to in the text as AgrC-N (N corresponding to
the Agr group) and the chimeras as AgrC-N:C (designating AgrC group N at the amino-

terminal end of the sensor domain and AgrC group C at the C-terminal end of the sens
domain).
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Preparation of AlP-containing supernatants
S. aureus strains were grown in CYGP broth with shaking at 37°C for 9 hr

starting with an inoculum of ~3xl07 cells/ml in 10 mL of broth. Cells were removed by
centrifugation at 4°C, and the supernatant was filtered (0.22-pm filter, Gelman). The

filtrate was stored at -80°C and used as a source of AIP. The group-specific activity
each supernatant was the same as that of the corresponding synthetic peptide.

Synthesis of the Thiolactone AIPs and Analogs, including trAIP-II lactam
In the initial published studies (Mayville et al., 1999), thiolactone peptides were
synthesized manually on preloaded t-butoxycarbonyl-amino acyl-3-mercapto
propionamide-polyethyleneglycol-poly-(N,N-dimethylacrylamide)
(Boc-AA-[COS]-PEGA) supports (Camarero et al., 1998) according to the in situ

neutralization O-benzotriazol-1 -yl-N,N,N',N',-tetramethyluronium hexafluorophosphat
(HBTU) activation protocol for Boc solid-phase peptide synthesis (Schnolzer et al.,

1992). After chain assembly, peptides were treated with HF for 1 hr at 0°C to give th
corresponding fully unprotected peptide-[COS]-PEGA resins, which were then washed
with cold ether and then CH3CN/ H20 containing 0.1% TFA. The alkyl-thioester
linkage between the peptide and the resin is completely stable to anhydrous HF

(Camarero et al., 1998). Unprotected peptides then were simultaneously chemoselectivel
cyclized (via attack by the sulfhydryl group from the cysteine) and cleaved from the
support by swelling the beads in a mixture of 0.1 M sodium phosphate buffer (pH 7.0)

and acetonitrile (80:20). After a 12-hr reaction, the beads were removed by filtration
washed with 0.1% TFA in water, and the peptides were purified from the filtrate by
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reverse-phase H P L C . In each case, the yield of thefinalcyclization/cleavage reaction was
between 60% and 90%, as determined by HPLC analysis of the crude reaction mixtures
and integration of the peaks. Key to this process is the ability to prepare a fully

unprotected peptide immobilized on a solid support through a reactive thioester bond.

Simply swelling such an unprotected peptide-[thioester]-resin in aqueous buffer resul
a chemoselective ligation reaction and concomitant cleavage of the peptide from the

support. This final step is made possible because of the excellent swelling propertie
the PEGA support in water (Mendal, 1992). However, the very sticky nature of PEGA
resin does incur handling losses.
A significant improvement to the above procedure involves the use of preloaded tbutoxycarbonyl-aminoacyl-3-mercapto-propionamide-4-methylbenzhydrylaminecopoly(styrene-l% DVB) (Boc-AA-[COS]-MBHA) support instead of the previously
used Boc-AA-[COS]-PEGA support. The 3-thiopropionic acid linker on MBHA resin is

labile to HF-cleavage conditions, thereby releasing linear thioester peptides upon gl

deprotection. Following removal of HF, crude peptide products were precipitated using
cold ether, washed thoroughly with ether, and then dissolved in 50% CH3CN/50%
water/0.1% TFA. After lyophilization, linear thioester peptides were dissolved again

CH3CN and water with 0.1% TFA, and cyclized in solution by the addition of at least l
volume of 0.1-0.2 M phosphate buffer at pH 7. The advantage of this solution-based

approach over on-bead cyclization is that the kinetics of cyclization can be more eas

monitored. In the majority of cases, >90% conversion of linear thioester to cyclic pr

was achieved in three hours or less. After cyclization, all peptides were purified by
preparative RP-HPLC and characterized by analytical RP-HPLC, ESMS, amino acid
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analysis, chemical reactivity to neutral hydroxylamine or sodium hydroxide, and 'H

NMR, which collectively demonstrated that all peptides were of the correct compositi

and >95% pure. In addition to AIP thiolactone peptides, the synthesis of trAIP-II lac

was carried out with this methodology (aided by Ehab Khalil), with the exception that
diaminopropionic acid (DAPA) was incorporated in place of cysteine in the following
peptide: Acetyl-DAPA-Ser-Ser-Leu-Phe. The amino group from DAPA (rather than the

usual sulfhydryl group from Cys) chemoselectively reacted with the activated carboxy

a-thioester to form the lactam analog. This strategy was possible due to the fact th
N-terminal amine of the AIP was acetylated.

Synthesis of Linear free acid peptides
In some instances, standard linear free acid peptides, e.g. linear AIP-I and AIP-II,
were prepared on a 0.1 millimole scale by automated continuous flow solid-phase
synthesis on a PE Biosystems Pioneer Peptide Synthesizer (kindly provided by the
Danishefsky laboratory) using standard 9-fluorenylmethoxycarbonyl (Fmoc) chemistry.
Fmoc-AAs ( > 4 eq.) were weighed into labeled, letter coded, 13 x 100 mm test tubes;

HATU ( < 4 eq.) was then added to each test tube. After placing the test tubes in the
appropriate racks, the appropriately preloaded NovaSyn TGA resin (-0.20 mequiv/g,
-500 mg) (NovaBiochem) was weighed into a synthesis column and washed in with
methanol. DMF was washed through the column on the synthesizer at a flow rate of
30 mL/min while the resin was compressed and released by successive tightening and
loosening of the column to remove bubbles and swell the resin. When no air bubbles

remained (about 1 minute, with gentle tapping when the resin was not compressed), the
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column was tightened to accommodate only the volume of the swollen resin and the flow
of DMF was stopped. Fmoc removal (deblock) was accomplished using a 1:1:48 (v:v:v)

mixture of DBU : piperidine : DMF for 5 minutes at a flow rate of 6 mL/min directly t
waste and was monitored by integrating over time the UV absorbance of cleaved Fmoc

chromophore. Each coupling step involved the reagents in a single test tube and exces
DIEA in DMF for 30 - 60 minutes at a recycling flow rate of 30 mL/min. Multiple
successive washes of DMF and methanol were used to prepare the growing resin-bound
peptide for successive steps. The final deblocked peptide was washed out of the
synthesis column with methanol into a manual peptide synthesis vessel and dried in
vacuo.
Linear peptides prepared by Fmoc synthesis on NovaSyn T G A resin were

cleaved in a manual peptide synthesis vessel for two hours under an argon atmosphere

with 7 mL of a cocktail prepared directly before usage consisting of approximately 9
TFA, 2.5 % triisopropylsilane, 2.5 % water (all by volume), and then filtered with
washing (to collect all peptide and to remove the resin) into a 250 mL round-bottom
by simply opening the stopcock. This solution was then rotavapped to remove most of

TFA, and peptide precipitated by addition of dry diethyl ether. The cold ether slurry

allowed to warm to room temperature over 10 minutes, at which time it was transferred

a conical tube and placed in a centrifuge and spun at 3.5 x 103 revolutions per minu

(krpm) for 5 minutes. The precipitate was washed three times with ether. Each time th

supernatant was decanted and the conical tube closed and vortexed for < 1 minute, unt

the solid clump loosened. Ether at room temperature was then added (20 mL), the tube

capped and the suspension vortexed for a short time and placed back in the centrifug
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5 minutes. After decanting the final wash, the conical cap was closed halfway and the

peptide placed under vacuum and dried on the lyophilizer. The linear fully-deprotecte
free acid peptides synthesized using this procedure were dissolved in 50% CH3CN/50%
water/0.1% TFA and purified by HPLC.

Synthesis of the Lactone and Lactam AIP-II Analogs.
The protected peptides Z-Gly-Val-Asn-Ala-Ser(t-Butyl)-Ser(Benzyl)Ser(Benzyl)-Leu-PheandZ-Gly-Val-Asn-Ala-DAPA(Boc)-Ser(Benzyl)-Ser(Benzyl)Leu-Phe, corresponding to the AIP-E sequence with a Cys-5-Ser modification [lactone]
and a Cys-5-diaminopropionic acid (DAPA) modification [lactam] respectively, were
synthesized manually on a Wang-resin by using a fluorenylmethoxycarbonyl (FMOC) N-

a-protection strategy with HBTU activation protocols. After chain assembly, the pepti
were cleaved from the support and the Ser-5 or DAPA-5 side chain deprotected by
treatment with a TFA-anisole-water mixture (90:5:5) for 4 hr.The partially protected
peptide-oc carboxylates then were dissolved in DMF (0.5 mg/ml) and treated with
benzotriazol-1 -yl-oxytripyrrolidinophosphoniumhexafluorophosphate (PyBop; Nova

Biochem) (5 eq) and DIEA, and in the case of the lactone precursor, a catalytic amoun
dimethylaminopyridine. The cyclization reactions were monitored with HPLC, which

indicated 2 hr to be sufficient for complete reaction. The remaining protecting group
were then removed by treatment with HF and the desired peptides purified by reversephase HPLC and characterized by MS and 2D 'H NMR spectroscopy.
As an alternative approach to the synthesis of the AIP-E and trAIP-E lactone
peptides, NovaSyn TGT resin (NovaBiochem) was utilized (vide supra). The advantage
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of T G T resin is that mild cleavage with 0.5% T F A in D C M yields protected peptide acid
fragments without any loss of 95% TFA-sensitive side-chain protecting groups, thus
allowing the use of TFA, instead of HF, for the analysis of trial macrolactonization

attempts. The protected peptides Boc-Gly-Val-Asn(Trityl)-Ala-Ser(Trityl)-Ser(t-Butyl)
Ser(t-Butyl)-Leu-Pheandacety-Ser(Trityl)-Ser(t-Butyl)-Ser(t-Butyl)-Leu-Phe,
corresponding respectively to the AIP-II and trAIP-E sequences with a Cys-5-Ser
modification, were synthesized on preloaded Phe-NovaSyn TGT resin (-500 mg
resin/peptide) as described for the synthesis of linear peptides by automated Fmoc

synthesis (vide supra). Peptides prepared by Fmoc synthesis on NovaSyn TGT resin were

cleaved for one hour with 7 mL of a cocktail prepared directly before usage consistin
approximately 1 % TFA / 5% triisopropylsilane in DCM. These cleavage conditions

cleave the peptide off the resin and selectively remove the trityl protecting group f

Ser5, while leaving the Asn3 trityl and other protecting groups intact. After one hou
cleavage mixture was filtered into a 250 mL round-bottom flask, rotavapped to near-

dryness, and precipitated by addition of dry diethyl ether. The cold ether slurry was

allowed to warm to room temperature over 10 minutes, at which time it was transferred

a conical tube and placed in a centrifuge and spun at 3.5 x 103 revolutions per minut

(krpm) for 5 minutes. The precipitate was washed three times with ether. Each time th

supernatant was decanted and the conical tube closed and vortexed for < 1 minute, unt
the solid clump loosened. Ether at room temperature was then added (20 mL), the tube

reclosed and the suspension vortexed for a short time and placed back in the centrifu

for 5 minutes. After decanting the final wash, the conical tube was closed halfway an

the peptide placed under vacuum and dried on the lyophilizer. Macrolactonization effo
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were as described above, with the exception that the use of H A T U was also attempted in
place of PyBop, in the presence of DIEA and DMAP in DMF.

Peptide Stock Solution Preparation
The concentrations of peptide stock solutions for bioassays (vide infra) were

calculated based on amino acid analysis, with the peptides dissolved in 45% CH3CN/55%
water/ 0.1% TFA. This amino acid analysis is associated with a ±10% error, as
determined by multiple hydrolyses and HPLC analyses of single samples. Amino acid
analysis and UV measurements of the same sample agreed closely (±20%) when UV
readings were measured at 280 nm for those peptides containing at least one tyrosine
residue (extinction coefficient for tyrosine = 1100 mol"1 cm"1). However, a major
discrepancy between amino acid analysis and UV measurements occurred for those

peptides for which the absorbance at 254 nm for phenylalanine was utilized (extinctio
coefficient for phenylalanine = 200 mol"1 cm"1). In these cases, the UV-determined

concentration was always substantially higher (-5-6 fold) than that determined by ami

acid analysis. This discrepancy is explained by the fact that thioesters are known to

absorb at 240 nm, thus yielding a characteristic shoulder to the right of the amide b

absorbance profile on the UV spectrum. This thioester absorbance results in an artifi
high reading at 254 nm. As such, the concentrations of all peptides were adjusted to

determined by amino acid analysis, and new extinction coefficients were calculated fo

each peptide based on the amino acid analysis. For example, the extinction coefficien
AIP-II at 254 nm is 1230 mol"1 cm"1, which is substantially higher than that of

phenylalanine (200 mol"1 cm"1). In contrast, the extinction coefficient for AIP-II lac
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which lacks a thioester linkage, is 350 mol"1 cm"1. Alternatively, the extinction coefficient

for AIP-I at 280 nm is 1290 mol"1 cm"1, which is similar to that of tyrosine (1100 mo
cm"1), due to the lack of thioester absorbance at 280 nm. The calculated coefficients
utilized in subsequent experiments when UV measurements were made on the same batch

of RP-HPLC purified and re-lyophilized peptides. However, this was rarely done as the

first aliquoting of AIP was usually more than sufficient for bioassays and analytical
characterization.
After UV measurements were performed on a peptide (dissolved in 45%
CH3CN/55% water/ 0.1%) and samples set aside for amino acid analysis and NMR, small

aliquots (usually 100 uL) were lyophilized in eppendorf tubes. Peptide stocks were ma

by dissolving the lyophilized peptides in 25% propylene glycol, 0.05 M phosphate pH 5
at a known concentration (based initially on UV absorbance and corrected later if

necessary by the amino acid analysis results) and serially diluting them into the sam
buffer for assays with cells. In some instances, e.g. trAIP-IV and trAIP-I/IV D/Y2A,

AIPs were insoluble in this solvent system due to their extreme hydrophobicity. In th
cases, DMSO was used initially to solubilize the peptides, which were then serially
diluted into 25% propylene glycol, 0.05 M phosphate pH 5.7, paying careful attention
avoid peptide precipitation.

NMR Spectroscopy for characterization and comparison of the AIPs
Two-dimensional •H NMR analysis yielded complete assignments for all

published synthetic peptides, and all chemical shift data are listed in Appendix 1. A
NMR spectra were recorded on a Bruker AMX-400 spectrometer and processed using the
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X W I N N M R software package (Bruker). The measurements were performed at 298 K
using 0.5-2.0 mM solutions of the peptides in 90% H2O/10% D20, pH 4.0 or DMSO-dg,

and all chemical shifts are referenced to the solvent signal [either TMS at 0 ppm (1H
the solvent signal of DMSO- d6 at 2.50 ppm (!H)]. Assignment of resonances was
achieved by 2D-NMR techniques (TOCSY (Bax, 1984) and ROESY (Kessler, 1987)).
Mixing times were 77 ms for TOCSY spectra and 200 ms for ROESY spectra. The

chemical shifts of the amide, alpha and beta protons were compared between the differ

peptides in the same solvent system and were normalized to the shifts of the most clo
related native AIP

RP-HPLC analysis of 8-toxin levels
A modification of the assay originally described by Otto and co-workers (Otto

and Gotz, 2000) was used to quantify 5-toxin in supernatants from various strains. Ea
exponential-phase cultures were treated with increasing concentrations of synthetic
peptides and then allowed to grow for nine hours. Supernatants, obtained by

centrifugation, were analyzed by re versed-phase HPLC on a Hewlett-Packard 1100 serie

instrument with diode array detection. Typically, 400 uL aliquots of supernatant were
injected onto a 1 mL Pharmacia Resource PHE column, which was eluted at 1 mL/min as

follows: isocratic at 35% buffer B in buffer A for 3 minutes, which allowed the major

of the UV-absorbing material to wash through the column, followed by a linear gradien
of 35-50% B in A over 20 minutes, where A = 0.1% TFA in water and B = 0.1% TFA in
90% acetonitrile/10% water. This optimized gradient achieved excellent separation of
8-toxin from other components (>95% pure by HPLC and MS), which permitted direct
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quantitation by peak integration. 5-toxin is usually N-formylated, and the additional 28
daltons of the N-formyl group was included in the calculated mass. We observed this
mass by ESMS on HPLC-purified fractions of 5-toxin: S. aureus group I and III,

observed mass for both groups = 3007.1 ± 2.2 Da, predicted (average) mass = 3006.5 Da

(all S. aureus agr groups encode identical 5-toxin); S. epidermidis strains, observed
= 2848.7 ± 1.5 Da, predicted (average) mass = 2848.4 Da, and S. warnerii strains,
observed mass = 2900.1 ± 0.8 Da, predicted (average) mass = 2899.4 Da. In summary,

8-toxin was detected in the following biotyped strains in the R.P.N, strain collecti
(NYU): S. epidermidis, RN9420, RN9421, RN9422, RN8111, ATCC, and TU3298
(kindly provided by M. Otto), S. aureus, RN6734 and RN8465, and S. warnerii, RN3178.
5-toxin was not detected in S. intermedius, RN9423 (vide infra).

Whole cell lysates and Northern blotting for RNAIII expression
Bacteria were collected at the indicated time points, and whole-cell lysates were
prepared as described (Kornblum et al., 1988). Cultures were centrifuged, fixed in
acetone-ethanol (1:1), and washed in N-tris(hydroxymethyl)methyl-2aminoethanesulfonic acid (TES)-sucrose buffer. Equalized cell samples were incubated
on ice for 30 min with lysostaphin (150 mg/ml) in TES-sucrose buffer (20% [wt/vol]
sucrose, 20 mM Tris [pH 7.6], 10 mM EDTA, 50 mM NaCl) and shaken for 1 h with
proteinase K (50 mg/ml; Sigma) and 2% SDS at 4°C. For Northern blotting (Vandenesch
et al., 1991), the same amount of cell lysate was electrophoresed through a 0.66 M
formaldehyde-1% agarose gel in MOPS (morpholinepropanesulfonic acid) buffer
(Maniatis, 1982). Nucleic acids were transferred to a nitrocellulose membrane
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(Amersham) with a VacuGene apparatus (Pharmacia) in 20x S S C (3 M NaCl, 0.3 M
sodium citrate [pH 7]) and fixed under UV light. The membrane was preincubated for 2
at 52°C in 2x Denhardt's solution (0.02% bovine serum albumin, 0.02% Ficoll, 0.02%
polyvinylpyrrolidone, 0.05 M EDTA [pH 8], 0.2% SDS, 5x SSC, with sonicated and
heat-denatured salmon sperm DNA [100 mg/ml]) and 10% (wt/vol) dextran (Sigma) and

then hybridized overnight with a 32P-labeled DNA probe in hybridization solution. 32P
labeled RNAEI probes were prepared by PCR using oligonucleotide primers
corresponding to nt 1259-1280 and nt 1558-1571 of RNAIE, and pRN6735 DNA as
template. In labeling reactions, dATP concentration was reduced to 2 uM and the
reaction mixture contained 50 pCi of [a-32P]dATP (Amersham; 1 Ci = 37 GBq). The blot
was exposed to a storage phosphor screen (Molecular Dynamics).

Agr activation and inhibition reporter-gene assays
Assays were performed with bacterial cultures in early exponential phase (~2xl08

cells/ml) and used a B-lactamase reporter gene readout. For activation assays, 80 pL o
cells (9xl08 cells/mL) were treated in duplicate with AIPs at varying concentrations
incubated with shaking at 37°C for 60 or 90 minutes in a THERMOmax microplate
reader (Molecular Devices) with monitoring of cell density at OD650, followed by
determination of agr activation by the B-lactamase/nitrocefin assay (Ji et al., 1995).

inhibition assays, 80 pL of cells (9xl08 cells /mL) were treated in duplicate with AI

analogs in the presence of the group-specific wild-type AIP agonist at a concentratio
100 nM, followed by the B-lactamase assay. An agonist concentration of 100 nM is a

saturating but not over-saturating dose of activator, which generates maximal activat
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against which to test various concentrations of inhibiting heterologous AIPs. The time of

incubation usually did not exceed 90 minutes, but in some cell preparations, an addit

30-60 minutes was required to achieve at least a 5-10 fold induction over basal activ
response to the AIPs.

Functional binding and competition experiments
RN9222 (CAI-I) cells or RN9372 (CA2-II) cells (both at 9xl08 cells/mL) were

treated for one hour with jAIP-I or -E at 1 pM. Aliquots (1 mL) of the cells were pel
and resuspended in 1 ml of CYGP broth. This washing procedure was repeated up to 10

times. After the washes, cells were resuspended in CYGP broth with or without AIP-I o
-II at a concentration of 1 pM. In one set of experiments, trAIP-II was added at 1.0

pM. Timepoints were then taken every 30 minutes for 3 hours to monitor the kinetics o

B-lactamase induction. Washing exerted only a minimal effect on subsequent growth, an

the data were normalized to cell density to account for any small differences. Contro

experiments in which activated cells were either untreated or re-activated with their
group-specific AIPs after washing showed that washing had a minimal effect on
subsequent activation. All experiments were performed at least twice, and the single
corresponding timepoints from all experiments were combined for error analysis.

Effects of antagonist AIP preincubation and washing on subsequent activation
In the case of cross-group inhibition, 3 mL of RN9222 (CAM) cells (9xl08

cells/mL) were pre-incubated for one hour (or five minutes) with either AIP-II at 1 u
25% propylene glycol, 0.05 M phosphate (pH 5.7) buffer. Time-point zero was then
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taken with 50 pL of cells added to 75 pL of C Y G P supplemented with sodium azide at 5
mM, and the samples were placed on ice. Cultures were then divided into 500 pL
aliquots, pelleted, washed with 1 mL of CYGP broth, pelleted again and then
resuspended in 495 pL of CYGP broth with addition of either buffer alone or AIP-I at
final concentration of 1 pM, bringing the total volume to 500 pL. Cells were then

incubated with shaking at 37° C and samples taken every 30 minutes as described above
The B-lactamase assay was performed at the conclusion of 210 minutes, and the data

were normalized by calculating the induction ratio (induced/basal) at each timepoint.
Data are quoted ± SEM, and are derived from several timepoints (150, 180 and 210
minutes) combined after normalization.
In the case of self-inhibition, 1 mL of RN9372 (CA2-II) cells were pre-incubated

with or without trAIP-E at 1 pM for 30 minutes at 37°C. The cells were pelleted, wash

pelleted again and resuspended in 1 mL of CYGP broth. The cells were then treated for

60 minutes with AIP-E at varying concentrations and agr activation was evaluated by t

nitrocefin assay. The data were used to plot concentration-response curves, from whic
EC50 values were derived. These values are quoted ± SEM.

Order of Addition experiments
RN9222 (CAM) cells (80 mL at 9xl08 cells/mL) were treated in duplicate with

varying [AIP-II]. AEM was added at 100 nM, either five minutes before, simultaneously,

or five minutes after addition of the antagonist. The cells were incubated at 37° C i

well plate with shaking during these five minute periods. The cells were then incubat

for 60 minutes at 37° C. Agr activation was evaluated by the B-lactamase assay as abo
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A similar series of experiments was performed on R N 9 3 7 2 (CA2-E) cells using AIP-II
vs. trAIP-II. Data were collected as 6-lactamase activity (V^, in mOD/min) and then
normalized to % maximal activation. Data are quoted ± SEM.

Agonist-Antagonist Interactions: Concentration-Response Curves
For the activation experiments, 80 uL of cells (9xl08 cells/mL) were treated in

duplicate with AIP agonist at varying concentrations in the absence or presence of th

antagonist at fixed concentrations up to 1000 nM. For inhibition experiments, 80 pL o

cells (9x10e8 cells/mL) were treated in duplicate with the antagonist in the presence

fixed concentration of the agonist at concentrations up to 1000 nM. In both instances
incubation was for one hour at 37° C, and agr activation was evaluated by the 8lactamase assay.

Data Analysis
The data from the 6-lactamase assay are plotted as initial B-lactamase reaction

velocity versus log peptide concentration. In some instances, the data are normalized
% maximal activation for comparison of curves between assays. Individual agonist or

antagonist concentration-response curves, in the absence and/or presence of antagonis

were fitted via nonlinear regression to the following four-parameter Hill equation, u
PRISM 3.0 (GraphPad Software, San Diego, CA, USA):
Emav-Basal
E = Basal +

^

— -

(l)

1 + 1Q(LogEC5o-U)g[A])nH
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where E denotes effect, [A] the agonist concentration, nH the midpoint slope, EC50 the
midpoint location parameter, and Emax and Basal the upper and lower asymptotes,
respectively. For inhibition curves, the midpoint location parameter from equation (1)
was the IC50, rather than the EC50. All EC50 and IC50 values are listed in tabular format
with a 95% confidence interval (CI), which represents the error associated with the
measurements using each peptide stock solution. EC50 is not a binding constant, but rather
a composite of equilibria for both binding and receptor activation. An advantage of EC50
is that it represents afunctional assay, so that a response, either activating or inhibiting,
indicates that mutant receptors are structurally intact. When Vmax is fully attained, one
assumes that receptor activation by the AIP proceeds normally. Under this assumption
therefore, variations in EC50 should represent differential agonist-binding ability. This
was confirmed in part through determination of antagonist potency (pA2) values (see next
paragraph and Results).
In those experiments generating concentration response curves in the presence of
varying antagonist concentrations, antagonist potency was determined by taking the
agonist EC50 values obtained in the absence and presence of antagonist and fitting them to
the following equation (Lew and Angus, 1995; Christopoulos et al., 2001) using
nonlinear regression:
pEC50 = -log([B]5+ 10pK) - log c (2)
where pEC50is the negative logarithm of the EC50, [B] is the antagonist concentration, pK
and log c are fitting constants, and s is equivalent to the Schild slope factor. Curves were
generated with either the Schild slope held constant at unity or with the slope allowed to
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vary, and the better-fitting model was determined by an extra-sum-of-squares test using

PRISM. In this test, a p value < 0.05 indicates a slope value significantly less than

Pull-down experiments with RN8559, RN9222, and RN6911
Various preparations of cells (RN8559, induced with methicillin, RN9222, and
RN6911) were concentrated in PBS to different cell concentrations, starting with an
initial concentration of 3000 klett units (kU). 14 pL of a 3000 kU culture in PBS is

to 5.04xl0e7 cells; concentration was therefore required to increase the number of ce
added while maintaining the same volume. 14 pL of cells from the various stocks were
added to 112 uL of PBS followed by 14 pL of a 1 uM AIP-I solution to a final

concentration of 100 nM AIP-I. The tubes were vortexed and left sitting for 5 minutes
followed by spin-down and assaying of 10 uL supernatant aliquots (in duplicate) with
pL of RN 9222 cells (kU60) for one hour in the Thermomax plate reader, followed by
the nitrocefin assay of 50 uL aliquots from each well.

Using Fluorescein-conjugated AIP-I to detect a covalent AIP-AgrC adduct
Agr-i- (RN6734) and agr-null (RN6911) cells (klett unit=800, ~6xl010 cells) were

incubated for five minutes with fluorescein-conjugated AIP-I at a final concentration

uM. Protoplasts were prepared to remove the cell wall (Novick, 1991), and the cells l
by the addition of lysostaphin and SDS buffer. Lysates were run on SDS-PAGE gels,

followed by in-gel fluorescence imaging. As a control, the Fl-AIP-I peptide by itself

strongly fluorescent in these gels. To increase the sensitivity of detection, SDS-PAG

gels were also transferred to nitrocellulose filters and subjected to Western blottin
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an anti-Fluorescein antibody (Molecular Probes, Inc.). In no instance was a fluorescent or
chemiluminescent band detected corresponding to fluorescent AgrC. In another
experiment, the use of a fluorometer was investigated for whole cell binding assays.

However, it was found that S. aureus cells are auto-fluorescent with a maxima near to
emission wavelength of fluorescein, thus rendering the use of this molecular probe
difficult. This was further confirmed using fluorescence microscopy (aided by M.
Goulian).

Using Biotinylated-AIP-I as a molecular probe for AIP-AgrC interactions
4.5 mL of S. aureus cells (RN9222 and RN9033) at 65 kU were incubated for one

hour with biotinylated-AIP-I, AIP-I, or buffer, with the peptides at a final concentr

of 500 nM. At the end of the hour, agr activation was confirmed by the nitrocefin met

in RN9222 cells treated with biotinylated-AIP-I or AIP-I, but not in any of the contr

(using 2x30 uL aliquots). 1 mL aliquots of the cells were taken in duplicate, spun-do
and the pellet washed once with 1 mL of Tris-buffered Saline, pH 7.8 (50 mM Tris,
0.85% NaCl). The cells were resuspended in 500 pL of CY broth + 100 uL of a 1:100
dilution of Streptavidin-conjugated Horseradish Peroxidase (Amersham), to which 100
pL of para-nitrophenyl phosphate (PNPP) (Sigma) was added. 100 pL aliquots were

transferred in duplicate to a 96-well plate, and the cells monitored kinetically with
shaking in a Thermomax plate xeader, reading at 405 nm and 650 nm. PNPP cleavage by

Streptavidin-conjugated Horseradish Peroxidase results in an increasing signal at 405

while cell growth is monitored at 650 nm. Control experiments demonstrated that a 1:1
dilution of Streptavidin-conjugated Horseradish Peroxidase still resulted in active
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cleavage of P N P P , while a 1:105 dilution was slightly detectable. However, in this
instance and in other similar experiments, there was no increased cleavage of PNPP in
agr+ (RN9222) cells that had been treated with biotinylated-AIP-I, in comparison to the
controls.
Similarly treated samples were lysed and run on SDS-PAGE gels, for Western
blot detection with Streptavidin-conjugated Horseradish Peroxidase. These efforts met
with limited success, due in large part to the many already biotinylated proteins in
metabolic pathways of S. aureus. However, even given the high background seen on
Western blots using Streptavidin-conjugated Horseradish Peroxidase as the "secondary
antibody" for ECL detection, no band corresponding to AgrC was seen in lanes
containing agr+ cell lysates (RN9222). It is noteworthy that dot blots with biotinylatedAIP-I on its own only gave a faint signal after incubation with Streptavidin-conjugated
Horseradish Peroxidase, followed by ECL detection. This could be because the peptide
did not bind well to the nitrocellulose filter (0.2 micron pore size), due to its small size.
However, it is formally possible that streptavidin did not bind well to the biotin, in the
context of their conjugation with Horseradish Peroxidase and AIP-I, respectively.

Acetylation and Purification of AIP-I in solution
To label the N-terminus of AIP-I in solution, the radioisotope, tritium 3H, was
chosen, using acetylation with acetic anhydride [3H] as the method of choice. The isotope
3H has the added advantage of a relatively long half-life, 12 years, making the preparation
of radioactive AIPs independent of decay considerations. However, if necessary, the
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Bolton-Hunter reagent (containing 125I) can be used for N-terminal acylation, if
considerably higher specific activities are required.
Initially, acetylated AIP-I was prepared via standard peptide synthesis methods

and was confirmed to have similar activity to that of AIP-I (see Results). Therefore,

range of conditions were initially tested for acetylation of AIP-I in solution (using

acetic anhydride), as radioactive acetylation during solid-phase peptide synthesis wo
contaminate all subsequent equipment. Conditions tested included: 10 eq. Ac20:1 eq.
AIP-I with 1% or 10% v/v DIEA, 1 eq. Ac20:l eq. AIP-I with 1% or 10% v/v DIEA, 10
eq. Ac20:1 eq. AIP-I with 10% v/v 0.2 M phosphate buffer, pH7.0, with each reaction
analyzed at 10 or 30 minutes, where 1 eq. of AIP-I was 7.5 pg dissolved in 90 pL DMF
and the total volume of the reaction was 106 uL. All conditions and time-points were
quenched with 100 pL 50%TFA/50%H20 on ice, and aliquots were injected onto

analytical RP-HPLC to determine acetylation yields. The best reaction conditions were
10 eq. Ac20:l eq. AIP-I with 10% v/v 0.2 M phosphate buffer, pH 7.0, for 10 or 30

minutes, which gave nearly quantitiative yields, with minor side-reactions. The conte
of this reaction were: 90 uL AIP-I (7.5 pg) in DMF, 10 pL 0.2 M phosphate buffer,
pH7.0, and 6 pL of a 1:1000 dilution of Ac20 in DMF.
As the lab did not have access to a radioactive HPLC, the use of disposable C18
SepPak columns was investigated for purification. 2 1-mL columns were connected in

series, and the remaining reaction (minus that used for analytical HPLC) diluted to 1
with Buffer A (0.1% aqueous TFA). This was loaded onto the column at a manual flowrate of ~1 mL/5 minutes. The column was washed with 1 mL of Buffer A at the same

flow-rate, followed by 10 mL of Buffer A over a 5 minute period. AIP-I was then elute
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with Buffer B (90% acetonitrile plus 0.1% T F A ) with 7 m L at a rate of 1 mL/min, with
collection of 1 mL fractions. The bed volume of the column is 2 mL, so 5 elution

fractions were collected. The fractions were individually analyzed and then combined,
and the recovery from the column deduced from the area under the curve on analytical
HPLC traces of the product, adjusted for volume differences before and after SepPak

purification. This purification procedure on 7.5 pg of AIP-I was repeated twice, with

recovered yields of 42% and 35%, respectively, with the vast majority of the material
found in the third elution fraction.
Given the quantitative conversion of AIP-I to acetylated-AIP-I with these reaction
conditions, the relatively low recoveries resulted most likely from loss of AIP-I on

SepPak column given the low amount of material added (7.5 pg). To investigate this, t
reaction was performed on ten times more material, 75 pg, of AIP-I, dissolved in 900
DMF, with 100 pL 0.2 M phosphate buffer, pH7.0, and 60 uL of a 1:1000 dilution of
Ac20 in DMF. The reaction was quenched after 10 minutes with 1 mL of
50%TFA/50%H20, and analytical RP-HPLC demonstrated quantitative yield with this
lOx scale-up. The reaction was diluted to 10 mL with Buffer A, and the purification
conditions on the SepPak column were slightly changed. This included: Loading at 10
mL/10 min, followed by an additional 10 mL/10 min Buffer A, then 2x with 10 mL/5 min
Buffer A, 10 mL/5 min 20% Buffer B, followed by elution with 70% Buffer B at 5 mL/5

min, with collection of 1 mL fractions. Once again, RP-HPLC analysis demonstrated tha
the vast majority of the material eluted in fraction #3, indicating that the peptide
dissociates readily from the column after the dead volume has been eliminated. The
overall yield for the reaction (including purification) was 90%, which was deemed
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acceptable for radioactive labeling experiments. Most importantly, 1 D - N M R analysis of
fraction #3, lyophilized and redissolved in dDMSO, revealed the complete absence of
acetic anhydride, which was of crucial importance for future whole cell binding
experiments.

Radioactive Labeling of AIP-I in Solution
Acetic anhydride [3H] was ordered from ICN and had a specific activity of 64
mCi/mmol, and a concentration of 677 pCi/pl. The reaction was set up with the same
10:1 ratio of Ac20:AIP-I. This included 100 pg AIP-I in 1200 pL DMF, 140 pL0.2 M
phosphate buffer, pH7.0, and 80 pL 1:1000 dilution of Ac20 [3H] in DMF. The reaction
proceeded for 30 minutes, as previous analysis had demonstrated that the difference

between 10 and 30 minutes was minimal in terms of yield. The reaction was divided int
two eppendorf tubes with 600 uL in each tube, and quenched with 100 pL
50%TFA/50%H20. Normally, a slight whitish precipitate forms during the labeling
procedure, which had always been ascribed to salt precipitation. Upon addition of
50%TFA/50%H20, this precipitate previously disappeared in non-radioactive labeling

efforts. On this occasion, the precipitate became worse, and it is possible that addi
more 50%TFjpA750%H20 might have made it better, as the previous large-scale attempt

used a 1:1 addition instead of a 1:6 addition. However, this was not attempted due to

concern about further precipitation, and the pH was already -1. Therefore, the precip

was removed by centrifugation. The precipitate resisted attempts to solubilize it wit
B, so it is unlikely that it was entirely salt. The supernatant was diluted to 10 mL

Buffer A. The loading, washing, and elution followed the same procedure as the large-
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scale non-radioactive attempt (vide supra), with the exception that the elution was at 10
mL/10 min, resulting in the collection of more fractions.
After elution, 100 pL aliquots of each elution fraction, along with aliquots from
the initial reaction, flow-through and washes of the column, were added to 4 mL

ReadySafe Scintillation fluid in 7 mL Scintillation vials and counted in a 6-counter

total radioactive counts per minute (adjusted for volume differences) in the diluted

starting reaction prior to SepPak purification and the various fractions counted aft

SepPak purification are shown in Table 4.1. It is apparent that all radioactivity wa

accounted for, and radioactive AIP-I appears in elution fraction #3, as evidenced by
spike in radioactive counts.

Table 4.1. Monitoring Radioactive Recovery
Material Counted

Counts per Minutes (cpm)

Diluted reaction mixture pre-SepPak

2.21xl07cpm

Flow-through

1.67xl07cpm

Washes

3.18xl06cpm

Elution Fraction #1

8.93xl04cpm

Elution Fraction #3

2.17xl06cpm

Elution Fraction #4

3.78xl05cpm

Elution Fraction #5

6780

Based on the radioactive counts, elution fractions #3 and 4 were combined to a

total volume of -2.5 mL, with a total cpm of 2.54 xlO6 cpm. It is interesting to note
this is roughly consistent with the 10:1 ratio of acetic anyhydride to AIP-1, as the
amount of radioactive acetic anyhydride in the reaction was 2.21xl07 cpm. However,
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only one acetyl group from the symmetrically labeled acetic anhydride should have
transferred to AIP-I, so the ratio should have been closer to 20:1. A calculation of

number of cpm's expected in the reaction mixture, based on the volume added, specific

activity (64 mCi/mmol) and concentration (677 pCi/pl) of acetic anhydride predicts th

8.04 xlO7 cpm should have been present. It is most likely the case that the problemat
precipitation and subsequent centrifugation removed radioactivity from the reaction
mixture in the pellet.
In preparation for bioassays, the acetonitrile was removed from the sample by

blowing N2 gas over the top of the vial. This was highly inefficient, as it took -two
to decrease the volume to -1 mL, and such a procedure carries some risk of oxidation
any methionine residues in the peptide (even with blowing N2 gas). In the future, it
recommended that samples be rotavapped to remove acetonitrile. The 1 mL aliquot was

then buffered with 1 mL of 0.05 M phosphate buffer, pH5.7, giving a final volume of 2
mL of presumably tritiated and acetylated AIP-I (* Ac -AIP-I).
To more accurately determine the specific activity and hence concentration of
*Ac-AIP-I, 4 uL aliquots of the 2 mL solution were counted in duplicate. The average

cpm from this counting was 486 ±31 cpm/1 uL solution, leading to a total count in 2 m
of 9.72xl05 cpm, which is a result more consistent with the 20:1 ratio of acetyl

group:AIP-I in the initial reaction mixture (see above). Also, the specific activity o
acetic anhydride [3H] was divided in half, 32 mCi/mmol, to reflect the incorporation
single acetyl group in AIP-I. Based on a counter efficiency of 63%, the cpm/fmol of

incorporated [3H] was calculated to be 0.04755 cpm/fmol. Based on this value and the

known cpm/uL of the *Ac-AIP-I solution, the concentration of the peptide was calculat
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as 10.22 p M in 2 m L , or 10.2 pg. The theoretical yield should be 100 u M in 2 m L , or 100

pg, thus leading to an overall yield for radioactive labeling and recovery of 10%. Th

dramatically lower than the 90% overall yield achieved in large-scale non-radioactive
labeling experiments. The precipitation encountered during the reaction could easily

explain the decreased yield. In addition, this was the first and only time that the r

was performed with radioactivity, so it is very likely that yields can be optimized i
future. In addition, the use of radioactive HPLC equipment and radioactive mass
spectrometry would vastly improve the quality of the procedure.
Lastly, *Ac-AEM was tested for agr activation of group I cells, which yielded an
ECS0 of 8 nM (95% CI, 4-14 nM), a value slightly lower than that seen with AIP-I and
-10-fold lower than that with cold Ac-AIP-I, with an EC50 of 98 nM (95% CI, 56-173

nM). It seems unusual that the overall yield of the labeling reaction is 10%, while t

biological activity of * Ac-AIP-I is 10-fold higher than that observed for the chemic
identical (non-radioactive) Ac-AIP-I. However, the calculations have been checked
repeatedly, and a source for a possible 10-fold error cannot be identified.

Radioactive Filter Binding to demonstrate AIP-I binding in induced RN8559 cells
250 pL of RN8559 cells (±methicillin) and 250 pL sodium phosphate buffer (pH

5.7) were incubated with 10 uL tritiated AIP-I (final concentration = 200 nM) for fiv
minutes at 37°C. Samples were filtered with a vacuum apparatus using 0.1 micron

Millipore filters. Filters were washed 3x with phosphate buffer, pH 5.7, and then suc

dry (the filtration was slow on the order of minutes). The filters were placed in 4 m

ReadySafe scintillation fluid (Beckman Coulter) in 7 mL vials and were counted in a 6
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counter after sitting overnight for effective dispersion, with a 2 minute count per vial to
narrow the confidence interval. Similar experiments to this one incorporating varied
times of incubation were performed twice more with RN8559, RN9222, and RN6911

cells, using either filter binding or radioactive cell pellet counting (vide infra an
Results).

Radioactive cell pellet counting from competition experiments
100 pL of RN8559 or RN6911 cells (3000 kU) were added to an eppendorf tube

with 380 pL 0.05 M phosphate buffer, pH 5.7, and 20 pL of a 10.22 uM stock solution o

tritiated AIP-I (all done in at least duplicate, and quadruplicate for RN6911). The c
were incubated for 5 minutes at 37°C with shaking, followed by spin-down, saving of

supernatants, and a lx wash of the intact pellet with 1 mL 0.05 M phosphate buffer, p

5.7. The cell pellet was resuspended in 450 pL of the same phosphate buffer, along wi
addition of either 50 pL of 25% propylene glycol in 0.05 M phosphate buffer, pH 5.7,

cold (non-radioactive) peptides in the same buffer at final concentrations of 25 uM f

AIP-1 and 10 pM for AIP-II. Cells were incubated for 10 minutes at 37°C with shaking,

followed by spin-down, saving of supernatants, no washing, and transfer of the pellet

into 7 mL scintillation vials, already containing 4 mL ReadySafe fluid, for radioacti

counting. The vials were vortexed thoroughly to disperse the pellets from the clipped

eppendorf tube tips, and were left standing several hours to overnight prior to radio
counting. 400 pL of the supernatant was also counted, which is 4/5 of the total

supernatant, thus confirming depletion of tritiated AIP-I in those tubes where cell b
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occurred. Similar experiments to this one with varied incubation times were performed
several times.

MALDI-ion trap Mass spectrometry.
The MALDI-quadrupole ion trap was constructed by members of the Chait
laboratory from a Thermo Finnigan LCQ Deca XP (San Jose, CA) as described for the

earlier LCQ version (Krutchinsky et al., 2001). Short ion injection times (typically 0
5.0 msec) were used for single stage MS experiments in order to prevent overfilling
effects. MS/MS and MS3 experiments were performed at longer injection cycles (200-

400 msec) using empirically optimized instrument specific parameters (isolation width

2.0 Da, normalized collision energy: 35% for AIPs, activation Q: 0.240, activation tim
300 msec). Acquisition times for HMS-MS studies varied from 30 sec to 1 min in order
to achieve acceptable signal/noise ratios.

Sample preparation for MS.
Approximately 0.5 mL of Staphylococcal culture supernatant were lyophilized
and resuspended in 100 pi 1% TFAAvater to which 5 pi of a suspension of hydrophobic
Poros 20 R2 beads (PerSeptive Biosystems, Framingham, MA) in 10-fold bed volume

2% formic acid were added to bind the AIPs. Using a 1 mL disposable syringe and a sel
made adapter piece (cut from a P200 pipette tip) a portion or the entire sample was
squirted through a ZipTip microcolumn (Millipore) that also served as a frit for the
material. The column bound material was washed with 20 uL 0.1% TFA before eluting it
directly onto the MALDI CD-plate using 2.5 pL of a half saturated solution of 2,5-
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dihydroxy benzoic acid ( D H B ) in 6 0 % methanol / 0.1% trifluoroacetic acid (TFA).
Synthetic peptides were simply spotted onto the MALDI CD-plate in 1 pL volumes of 1
nM solutions (or a dilution series) to which 1 pL of matrix solution were added
subsequently.

Agr induction by the Lactone 5. intermedius AIP
This experiment was performed by Yvonne Benito. The stationary-phase filtered
bacterial supernatant from an overnight 25 mL culture of S.intermedius strain RN9423

(CCM5739) was lyophilized. BHI broth was also lyophilized to use as a control. From 5

mL of a 1 hour-growing culture, 25 ml were poured in a flask containing the lyophiliz

supernatant and 25 ml in another flask containing the lyophilized BHI. Timepoints wer

then taken at 0, 30, 60, and 90 minutes, with 1 mL aliquots taken at each timepoint a

cell densities measured. The 1 ml cultures were spun down and the pellets resususpend
with dilution or concentration to obtain equal cell densities of 0.5 measured at 540

Equal volumes of cells were then frozen in preparation for Northern blotting. Whole-c

lysates and Nothern blotting were performed as described (vide supra). Parantheticall

the procedure of using lyophilized supernatants results in a final concentration of A

approximately equal to native conditions, rather than a diluted concentration as woul
result with addition of supernatants at 1/10* volume.

MBP-AgrC fusion constructs
Bacterial strains (E. coli, TBI) containing the MBP-AgrC(Ser.173) and MBPAgrC(Ser.199) plasmid constructs, encoding the MBP-3rd loop-TM helix-AgrC HK and
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M B P - A g r C H K proteins, respectively, were obtained from G. Lina (Lina et al., 1998).
Both plasmid constructs were verified by restriction digest mapping, and the DNA was

sequenced for MBP-AgrC(Ser.173). It is noteworthy that both plasmids were derived fro

the vector, pMal-p2, rather than pMal-c2, thus directing expression of fusion protein

the periplasm instead of the cytoplasm of E. coli. Bacterial cultures of these two st
were grown at 37°C with shaking and induced with IPTG for two hours at a

concentration of 0.5 mM. In accordance with the previous paper (Lina et al., 1998), th
proteins were not recovered by osmotic shock of the cells, but rather the cells were
by French press or sonication, and the proteins purified from clarified supernatants
affinity chromatography on amy lose columns according to the manufacturer's

instructions (New England Biolabs). Overall, the yield of protein from lysed cells wa
mg/L and >30 mg/L of the MBP-3rd loop-TM helix-AgrC HK and MBP-AgrC HK
proteins, respectively. The relatively low yield of MBP-3"1 loop-TM helix-AgrC HK
resulted from poor expression in comparison to MBP-AgrC HK in whole cell lysates

(very little material was detected in the pellet or the supernatant). Attempts to pur
MBP-AgrC HK protein by osmotic shock resulted in a >90% decrease in yield, perhaps
due to poor outer cell membrane lysis or due to cytoplasmic expression of protein en
route to the periplasm (data not shown).
Two other MBP-fusion protein plasmids were constructed, using the pMAL-c2
cytoplasmic expression vector from NEB. The first of these encodes a protein (named
4A-2) similar to MBP-3rd loop-TM helix-AgrC HK, but with a few extra residues at the
junction between MBP and AgrC. The second construct (named 3A-2) encodes the same
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version of M B P - A g r C H K , but with an extra Factor X a site between the M B P and the
AgrC HK domain, along with cytoplasmic expression instead of periplasmic expression.
The junction sites of all MBP constructs are illustrated below, with the portions

from AgrC-I underlined, a series of N's from MBP included for orientation, an asteris
on *MBP to indicate a signal sequence and periplasmic expression, and the Factor Xa
sites (IEGR) highlighted in bold:
4A-2: MBP.. .NNNNNNNNLGIEGRISEFIEGRSOINSDEAKVEIOYS.. ..cont...
MBP-3rd loop-TM helix-AgrC HK:
*MBP.. .NNNNNNNNLGIEGRISEFSDEAKVEIOYS.. ..cont...
3A-2: MBP.. .NNNNNNNNLGIEGRISEFIEGRSOFLLKEMKYKRNOE...cont...
MBP-AgrC HK: *MBP.. .NNNNNNNNLGIEGRSOFLLKEMKYKRNOEE.. .cont..
The following non-PAGE-purified primers (Invitrogen) were used for the
construction of 4A-2 and 3A-2, with the restriction sites underlined:
4A-2: EcoRI-FXA - 3TMK forward: 5'-CGCCGCGAATTCATCGAAGGTCG
TTCACAAATAAACTCGGATGAAGCTAAAGTAATAAGG-3'
3A-2: EcoRI-FXA - kinase forward: 5'-CGCCGCGAATTCATCGAAGG
TCGTTCTCAATTTCTCCTTAAAGAGATGAAATATAAACGTAATC-3'
Reverse primer used for both constructs:
PstI -kinase reverse primer:
5'-AAAAGACTSCAGTCAACTTTTTGAATAAAAGAAACCATTTTCG-3'
The plasmids were constructed using standard methods (and see below for Histagged AgrC constructs), and both plasmid constructs were confirmed by DNA
sequencing.
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The 3A-2 and 4A-2 proteins were expressed and purified as described above, with
yields, respectively, of 30 mg/L and 2 mg/L (as determined by comparison to BSA
standards run on the same gel). The expression of 4A-2 was low, similar to that seen
the MBP-3rd loop-TM helix-AgrC HK protein, thus suggesting that inclusion of a
normally transmembrane helix in these MBP fusion proteins decreases protein
expression.
The molecular weights of these proteins are: 3A-2: 69303 Da; 4A-2, 72963 Da;
MBP-3rd loop-TM helix-AgrC HK, 74614 Da; and MBP-AgrC HK, 71397 Da. The
molecular weight of the added signal sequence in *MBP is 2566 Da, thus accounting in
part for the large difference in mass between 3A-2 and MBP-AgrC HK. After
purification, all proteins were run on SDS-PAGE gels using molecular weight markers,
which confirmed their approximates masses (relative to each other).

Attempts to develop His-tagged AgrC constructs
A cloning strategy was devised to express His-tagged version of AgrC in E. coli,

for subsequent purification and in vitro characterization. Two proteins were envision
along the lines of the MBP-AgrC HK and MBP-3rd loop-TM helix-AgrC HK proteins,
with the substitution of MBP by a His-tag. These beginning amino acid sequences of
these proteins are listed below, where the beginning portion of AgrC-I is underlined
the incorporated FactorXa site highlighted in bold:
His-AgrC HK protein: HHHHHHSSGI .VPRGSHMIEGRSOFLLKEMKYKRN.. .cont..
Irlis-Y loop-TM helix-AgrC HK protein:
HWJHHHSSGLVPRGSHMIEGRSOINSDEAKVIR.. .cont...
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The non-PAGE-purified primers (Invitrogen) for this cloning, with the restriction
sites underlined, were:
His-AgrC HK protein: Ndel -FXA- kinase forward,
5' -GGGA ATTCCATATGATCG AAGGTCGTTCTCAATTTCTCCTTA AAG AGA
TGAAATATAAACGTAATC-3'
His-S"1 loop-TM helix-AgrC HK protein: Ndel -FXA- 3TMK forward,
5' -GGG A ATTCCATATGATCG AAGGTCGTTCAC A A AT AA ACTCGGATGA A
GCTAA AGT A ATA AGG-3'
The common reverse primer for both constructs was:
BamHI -kinase reverse primer,
5' -CGCCGCGGATCCTC A ACTTTTTGAATAA A AGA A ACC ATTTTCG-3'
The PCR products, using the plasmid pRN7062 as template were restrictiondigested with BamHI/Ndel, followed by Dpnl digestion to remove plasmid template, and
then QiaQuik PCR purification (Qiagen). These digested products were then ligated to

the similarly digested and Calf-Intestinal Alkaline Phosphatase (ClP)-treated His-vec
pET15b (Novagen). Unfortunately, after DH5a transformation and plating, no colonies

were recovered, indicating that some step of the cloning had failed. The lack of PAGE

purification of the primers could have resulted in a primer error, or else the double
digestion with Ndel and BamHI of the PCR product or cloning plasmid may not have
gone to completion. In any case, the poor behavior of the AgrC HK domain on its own
after cleavage from MBP in the MBP-fusion proteins (see Results) may make the
expression of His-tagged AgrC HK domains (with or without transmembrane helices)
difficult.
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Histidine Kinase Activity Assays
Low NaCl concentration (< 25mM) was found to be critical for high HK activity.

After purification of MBP-fusion proteins according to the manufacturer's instruction
(NEB), the proteins were dialyzed into 20 mM Tris pH7.2, 200 mM NaCl, 5 mM MgCl2,
and 0.2 mM DTT, mainly to remove EDTA, to replace 6-Mercaptoethanol with DTT and
to add the necessary magnesium cofactor for the enzyme. For the kinase assays, the

protein was diluted into phosphorylation buffer, consisting of 20 mM Tris pH7.5, 5 mM
MgCl2, 5 mM MnCl2, and 50 mM KCI, to which was added radioactive ATP analogs,
cold ATP or buffer. The manganese was included because control experiments utilizing
manganese instead of magnesium showed a slight increase in kinase activity with
manganese. The dilution of protein by phosphorylation buffer was critical, as 1:2

dilutions resulted in poor activity, while 1:8 dilutions resulted in high activity, l

the conclusion that low NaCl concentration was critical for high kinase activity, a r
found for at least one other HK domain (Wright et al., 1993). The ATPf 2P and ATPf5S
were ordered from NEN, cat #s BLU502A, 250 pCi in 25 pL, and 502H Eztides, 3000
Ci/mmol (sp. Activity), respectively. For most experiments, timepoints were taken at
30, 60 and 90 minutes, with quenching with 6xSDS running buffer, including EDTA. The
samples were then loaded and run on SDS-PAGE gels. One gel was dried and subjected

to autoradiography. Usually, a parallel gel was Coomassie-stained to verify equal pro

loading, as it is well-known that 3-phosphohistidine does not survive the acidic stai
procedure. However, athough never fully verified, it was noted on SDS-PAGE analysis
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on at least one occasion that a slight band shift upward occurred with M B P - A g r C H K
proteins that had been phosphorylated by ATP addition.

Expressing truncated AgrC in vivo
The same shuttle vector, pRN7035, was used as for the original group I, II, and IV

reporter strains. This vector carries a P3:blaZ reporter, an ori from pT181 (for repl
in S.aureus), the ermC gene from pE194 (for selection in S.aureus), and an

ampicillin/ColEl ori fragment from pUC19 (for replication and selection in E.coli). PC
fragments, containing truncated forms of agrC, full-length agrA, and downstream
termination signals, amplified from the genomic DNA of agr group I, were cloned into
the Pstl/SphI sites of the pUC polylinker of pRN7035 (that had been adapted for more
efficient double-digestion). The following PAGE-purified primers (Integrated DNA

Technologies, Inc.) were used in the PCR reactions, with the restriction sites underl
the agrC-derived portions in bold, and the ribsome-binding site (derived from the
tetracycline promoter) italicized:
AgrC HK only, forward primer:
5' -GTAAATCTGCAGrAGAGAGrGrGArAGrAGATGCTCCTTAAAGAG-3'
AgrC-3TM-HK, forward primer:
5'-GTAAATCTGCAG7AGAGAGrGrGArAG7AGATGTCACAAATAAAC-3'
AgrC-TM3TM-HK, forward primer:
5'-GTAAATCTGCAGrAGAGAGrGrGA7AGrAGATGATTAGCACACCA-3'
The common reverse primer used in these reactions was Orf7 Reverse AgrCA:
5' -GGTGA AGCATGCAGTTTGCCA AC ATTAC AAGAGGTTGAACA AGC A
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T T T T A A - 3 ' located in a downstream open-reading frame, Orf7, from the agr operon.
Restriction digest mapping and DNA sequencing of the cloning junctions was

used to verify the plasmid constructs. Plasmid DNA isolated from single colonies of t

E. coli DH5a derivative was introduced into the restriction-defective S. aureus strai
RN4220, by the protoplast method (Novick, 1991). Plasmids were then moved into the

Group I agr+ cell line, RN6734, or the agr-null cell line, RN6911, by phage transducti

(Novick, 1991). Plasmid minipreps of independent clones of S. aureus cells verified th
presence of the correct molecular weight plasmids, which were further confirmed by

restriction digest mapping. The truncated AgrC proteins start with the following amin
acid sequences:
AgrC-HKprotein: MLLKEMKYKRNQEEIET....cont....
AgrC-3TM-HK protein: MSQINSDEAKVIRQYSFIF....cont....
AgrC-TM3TM-HK: MISTPYLILNKGFLIVISTILLLTFSLF... .cont....
Each construct also produces AgrA.
The portions from AgrC in the above constructs consist of the kinase alone, the

3rd extracellular loop-6th TM helix-kinase or the 5th TM helix-3rd extracellular loop
TM helix-kinase.
At least two independent plasmid clones from each construct isolated originally in

E. coli were tested in S. aureus for HK activity or a dominant-negative effect, using
nitrocefin method and the 5-toxin HPLC assay (see Results). To test for HK activity,
these plasmids were introduced into the agr-null strain, RN6911, and the B-lactamase
activity was compared to RN9222, which contains full-length AgrC/AgrA, in the

presence or absence of AIP-I at 1 pM. The basal activity of these strains was no diff
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than that seen previously with the control strain, RN9033, which contains the shuttle

vector alone, with no insert. These strains were NOT inducible by AIP-I as compared t
RN9222, consistent with the requirement of the sensor domain of AgrC for inducible
activation. To test for a dominant-negative effect, the 3 independently derived AgrC

plasmids were introduced into the agr+ strain, RN6734, and their effect on native agr

activation monitored during cell growth by the nitrocefin method and the 5-toxin HPLC

assay. For the nitrocefin method, aliquots were taken during cell growth at different
timepoints and analyzed. The control with the pRN9033 plasmid value was performed

with triplicate cultures of the same clone, with a single nitrocefin analysis per cul

The 6-lactamase values at the 4 hour timepoint were taken from 3 independently derive
clones of AgrC HK in culture, which were each measured by nitrocefin analysis in

triplicate and the means of the triplicate nitrocefin analyses combined to generate a
overall mean ± SEM for each clone. For the 5-toxin assay, RP-HPLC was used to

quantify 8-toxin levels in the supernatant of a single culture of p9033 and in the 3
independently cloned AgrC-HK cultures (single HPLC injection per culture only). This
experiment was conducted twice, so the means for pRN9033, 6A, 6B, and 6C from the
two assays were independently derived and then combined to generate the overall mean
fa each clone ± SEM.

Anti-AgrC Antibody Development and Testing
The peptide, C-Ahx-INSDEAKVIRQY, was synthesized (by B. Ayers) on PAM

resin using standard Boc-based peptide synthesis methods (vide supra). The peptide wa
purified and subsequently conjugated to maleimide-activated KLH according to the
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manufacturer's instructions (Pierce). This material (15 m g ) was sent to Charles Rivers
Inc. for rabbit polyclonal antibody production. Two rabbits were pre-immune bled and
then immunized each with 1 mg of the KLH-peptide, including complete Freund's

adjuvant (CFA). The rabbits were boosted (each time with 0.5 mg) and test-bled 4 time

at - 3 week intervals, followed by a terminal bleed - one month after the final boost

decision to terminally bleed the rabbits came after dot blotting demonstrated reactiv

the test-bleed sera (but not the pre-immune bleed sera) (1:500 dilution) with the C-A
INSDEAKVIRQY peptide down to a dotted dilution amount of 2.88 pmol (but not with
0.288 pmol). Dot blots were performed with 0.2 micron size nitrocellulose membrane

(Pierce) to increase the chance of peptide retention on the membrane, with the peptid
solutions (5 uL) dotted onto dry membranes, followed by incubation at 37°C to
accelerate drying of the dotted mixtures. The sera also recognized dot-blotted KLHconjugated peptide.
Western blotting with protoplast lysates from agr+(RN6390) and agr-null

(RN6911) early-stationary phase cultures did not reveal any strong band for AgrC, -50

kDa, in the agr+ lysate. In sharp contrast, a very strong doublet signal was detected
agr-null lysates at -46 and 50 kDa. It is well-known that protein A expression is
dramatically up-regulatated in agr-null strains in stationary phase cultures, due to
of down-regulation by the agr pathway. Furthermore, it is also well-documented that

protein A contains an epitope that is strongly bound by a consensus binding site on t

constant fragment (Fc) of immunoglobulin G (IgG) (Hoffman et al., 1996). Therefore, it

is not surprising that protein A gave a strong signal in Western blotting. However, t

unfortunate co-migration of protein A with AgrC made it very difficult to determine w
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any precision whether a faint band was present in the agr+ lysate that was not present in
the agr-null lysate. Furthermore, the sera reacted with many other proteins from the

lysate, as evidenced by multiple bands on Western blot, thus indicating that affinity
purification might be helpful.
Affinity purification was carried out using SulfoLink Gel (Pierce) according to

the manufacturer's instructions, starting with 14 mL of sera from rabbit #1 and yield

2 mL solution of antibody at 0.84 mg/mL. This affinity-purified and concentrated samp

recognized 0.288 pmol of the epitope on dot blots at a 1:500 dilution, which confirm
good recovery and concentration of the antibody.
The bacterial strains tested by Western blotting of whole cell lysates or membrane
preparations (with and without AgrC and induced or not, with AIP-I or methicillin,
depending on the strain) were: RN6390 (agr+), RN6911 (agr-null, RN9222 agr+),
RN9033 (agr-null), RN7736 (agr+ protein A-null), RN9397 (agr-null protein A-null),
RN8976 (agr-null protein A-null), and S. aureus strains containing various AgrC
truncated proteins (vide supra and Results). In addition, various MBP-AgrC fusion
proteins purified from E. coli were tested as well (see Results).
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Appendix 1 -

*![ chemical shift assignments for AIPs and analogs derived thereof.

residue
Gly
Val
Asn
Ala
Cys
Ser
Ser
Leu
Phe

NH

Ha

HP

Hy

8.41
8.53
8.3
8.36
8.53
8.29
7.96
8.43

4.10
4.64
4.24
4.49
4.38
4.24
4.04
4.88

2.01
2.78, 2.68
1.30
3.37, 2.99
3.82
3.90
1.17
3.34, 2.78

0.86

JP-IIV2A chemicai shifts in 9C) % H,O/10% D,0, p H 4.0, 298 K
residue
NH
Ha
HP
Gly
Val
8.54
4.29
1.31
.Asn
8.46
4.60
2.79, 2.69
Ala
8.27
1.30
4.23
Cys
8.36
4.48
3.36, 2.99
Ser
8.54
4.48
3.81
Ser
8.29
4.25
3.90
7.95
4.04
1.17
Leu
3.45, 2.79
Phe
8.43
4.88

AIP-II N 3 A chemical shifts in 9 0 % H-,0/10% D 2 0 p H
NH
Ha
residue
Gly
4.04
8.35
Val
4.19
8.38
Ala
4.14
8.25
Ala
4.42
8.34
Cys
4.32
Ser
8.53
4.18
Ser
8.29
3.97
7.91
Leu
4.83
8.39
Phe

4.0, 298 K
HP
1.95
1.26
1.22
3.30, 2.90
3.75
3.85
1.19, 1.09
3.40, 2.72

AIP-II S 6 A chemical shifts in 9 0 % H,O/10% D 2 0 pH4.0,298K
Ha
NH
HP
residue
Gly
2.01
4.10
8.41
Val
2.78, 2.68
4.67
8.54
Asn
1.28
4.23
8.29
Ala
4.42
3.30,
2.90
8.33
Cys
1.35
4.26
8.52
Ala
3.87
4.23
8.31
Ser
1.19
4.03
7.96
Leu
3.46,
2.78
4.89
8.47
Phe

others

-NH2 7.53, 6.84

1.03

0.74, 0.66
Ar. 7.29, 7.19

Hy

others

-NH2 7.53, 6.86

1.03

0.72, 0.66
Ar. 7.29, 7.19

Hy

others

0.81

0.96

0.66, 0.60
Ar. 7.24, 7.13

Hy

others

0.85
-NH2 7.53, 6.84

1.01

0.72, 0.66
Ar. 7.29, 7.20
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JP-II S 7 A chemi :al shifts in 9 0 % H,O/10% D,0p H 4.0, 298 K
residue
NH
Ha
HP

Gly
Val
Asn
Ala
Cys
Ser
Ala
Leu
Phe

8.41
8.53
8.29
8.36
8.48
8.46
7.75
8.32

4.11
4.68
4.25
4.51
4.39
4.13
4.09
4.90

2.03
2.79, 2.70
1.31
3.38, 2.95
3.78
1.42
1.27
3.48, 2.85

UP-II L 8 A chemi cai shifts in 90% H2O/10% D,0 p H 4.0, 298 K
residue
NH
Ha
Hp

Gly
Val
Asn
Ala
Cys
Ser
Ser
Ala
Phe

8.41
8.52
8.28
8.35
8.51
8.44
8.14
8.39

4.09
4.63
4.23
4.49
4.42
4.24
4.05
4.85

2.01
2.77, 2.67
1.29
3.37, 2.97
3.38
3.92
0.94
3.44, 2.79

JP-II F 9 A chemi :al shifts in 9 0 % H2O/10% D,0p H 4.0, 298 K
residue
NH
Ha
HP

Gly
Val
Asn
Ala
Cys
Ser
Ser
Leu
Ala

8.41
8.52
8.28
8.35
8.51
8.44
8.14
8.39

4.12
4.65
4.24
4.45
4.43
4.23
4.32
4.63

2.02
2.79, 2.69
1.30
3.34, 2.96
3.80
3.94
1.73
1.35

JP-II lactam chemical shifts in9 0 % H2O/10% D20, p H 4.0, 298 K
Ha
NH
HP
residue

Gly
Val
Asn
Ala
Dapa

Ser
Ser
Leu
Phe

8.41
8.56
8.29
8.22
8.46
8.78
7.94
7.75

4.12
4.67
4.28
4.40
4.46
4.02
3.99
4.64

2.04
2.81,2.70
1.33
3.79, 3.29
3.92
3.86
1.23
3.40,2.93

Hy

others

0.89
-NH2 7.53, 6.85

1.09

0.74, 0.68
Ar. 7.30, 7.22

Hy

others

0.86
-NH2 7.53, 6.84

Ar. 7.29, 7.20

Hy

others

0.88
-NH2 7.52, 6.85

1.62

0.86, 0.82

Hy

others

0.89
-NH2 7.54, 7.06
-NH 7.65

1.09

0.70, 0.66
Ar 7.31, 7.14
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residue

NH

Ha

HP

Hy

Gly
Val
Asn
Ala
Ala
Ser
Ser
Leu
Phe

8.42
8.52
8.30
8.23
8.17
8.10
8.00
8.38

4.09
4.65
4.21
4.25
4.37
4.36
4.22
4.72

2.00
2.77, 2.68
1.31
1.33
3.76
3.81
1.44
3.24, 2.85

0.86

1.33

0.79, 0.73
Ar 7.28, 6.94

NH

Ha

HP

Hy

others

8.44
8.36
7.99
8.36
8.07
7.64
8.12
8.69

3.63
4.34
4.56
4.26
4.37
4.23
4.27
3.93
4.56

1.96
2.59, 2.40
1.19
3.18,2.94
3.65, 3.52
3.61
1.40
3.32, 2.85

0.89, 0.82

residue

Gly
Val
Asn
Ala
Cys
Ser
Ser
Leu
Phe

others

-NH2 7.26, 6.85

16 , t.yo IV

AIP-II lactam chemical shifts in p M S O - d ^ , 298 K
residue
NH
Ha
Gly
3.65
Val
8.44
4.35
Asn
8.36
4.57
Ala
7.92
4.30
8.04
4.38
Dapa
Ser
4.36
8.01
3.84
8.72
Ser
3.95
Leu
7.67
7.44
4.39
Phe

1.22

HP

Hy

1.98
2.60, 2.41
1.20
3.71, 2.89
3.85
3.65
1.25
3.23, 3.03

0.87

AIP-II line-ar C-terminal free acid in D M S O - d 6 , 298 K
Ha
NH
HP
residue
3.64
Gly
1.99
4.35
8.46
Val
2.61, 2.41
4.58
8.37
Asn
1.22
4.23
7.99
Ala
2.78
4.41
8.15
Cys
3.61
4.33
7.98
Ser
3.62
4.32
7.93
Ser
1.60,1.40
4.29
7.89
Leu
3.04, 2.92
4.37
8.03
Phe
trAIP-II in D M S O - d . , 298 K
residue
NH
1.86
acetyl
8.46
Cys
8.12
Ser
7.61
Ser
8.14
Leu
8.69
Phe

-NH2 7.41, 6.94

Ha

HP

4.40
4.23
4.27
3.93
4.56

3.15,2.87
3.66, 3.54
3.59
1.43
3.33, 2.85

-OH 5.04
-OH 5.14
0.73
Ar. 7.25, 7.21

others

-NH, 7.39, 6.94

1.06

Hy

-NH7.64
-OH 5.39
-OH 5.35
0.73, 0.72
Ar 7.26, 7.20

others

0.86
-NH2 7.42, 6.95

-OH 5.12
0.84

0.84
Ar 7.26, 7.21

Hy

others

1.23

-OH 5.06
-OH 5.17
0.73
Ar. 7.26, 7.21
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AIP-II lactam in D M S O - d * , 298 K
residue
NH
acetyl
1.83
Dapa
8.10
8.03
Ser
8.67
Ser
7.71
Leu
7.48
Phe
AIP-I in DMSO-d^, 298 K
residue
NH

Tyr
Ser
Thr
Cys
Asp
Phe
lie
Met

8.73
7.94
8.22
8.21
7.84
8.32
8.98

Ha

HP

4.38
4.32
3.85
3.95
4.37

3.63, 2.86
3.77
3.63
1.26, 1.09
3.22, 3.01

Ha

HP

4.03

3.03, 2.80

4.56
4.25
4.39
4.42
4.49
3.73
4.28

3.69, 3.60
4.06
3.19,2.91
2.48, 2.38
2.98
1.93
1.94

AIP-I linear C-termindfreeacid in DMSO-d,;, 298 K
residue
NH
Ha
HP
Tyr
3.97
3.01,2.76

Ser
Thr
Cys
Asp
Phe
He
Met

8.71
7.97
8.26
7.93
7.79
7.96
8.23

AIP-I D 5 N in DMSO-d^, 298 K
residue
NH

Tyr
Ser
Thr
Cys
Asn
Phe
De
Met

8.71
7.91
8.23
8.11
7.86
8.34
9.00

AIP-IV in DMSO-d,;, 298 K
NH
residue

Tyr

4.56
4.29
4.51
4.44
4.54
4.18
4.32

Hy

others

1.38

0.75
Ar. 7.14, 7.31

Hy

1.04

others
Ar. 7.07, 6.70
-OH 9.31
-OH 5.21
-OH 4.92

0.89
2.43

Ar. 7.30, 7.21
0.85
2.19

Hy

3.65, 3.65
4.10
2.63, 2.41
2.69
2.98, 2.80
1.72
1.87

1.46
2.47

Hy

others
Ar. 7.06, 6.69
-OH 9.30

1.06

Ar. 7.21,7.18
0.85
1.99

Ha

HP

4.00

3.04, 2.79

4.56
4.25
4.37
4.40
4.48
3.76
4.27

3.64
4.07
3.18,2.90
2.39, 2.28
2.97
1.92
1.93

1.04

others
Ar. 7.07, 6.70
-OH 9.31
-OH 5.21
-OH 4.92

1.10
2.49

-NH2 7.39, 6.90
Ar. 7.30, 7.21
0.75
2.19

Hy

Ha

HP

3.98

3.04, 2.78

Ser
Thr
Cys
Tyr

8.70
7.93
8.21
7.99

4.56
4.21
4.27
4.20

3.64
4.09
3.16, 2.87
2.59

Phe
He
Met

8.00
8.22
9.07

4.47
3.76
4.23

2.95
1.93
1.92

1.00

others
Ar. 7.07, 6.70
-OH 9.31
-OH 5.27
-OH 4.86

1.14
2.48

Ar. 6.80, 6.60
-OH 9.16
Ar. 7.30, 7.22
0.75
2.19
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AIP-IV Y 5 F in D M S O - d . 298 K
residue
NH

Tyr
Ser
Thr
Cys
Phe
Phe
He
Met

8.74
7.94
8.18
8.08
8.05
8.23
9.07

AIP-I D 5 A in D M S O - d , 298 K
residue
NH

Tyr
Ser
Thr
Cys
Ala
Phe
lie
Met

8.72
7.95
8.22
8.03
7.80
8.28
9.06

AIP-I M 8 I in D M S O - d . , 298 K
residue
NH

Tyr
Ser
Thr
Cys
Asp
Phe
He
He

8.74
7.95
8.20
8.30
7.70
8.48
8.91

Ha

HP

4.03

3.05, 2.80

4.55
4.18
4.26
4.25
4.50
3.78
4.24

3.70, 3.56
4.09
3.15,2.87
2.68
2.97
1.93
1.93

8.71
7.97
8.26
7.93
7.79
7.96
8.23

1.15
2.49

Ar. 7.21, 7.03
Ar. 7.31,7.22
0.76
2.18

Ha

HP

4.04

3.02, 2.80

4.56
4.26
4.26
4.25
4.50
3.77
4.26

3.63
4.04
3.16,2.89
1.03
2.95
1.93
1.93

1.06

others
Ar. 7.07, 6.69
-OH 9.33
-OH 5.22
-OH 4.93

1.15
2.48

Ar. 7.27, 7.19
0.76
2.17

Hy

Ha

HP

4.02

3.04, 2.79

4.55
4.26
4.35
4.44
4.54
3.58
4.21

3.70, 3.59
4.04
3.17,2.90
2.52, 2.42
2.98
1.97
1.65

JP-I linear C-terminalfreeacid in D M S O - d 6 , 298 K
Ha
residue
NH
HP
3.01, 2.76
3.97
Tyr

Ser
Thr
Cys
Asp
Phe
lie
Met

0.97

others
Ar. 7.08, 6.70
-OH 9.33
-OH 5.27
-OH 4.85

Hy

4.56
4.29
4.51
4.44
4.54
4.18
4.32

3.65
4.10
2.63, 2.41
2.69
2.98, 2.80
1.72
1.87

Hy

1.03

others
Ar. 7.08, 6.70
-OH 9.32
-OH 5.20
-OH 4.86

1.02
1.04

Ar. 7.28, 7.20
0.72
0.88

Hy

others
Ar. 7.06, 6.69
-OH 9.30

1.06

1.46
2.47

Ar. 7.21,7.18
0.85
1.99
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..cetyl-AIP-I in DMSO-dfi, 298 K
residue
NH
acetyl
1.74
8.01
Tyr

Ser
Thr
Cys
Asp
Phe
He
Met

2.92, 2.62

4.39
4.21
4.36
4.39
4.48
3.74
4.26

3.62
4.03
3.18,2.91
2.45, 2.37
2.97
1.91
1.93

Ha

1.01

Ar. 7.05, 6.63
- O H 9.13
-OH 5.11
-OH 4.84

1.10
2.45

Ar. 7.27, 7.19
0.76
2.18

HP

Hy

others

4.28
4.34
4.48
3.82
4.29

3.13,2.83
2.46, 2.30
2.97
1.90
1.95

1.17
2.48

Ar. 7.26, 7.19
0.76
2.17

Ha

HP

Hy

others

4.23
4.08

3.05, 2.84
2.46

4.53
3.85
4.14

2.95
1.90
1.94

1.20
2.47

Ar. 6.84, 6.59
- O H 9.20
Ar. 7.29, 7.22
0.78
2.19

Ha

HP

Hy

others

4.25
4.03
4.52
3.73
4.25

3.14,2.84
1.04
2.95
1.97
1.94

1.14
2.48

Ar. 7.27, 7.20
0.76
2.18

NH

Ha

HP

Hy

others

8.44
8.36
7.92
8.42
8.09
7.88
8.28
9.04

3.61
4.31
4.55
4.24
4.30
4.41
4.49
3.78
4.25

1.96
2.58, 2.40
1.15
3.15,2.93
2.39, 2.34
2.97
1.91
1.94

0.86

8.15
7.70
8.22
8.18
7.85
8.32
8.99

8.07
8.06
9.17

trAIP-I D 2 A in D M S O - d . 298 K
residue
NH
acetyl
1.85
Cys
8.47
Ala
8.11
Phe
7.75
8.32
He
Met
9.06

Gly
Val
Asn
Ala
Cys
Asp
Phe
lie
Met

4.48

others

trAIP-IV in D M S O - d , 298 K
residue
NH
acetyl
1.76
Cys
8.41
Tyr
7.80

residue

HP

Hy

trAIP-I in D M S O - d , 298 K
residue
NH
acetyl
1.83
8.44
Cys
8.14
Asp
7.90
Phe
8.33
He
9.07
Met

Phe
He
Met

Ha

-NH2 7.39, 6.92

1.14
2.42

Ar. 7.25, 7.20
0.77
2.19
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JP-I/II in D M S OA , 298 K
residue
NH

Ha

HP

4.04

3.03, 2.80

4.56
4.26
4.42
4.22
4.27
3.94
4.55

3.69, 3.60
4.08
3.19,2.91
3.66,3.51
3.60
1.39
3.32, 2.86

AIP-III heptapeptide in D M S O - d , 298 K
residue
NH
Ha
He
3.61
Asn
8.60
4.58
8.31
Cys
4.34
8.17
Asp
4.47
Phe
7.93
4.40
Leu
8.34
3.97
Leu
8.78
4.23

HP

Hy

1.82
2.47
3.14,2.79
2.43
2.98
1.62, 1.46
1.67

1.15

others
0.92
-NH2 7.30, 6.93

1.17

Ar. 7.26, 7.21
0.77
0.87

AIP-III octapeptide in DMSO-dft, 298 K
residue
NH
Ha
Tyr
4.02

2.76

Tyr
Ser
Thr
Cys
Ser
Ser
Leu
Phe

He
Asn
Cys
Asp
Phe
Leu
Leu

8.73
7.97
8.20
8.12
7.63
8.12
8.69

1.05

1.22

Hy

others
Ar. 7.07, 6.70
- O H 9.31
- O H 5.24
-OH 4.93
-OH 5.03
-OH 5.14
0.72
Ar. 7.26, 7.22

others
Ar. 7.03, 6.72
-OH 9.30

4.29
4.56
4.33
4.48
4.37
3.96
4.22

1.75
2.39
3.16, 2.74
2.45, 2.41
2.98
1.63, 1.45
1.67

0.89

1.24

Ar. 7.22, 7.08
0.79
0.88

AIP-III nonapeptide in D M S O - d . 298 K
Ha
residue
NH
3.75
Ala
4.56
Tyr
8.49

HP

Hy

others

1.32
2.94, 2.68

4.21
4.53
4.33
4.48
4.40
3.97
4.26

1.74, 1.45
2.51,2.39
3.16,2.75
2.51,2.39
2.98
1.61, 1.43
1.67

He
Asn
Cys
Asp
Phe
Leu
Leu

8.55
8.40
8.04
8.23
7.93
8.36
8.74

HP

Hy

8.01
8.28
8.01
8.24
7.93
8.37
8.73

-NH2 7.30, 6.89

Ar. 7.08, 6.65
- O H 9.18
1.08,0.83
-NH2 7.28, 6.88

1.18

Ar. 7.28, 7.19
0.76
0.88
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